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Abstract
Adenosine is . a neuromodulator with complex effects on nociceptive pathways. 
Mice lacking the adenosine À2a receptor are hypoalgesic and a role for the Â2a 
receptor in sensitizing afferent fibres projecting to the spinal cord has been 
suggested. To test this hypothesis adenosine A2A receptor knockout mice and 
wildtype controls were used in behavioural and autoradiographic experiments.
Adenosine A2A receptor knockout mice had substantially reduced spinal cord 
NMDA glutamate binding whereas spinal cord AMP A glutamate receptor binding 
was increased, spinal cord substance P receptor binding was unaffected. 
Additionally, there was reduced uptake of [^"^C]-2-deoxyglucose into spinal cord 
sections from adenosine A2A receptor knockout mice.
In the formalin test there was a significant reduction in nociceptive behaviour 
displayed by adenosine A2A receptor knockout mice during both phases of the test. 
The selective adenosine A2A antagonist SCH58261 also antagonized both phases 
of the formalin test in wildtype mice. Spinal cord NMDA glutamate receptor 
binding was significantly reduced following formalin injection in wildtype mice 
whereas AMP A glutamate receptor binding and uptake of [^"^C]-2-deoxyglucose 
were significantly increased following formalin injection in wildtype mice. There 
were no significant changes in any of the measures examined in spinal cords from 
adenosine A2A receptor knockout mice.
Following repeated PGE2 injection and mechanical paw pressure, spinal cord 
NMDA glutamate receptor binding and uptake of [^"^C]-2-deoxyglucose into the 
spinal cord was significantly greater in adenosine A2A receptor knockout mice 
compared to wildtype mice. This may reflect loss of inhibitory adenosine A2A 
receptors located on inflammatory cells.
The reduced response to formalin injection and decrease in NMDA glutamate 
receptor binding could reflect reduced peripheral sensory input to the spinal cord 
and be responsible for the hypoalgesia in adenosine A2A receptor knockout mice. 
These results support a key role for adenosine A2A receptors in peripheral 
nociceptive pathways.
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Chapter 1 :
General Introduction
1.0 In troduction
Pain is something that affects everyone at some point in their life and according to 
a Europe-wide pain survey (Breivik et al. 2006), 19% of 46,394 respondents 
willing to participate had suffered pain for more than 6 months, with their last 
episode of pain within the last month. Of those people, 59% had suffered pain for 
more than 2 years and 40% had inadequate management of their pain using 
current treatment methods. The report stated that the most common types of pain 
were back problems, headaches and joint pain. The list highlights that the problem 
of recurrent pain is not an “exotic” disease but an everyday occurrence and yet the 
mechanisms which lead to the sensation are not fully understood.
1.1 Pain pathways
The International Association for the Study of Pain (lASP) defines pain as: “An 
unpleasant sensory and emotional experience associated with actual or potential 
tissue damage, or described in terms of such damage” (1994). This definition 
takes into consideration both the subjective nature of pain but also the 
physiological basis involving tissue damage. At this point it should be noted that 
there is a difference between the terms "nociception" and "pain". The term "pain" 
is a subjective experience that typically accompanies nociception, but can also 
arise without any stimulus, and thus includes the emotional response. 
"Nociception," by definition is a defensive response to a noxious stimulus (i.e. a 
stimulus that is damaging to tissues or would be if  prolonged). It is a term that 
denotes specific activity in nerve pathways as a result of noxious stimuli, and does
not include the emotional component of pain. Thus, in animals the term 
nociception is used in preference to pain as the subjective response to a noxious 
stimulus cannot be measured. To this end the use of nociceptive behaviour is 
used, such as vocalization or paw lifting/shaking, to provide a behavioural 
measure of pain. Whilst the focus of this report is to describe peripheral 
mechanisms of nociception, both terms will be used when appropriate. The 
nociceptive processing/pain pathways can be approximately divided into three 
sections namely detection of noxious stimuli, initial processing within the spinal 
cord and then final discrimination within the higher centres of the brain (see 
figure 1.). These will be briefly described and followed with a more detailed 
description of peripheral sensitization of primary afferent fibres.
Noxious
stimulus
Brain
Spinal
cord
periphery
Figure L Schematic diagram o f main elements ofpain pathway. The detection 
of a noxious stimulus occurs in peripheral tissues which are relayed to the dorsal 
horn of the spinal cord before being transmitted to the brain for processing.
L L l  Peripheral induction o f  nociception
The induction of pain begins with application of a noxious stimulus to a 
nociceptor located at peripheral sites. There are three main types of noxious 
stimulus detected by nociceptors which are; chemical, thermal and mechanical. 
Electrical recordings taken from the femoral cutaneous nerve of the cat and 
squirrel monkey showed that a proportion of fibres tested by applying a 
mechanical stimulus were apparently unresponsive. However, if  an intense 
stimulus was applied the fibres would illicit a response, these fibres were termed 
nociceptors as they were selectively activated by stimuli that would cause tissue 
damage (Burgess and Perl 1967; Perl 1968). The nociceptors described in the 
studies form the distal-most part of one of three types of sensory fibres that 
respond to noxious stimuli; they are named according to their conduction velocity 
and physical properties (see table 1). These fibres are often collectively referred to 
as first order neurones and consist of C, Aô and Ap fibres (see Julius and 
Basbaum 2001). The fibres that are most commonly associated with nociception 
are Aô and C-fibres. The initial response to a noxious stimulus is transmitted 
along thinly myelinated Aô fibres which have a conduction velocity of 
approximately 12-30 m/s. They are responsible for the ‘sharp’ first-wave pain 
sensation whilst smaller, unmyelinated C-fibres, with a slower conductance 
velocity of approximately 0.5-2.0 m/s, are associated with the ‘dull’ second wave 
pain that follows. Larger, Ap fibres do play a role in pain, although under normal 
physiological conditions are involved in sensing innocuous touch (see Guirimand 
and Le Bars 1996; Millan 1999). Ap fibres are usually only recruited during 
reorganization of nociceptive pathways as a result of more complex pathological 
pain states such as allodynia, which is a condition where normally innocuous
stimuli produces pain (see Guirimand and Le Bars 1996; Millan 1999). They are 
fully myelinated and have a conduction velocity of 30-100 m/s.
Fibre name Characteristics Velocity Diameter
C Unmyelinated, responds 
to mechanical, thermal 
and chemical stimuli
Slow
0.5-2.0 m/s
Small 
0.4—1.2pm
AÔ Thinly myelinated, 
responds to mechanical, 
thermal and chemical 
stimuli
Intermediate 
12-30 m/s
Medium
2 -6 pm
Ap Fully myelinated, 
involved in complex 
pathological pain states
Fast
30-100 m/s
Large
> 1 0 pm
Table 1. Comparison of primary afferent fibres involved in nociception. Adapted 
from Millan (1999) and Julius and Basbaum (2001).
1.1,2 Laminar organization o f  spinal cord
The spinal cord receives inputs from primary afferent fibres and initial processing 
of the nociceptive signal occurs here. The spinal cord itself contains both white 
and grey matter with the grey matter being the site of primary synapse. It is 
divided into ten segments called laminae: I, II, III, IV, V, VI, VII, VIII, IX, and X 
which was originally proposed using histological techniques to describe the spinal 
cord of the cat (Rexed 1952). The author noted that the cells showed a consistent 
pattern throughout the spinal cord (See figure 2). A similar analysis has also been 
provided for the rat (Molander et al. 1984; Molander et al. 1989).
Spinal cord laminae are grouped according to their location, lamina I -  VI make 
up the dorsal horn where sensory information enters such as noxious chemical, 
innocuous touch etc, whereas VII -  IX constitute the ventral horn whose main
purpose is involved with motor functions. Lamina X is located around the central 
canal of the spinal cord (Rexed 1952; Molander et al. 1984; Molander et al. 1989). 
Spinal cord white matter is separated into three sections corresponding to 
location: the dorsal fiiniculi, ventral funiculi and lateral funiculi (see figure 2 ) are 
the tracts of the white matter that contain the pathways of second order neurones 
which ascend or descend from higher spinal cord regions or the brain (see 
Almeida et al. 2004).
Dorsal funiculi
Lateral funicmi
Ventral funiculi
Figure 2, laminar organization o f spinal cord. Coronal section of the cervical 
spinal cord showing lamina boundaries of the grey matter which are indicated 
with corresponding number on right side. The left side highlights groupings of 
lamina into superficial (A, laminae I-II) intermediate and deep layers (B, III-VI) 
of the dorsal horn. The ventral horn (C, laminae VII-IX) and central grey matter 
(D, lamina X). These collectively represent the grey matter of the spinal cord. The 
white matter comprises lateral, dorsal and ventral funiculi. Adapted from Paxinos 
and Watson (1986).
1.1,3 Initial processing o f  nociception in spinal cord
The first stage of nociceptive processing occurs in the spinal cord where 
peripheral afferent fibres enter and synapse onto intrinsic neurones within the
laminae of the dorsal horn. These intrinsic neurones promote the interaction of 
excitatory and inhibitory stimuli, and are also responsible for the transfer of 
information to supraspinal structures (see Guirimand and Le Bars 1996; Millan 
1999; Almeida et al. 2004). The neurones are classified into either projection 
neurones that relay directly to higher centres and form the ascending pathways to 
brain regions such as the thalamus or intemeurones which modulate the activity of 
projection neurones and are further classified according to the nociceptive input 
they receive. Wide dynamic range (WDR) neurons receive input over a wide 
range of stimulus intensities and will respond to multiple stimuli such as 
mechanical, thermal and chemical noxious stimuli (e.g., Carstens 1997; Bester et 
al. 2000). WDR cells allow stimulus intensity information to be encoded as they 
respond to a wide range of stimulus intensities. It has been shown that 
sequentially increasing the concentration of carrageenan injected into rat hind paw 
increased c-fos expression within spinal cord cells (Buritova et al. 1998). Also 
increasing the mechanical pressure applied to rat paw caused a complimentary 
increase in the activity of cells within identified projection neurones (Bester et al. 
2000). However, nociceptive-specific neurons (NS), which respond exclusively to 
noxious stimuli, have been shown to encode the stimulus intensity more precisely 
than WDR neurones as Aô fibres are the predominant input to NS whereas C- 
fibres are the predominant input to WDR cells (Andrew and Craig 2002b). Using 
comparative human and rat studies it is has been shown that C-fibres “adapt” to 
ongoing noxious stimulus and therefore this reduces their ability to encode the 
intensity (Andrew and Greenspan 1999). Also, NS cells located in lamina I allow 
initial processing of the location of the noxious stimulus as the fibres enter the 
spinal cord in such a way that it represents the location of origin (see Brown et al.
1998; see Almeida et al. 2004). The final group of neurons are labelled non­
nociceptive and as their name suggests they are not normally involved in 
nociceptive processes except in more complex pain states (see Guirimand and Le 
Bars 1996; Millan 1999).
L L 4  Monosynaptic ascending pathways
Monosynaptic ascending pathways allow direct projection of nociceptive signals 
to the stated supraspinal target area with all fibres travelling contralateral to the 
side of entry into the dorsal horn. A brief overview of each of the pathways shall 
be given but for more specific reviews on this topic see Almeida (2004). The 
spinothalamic pathway is the main pathway for identifying the modality, intensity, 
location and time-course of the pain stimulus which is referred to as the sensory- 
discriminative component of pain. The motivational-affective component of pain 
which involves the emotional and aversive behaviour that accompanies pain is 
primarily mediated by the spinoparabrachial pathway although there is a large 
overlap of function between the various pathways.
Cells that project via the spinothalamic pathway originate in all laminae of the 
spinal cord following retrograde transport of horseradish peroxidise injected into 
the thalamus, with the greatest labelling in laminae I and V (Willis et al. 1979). 
Mechanical stimulation of spinothalamic tract neurones in lamina I of the 
lumbosacral spinal cord of anaesthetized cats produced a complimentary increase 
in electrical recordings within the thalamus (Andrew and Craig 2002a). A similar 
response was seen following application of noxious heat with responses detected 
in the thalamiis (Craig and Andrew 2002). Neurones forming the spinothalamic
pathway travel within the dorsolateral funiculi of the spinal cord white matter as 
lesioning of the dorsolateral funiculi almost completely abolished retrograde 
labelling of cells within the dorsal horn (Giesler et al. 1981). Further, selective 
lesions of dorsolateral fibres causes a great reduction in nociception in monkeys 
(Greenspan et al. 1986), and rats (Vierck and Light 1999).
The spinomesencephalic tract carries information from all sensory laminae and 
terminates in the midbrain, particularly the periaqueductal gray (PAG) (see Fig. 
3). Anterograde transport of wheat germ agglutinin conjugated to horseradish 
peroxidise (WGA-HRP) following application to the spinal cord of rats, cats and 
monkeys was analyzed using serial sections taken from the midbrain and high 
levels of staining were identified throughout the midbrain establishing the link 
between the spinal cord and midbrain structures (Yezierski 1988). Also, there was 
increased firing in neurones projecting to the PAG in the macaque monkey 
following peripheral administration of capsaicin, an exogenous peripheral 
sensitizing agent, demonstrating a role in the response to inflammation 
(Dougherty et al. 1999).
The spinoreticular tract terminates in the reticular formation of the brainstem and 
carries information from laminae I, and V but also VII, VIII and X of the spinal 
cord which would indicate they receive input from wide-dynamic range neurones 
as well as nociceptive-specific neurones (Kevetter et al. 1982). Hemisection of 
thoracic spinal cord white matter containing neurones projecting to the reticular 
formation in rat was able to ablate nociceptive responses to noxious pinch of the 
paw (Hubscher and Johnson 2002). The spinoreticular pathway is also believed to
initiate descending inhibition of afferent fibres as activation of the pathway in 
human subjects reduced the nociceptive reflex following sural nerve activation 
(De Broucker et al. 1990).
Spinoparabrachial projection neurones were initially identified using anterograde 
and retrograde transport of WGA-HRP in common with many other studies. In the 
rat, projection neurones were heavily concentrated in lamina I of the spinal cord 
with very little labelling elsewhere (Cechetto et al. 1985). This would indicate that 
the projection neurones are formed firom nociceptive-specific fibres and indeed it 
has been shown that neurones projecting to the parabrachial nucleus respond 
exclusively to noxious heat and mechanical stimuli (Bester et al. 2000). Also, 
following carrageenan-induced peripheral inflammation, the number of c-fos 
positive parabrachial-projecting fibres was significantly increased, further 
implicating this pathway in nociceptive processing (Buritova et al. 1998) Also, 
activation of this pathway is thought to mediate the autonomic changes following 
application of a noxious stimulus as blockade of the pathway, with either cobalt 
chloride or lidocaine, attenuated the cardiovascular response to electrical 
stimulation of the mandibular nerve in rats (Allen and Pronych 1997).
The spinohypothalamic tract has been identified to receive nociceptive input fi*om 
laminae I, V and X primarily with sparse labelling of other laminae (Burstein et 
al. 1990). Noxious mechanical stimulation of the anaesthetized macaque monkey 
was used to stimulate primary afferents that projected to the hypothalamus. The 
spinohypothalamic neurones preferentially responded to noxious stimulation 
providing evidence that this pathway is indeed involved in the nociceptive
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pathway (Kostarczyk et al. 1997). The hypothalamus is a key area involved with 
the emotional impact of pain as there are many afferents to the limbic system (see 
Saper 2002).
Somatosensoiy cortex Giiigulated cortex
Rcticulm* foiinatioii 
of brainstem
From spinal cord
Figure 3. Target brain areas receiving nociceptive input. These brain areas 
receive input from synaptic pathways which project directly from the spinal cord. 
Spinothalamic tract (green), spinobrachial tract (grey), spinomesencephalic tract 
(blue), spinohypothalamic tract (orange), spinoreticular tract (black). The 
positions indicated are approximate and are taken from Paxinos and Franklin 
(1995).
IL S  Polysynaptic ascending pathways
These polysynaptic ascending pathways include the spinocervical tract and the
.
polysynaptic dorsal column; they act as a relay for 2" order neurons as they 
ascend the spinal cord (see Almeida et al. 2004). The afferent projections from 
different regions of the spinal cord are processed at differing brain nuclei, which 
allows the spatial discrimination of the impulse. The gracile nucleus receives 
input from the lower body and will synapse with neurons from lumbar and sacral 
spinal regions, whereas the cuneate nucleus will receive input from the cervical
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and thoracic regions (Nahin et al. 1992; Hirshberg et al. 1996; Al-Chaer et al. 
1997). The fibres all travel ipsilateral to the site of entry into the dorsal horn until 
reaching the spinal target (e.g. lateral cervical nucleus) before crossing to the 
contralateral side and ascending to their supraspinal target (see fig. 4). There is 
evidence to suggest that the polysynaptic pathways are a key signalling pathway 
for transmission of visceral pain (see Palecek 2004). The number of neuronal 
inputs to the dorsal column firom visceral organs is equal to that of the 
spinothalamic tract following colorectal distension in the macaque monkey (Al- 
Chaer et al. 1999). Whilst this does provide evidence that the visceral organs do 
have input to . the dorsal column, the role of this pathway in visceral pain comes 
from a number of other studies. A lesion to the dorsal column of rats significantly 
reduces signalling input to the thalamus following colorectal distension (Al-Chaer 
et al. 1997; Willis et al. 1999). Also, in human studies a lesion of the dorsal 
column in the thoracic segment of the spinal cord virtually eliminates pelvic pain 
due to cancer (Hirshberg et al. 1996; Willis and Westlund 2001).
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To the brain
Lateral cervical nucleus
Dorsal horn of spinal cord
Periphery
Figure 4. Polysynaptic ascending nociceptive pathways. The spinocervical 
pathway acts as a relay to provide spatial localization of noxious stimulation. 
Nociceptive fibres enter the dorsal horn of the spinal cord and travel ipsilateral to 
entry and synapse onto the lateral cervical nucleus before crossing the midline and 
ascending to higher brain centres. Adapted from Almeida et al. (2004).
1.1.6 Supraspinal targets
The thalamus is a key supraspinal area involved in the pain pathway due to its 
innervation by the many afferent ascending pathways. All of the second order 
neurons eventually project to the thalamus and it is here that the third order 
neurons will synapse before travelling to the cortex for the final discrimination of 
pain (see Fig. 3). Using imaging studies, the thalamus has consistently been 
highlighted as active following application of noxious stimuli (e.g., Casey 1999; 
Laurent et al. 2000; Peyron et al. 2000). Also lesions of the thalamus (LaBuda et 
al. 2000) or excitation by injecting glutamate (Jensen and Yaksh 1992) caused 
spontaneous pain behaviours. Further, the thalamus responds to all types of 
noxious stimuli regardless of origin indicating a role in the integration of pain 
(Monconduit et al. 2003). The thalamus also receives input from other cortical
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areas and the limbic system; indeed it is within the thalamus that sensory- 
discriminative and motivational-affective pathways of pain are finally integrated 
before projection to the cortex (see Millan 1999; see Almeida et al. 2004).
Human studies employing various imaging techniques implicate the area 
surrounding the somatosensory cortex in the final processing of pain as this area is 
identified as active following noxious stimulation (e.g., Kwan et al. 2000; Lin and 
Forss 2002; Torquati et al. 2005). Indeed, in human subjects injected with 
ascorbic acid the intensity and duration of pain indicated by the patients matched 
the increased fMRI signal recorded in the secondary somatosensory cortex exactly 
(Porro et al. 1998). Also, following noxious cold, heat or tactile stimulation, there 
was increased activation in the somatosensory cortex and the insula, an area 
adjacent to the cingulate cortex (Davis et al. 1998). Further, the increased activity 
recorded in the cortex was dependent on the stimulus applied as it has been shown 
that the relative signal intensity increased when human patients received noxious 
cold stimuli immediately preceded by innocuous cooling (Kwan et al. 2000).
1.1.7 Descending pathways
The dorsal horn of the spinal cord also receives many descending pathways which 
act to either suppress or enhance the activity of neurons belonging to the 
ascending pathways. No detailed explanations of the descending pathways are to 
be discussed as they are not relevant to this report. However, suffice it to say that 
the mechanisms are complex, possibly more so than those of the ascending 
pathways. Descending inhibition of neurons in the dorsal horn is brought about by 
many systems but the main ones involve adrenergic, serotonergic, dopaminergic
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and opioid receptor systems. The periaqueductal gray (PAG) plays a vital role in 
the coordination of descending pathways. An excellent, detailed review of this 
topic has been written by Millan (2002).
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1,2 Inflammatory sensitization ofprimary afferent fibres
1.2.1 Inflammatory mediators
It is recognized that there are three types of pain which are defined as acute, 
inflammatory and neuropathic. Although nociceptive signals are transmitted via 
the same pathways as outlined in the previous section there are differences 
between the three types. For a comprehensive review of the different types of pain 
and the differences between them see Millan (1999). However the focus of this 
report is the role of adenosine A2A receptors in predominantly inflammatory pain 
models. Inflammatory pain is preceded by damage to tissues and often causes 
increased sensitivity in the area surrounding the site of injury. This is termed 
primary hypersensitivity and is mediated by an increase in firing rate of the 
primary afferent fibre (see Millan 1999). The mechanisms by which this increased 
sensitivity is induced are complex and involve many local mediators such as 
prostaglandins, substance P and ATP. Many are important for homeostatic 
functions but when there is an excess, they actively contribute to the 
hypersensitivity (see Julius and Basbaum 2001). Adenosine is released among 
these and so it is necessary to include a brief overview of the others to help 
understand the potential role for adenosine in modulating peripheral nociception.
1.2.1.1 Bradykinin
Kinins are produced in response to tissue damage and inflammation and are 
formed by kallikrenin enzymes which are found in both plasma and tissue (see 
Moreau et al. 2005). These enzymes produce two main products from precursor
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proteins called kininogens depending on site of action, with bradykinin produced 
from high molecular weight kininogen in plasma, whereas low molecular weight 
kininogen in tissues produces kallidin (Moreau et al. 2005). These peptides are 
rapidly metabolised into des-arg%radykinin and des-arg^^kallidin respectively 
which are also physiologically active (Couture et al. 2001). Kinins mediate their 
biological actions via specific cell surface receptors termed Bi and B2 which are 
part of the G-protein coupled seven transmembrane domain superfamily of 
receptors (see Alexander et al. 2006). They primarily exert their biological 
functions through phospholipase C second messenger signal transduction 
pathways which act to increase local calcium release and activate protein kinase C 
(Linhart et al. 2003).
Bradykinin B2 receptors are constitutively expressed whereas Bi receptors are 
generally absent in normal tissues but are rapidly induced and expressed 
following tissue injury (see Couture et al. 2001). An increase in the availability of 
selective ligands for the receptor subtypes and creation of transgenic mice lacking 
either bradykinin Bi (Pesquero et al. 2000) or B2 (Borkowski et al. 1995) receptor 
subtypes have helped to further elucidate their role in inflammatory nociception.
Bradykinin is only effective after the initiation of inflammation within peripheral 
tissues as both Bi and B2 receptor knockout mice have unaltered baseline paw 
withdrawal thresholds compared to wildtype mice (Ferreira et al. 2001). However, 
following initiation of inflammation by intradermal injection of complete 
Freund’s adjuvant (CFA), bradykinin Bi receptor knockout mice had a significant 
improvement in nociceptive latency compared to wildtype mice, which was
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mimicked by the selective bradykinin Bi receptor antagonist des-Arg^-[Leu^]- 
bradykinin (Ferreira et al. 2001; Fox et al. 2003). Also, systemic administration of 
the bradykinin Bi receptor antagonist des-Arg^-[Leu^]-bradykinin reduced 
nociceptive behaviour in the formalin test, but only during the second 
inflammatory phase (Rupniak et al. 1997). Further evidence supporting the role of 
bradykinin was obtained using the selective bradykinin B% receptor ligand 
HOE 140 as systemic administration of the drug 10 minutes prior to formalin 
injection was able to reduce the response in rats during both phases of the 
formalin test (Correa and Calixto 1993). Further, electrophysiological studies 
have shown that after induction of inflammation by CFA, primary afferent fibres 
taken from rat skin became sensitive to a concentration of bradykinin that was 
previously inactive. This effect was completely reversed in the presence of the 
bradykinin Bi receptor antagonist D-Arg-[Hyp3,Thi5,8,D-phe7]-Bradykinin 
(Banik et al. 2001).
A further important consequence of bradykinin receptor activation is the induction 
of phospholipase Ai enzyme activity which releases arachidonic acid from 
precursor phospholipids and subsequently increases the production of 
prostaglandins (Hsieh et al. 2006; Hsieh et al. 2007). Indeed, it has been shown 
that prostaglandins are able to augment the inflammatory hyperalgesia produced 
by bradykinins and NSAIDs reduce bradykinin-mediated peripheral sensitization 
(Petho et al. 2001; Mayer et al. 2006).
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1.2,1,2 Prostanoids
The term prostanoids refers to a group of chemical mediators comprising 
prostaglandins (PGs), prostacyclin and thromboxane (TXA2). They are all 
produced by a common pathway from arachidonic acid containing phospholipids, 
a component of all cell membranes, and are released by the action of 
phospholipase A2 (PLA2) enzymes (Samad et al. 2002). Arachidonic acid is then 
metabolized by cyclooxygenase (COX) enzymes to produce the intermediate 
metabolites prostaglandin G2 and then prostaglandin H2 following which tissue 
specific synthase enzymes catalyse the formation of the specific end products: 
PGs, TXs and prostacyclin (Smith et al. 2000).
There are two well accepted isoforms of the COX enzymes termed COX-1 and 
COX-2. COX-1 is generally known as being constitutively expressed whereas, 
COX-2 was thought to be the inducible form, however this view is complicated 
with evidence supporting constitutive expression of COX-2 in the kidney and the 
spinal cord while COX-1 is inducible in many tissues (see Samad et al. 2002). 
Nevertheless, within peripheral tissues the general view is that COX-1 is involved 
constitutively expressed whereas COX-2 is involved with the production of 
prostanoids under inflammatory conditions.
The prostanoids exert their biological function through specific receptors, all of 
which are G-protein coupled and are members of the 7 transmembrane domain 
superfamily (see Samad et al. 2002; Zeilhofer 2006). PGE2 mediates its biological 
action via four specific cell-surface receptors which are termed EPl-4 whereas 
most other prostanoids bind to a single specific receptor, classified according to
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the ligand that is preferentially bound to it (Samad et al. 2002; Zeilhofer 2006). 
Thromboxanes bind to TP receptors, Prostaglandin D (PGD) binds to DPi and 
DP2 receptor subtypes, PGF binds to FP receptors and prostacyclin (PGI2) binds 
to IP receptors (see Samad et al. 2002). The signalling pathway that is activated 
after receptor activation is not uniform. The main pathways involve adenylyl 
cyclase, either to increase production of cAMP (EP2/4/3 receptors, DP receptor and 
IP receptor), or to reduce production of cAMP (TP) or the mobilization of calcium 
stores (EPi/3, FP and TP) (Narumiya and FitzGerald 2001).
Prostanoids are generated in response to injury or inflammation, notably PGI2 and 
PGE2 and they have been shown to sensitize, or directly activate, sensory nerve 
endings in several animal models of nociception. Although PGE2 has been used 
most frequently as a sensitizing agent in these studies PGI2 is most probably the 
most potent sensitizing agent (Smith et al. 1998). The potency of prostanoids has 
been studied using dorsal root ganglion cells cultured from rats with an 
experimental model of cystitis using cAMP formation as a measure of potency, 
and the PGI2 agonist iloprost produced a level of cAMP that was significantly 
greater than all other compounds tested (Nakae et al. 2005). This suggests that 
PGI2 is a key molecule in mediating the increased primary afferent fibre firing in 
inflammatory conditions (Smith et al. 1998). Indeed, mice lacking the IP receptor, 
at which PGI2 is the preferred endogenous ligand, have been created and are 
viable but they have altered nociceptive processing (Murata et al. 1997). IP 
receptor knockout mice had a significant reduction in number of writhes 
following injection of acetic acid which was indistinguishable from the response 
seen following pre-treatment with the NSAID indomethacin (Murata et al. 1997).
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Further, following carrageenan injection into the paw, IP receptor knockout mice 
had reduced oedema formation compared to wildtype mice and which was similar 
to the reduction seen with indomethacin pre-treatment (Murata et al. 1997; Ohishi 
et al. 1999; Yuhki et al. 2004). However, despite this apparent potency, there are 
drawbacks to the use of PGH in experimental models as it is more unstable which 
is why PGEi is favoured (Smith et al. 1998).
The role of PGEi in peripheral sensitization is not in doubt as in countless studies, 
both in vitro and in vivo, it has been shown that PGE2 is involved in the increased 
afferent excitability following the onset of inflammation. For example, application 
of PGE2 to cultured rat dorsal root ganglion cells caused an increase in the peak 
amplitude recorded using the patch clamp method and a single further stimulation 
produced a train of action potentials (England et al. 1996; Gold et al. 1996; Gold 
et al. 1998). Further, peripheral administration of PGE2 caused an approximate 
30% reduction in latency to nociceptive behaviour in models of mechanical 
hyperalgesia (Khasar et al. 1995; Aley et al. 1998; Aley and Levine 1999; Aley et 
al. 2000). Moreover, transgenic mice lacking prostaglandin E-type receptors have 
been created and display behaviour which corroborates the in vitro evidence as 
EP3 or EPi receptor knockout mice had reduced nociceptive responses in the 
formalin test but only during the second phase (Minami et al. 2001). Thus, the 
lack of EP receptors at which PGE2 is the preferred ligand is only apparent 
following the onset of inflammation which occurs during the first phase of the 
formalin test. Furthermore, EPI receptor knockout mice also had a reduced 
nociceptive response in the acetic acid writhing test with a 50% reduction 
compared to wildtype control mice (Stock et al. 2001).
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L Z L 3 A T P
ATP is a ubiquitous signalling molecule within the body and is found in all cells 
at concentrations. The existence of ATP in sympathetic neurones where it is co­
localized with noradrenaline was an important step in its recognition as a bone 
fide neurotransmitter (for historical review see Bumstock 2006). It is now known 
that ATP binds to specific receptors termed purinoceptors, which are divided into 
ionotropic P2X and metabotropic P2Y receptors. The receptors are further 
classified into subtypes based on their pharmacology with seven P2X subtypes 
now identified (P2 X1.7) and eight P2 Y subtypes (P2Y%,2,4,6,11-14). P2X receptors are 
all intrinsic ion channels with P2 Xi, P2 X2 and P2 X4 receptor subtypes having 
significant calcium permeability. The majority of P2Y receptors exert their 
biological action via the Gq/n pathway leading to activation of PLC (Ralevic and 
Bumstock 1998). ATP is readily broken down after release by ecto-nucleotidases 
which sequentially break down ATP to ADP to AMP to adenosine which is itself 
active and will be discussed later (Zimmermann et al. 1998).
The ATP receptor P2 X3 is found extensively on dorsal root ganglion cells and 
mediates a fast inward sodium current into cells (Cook et al. 1997; Dunn et al. 
2001). The release of ATP fi*om damaged cells is inevitable due to the high 
intracellular concentration and it has therefore been suggested that this is an 
important messenger in the detection of cell damage. Cook and McClesky (2002) 
used electrophysiological recordings to show that damaged cells release ATP and 
cause a fast depolarising current which was blocked by the use of receptor 
blockers such as suramin. Further, it has been shown that blockade of the P2 X3
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receptor, through use of antisense nucleotides, can ablate the role of the receptor 
in mediating ATP-induced nociceptive behaviour (Tsuda et al. 2000; Barclay et 
al. 2002). Animal behavioural studies using ATP and analogues provide further 
evidence as the P2X agonist a,p-methylene ATP is able to elicit nociceptive 
behaviour in a dose dependent fashion for up to 15 minutes after subplantar 
injection in rats (Bland-Ward and Humphrey 1997). Indeed, P2Xg receptor 
knockout mice have reduced nociceptive behaviour in the formalin test but show 
unaltered responses to acute noxious stimuli (Souslova et al. 2000). There is also 
evidence to suggest that a multimeric receptor conformation exists comprising 
P2X2/3 receptors and these are also a target for ATP released during cell damage 
(Lewis et al. 1995). There is also evidence that ATP binding to P2Xj and P2X? 
receptor subtypes is also implicated in nociceptive processes but particularly 
neuropathic pain states.
P2X? receptor knockout mice have been created, are viable and breed normally 
(Solle et al. 2001). The P2X? receptor knockout mice displayed identical 
behaviour when compared to wild type control mice in acute models of thermal 
and mechanical nociception, but there were genotype differences observed 
following partial nerve ligation, a model of neuropathic pain (Chessell et al.
2005). P2X? receptor knockout mice did not display hyperalgesia following nerve 
ligation at any of the time points investigated in the study, whereas there was 
significant hyperalgesia observed in wildtype mice measured by the weight­
bearing ratio of ipsilateral/contralateral paw and the latency to nociceptive 
response in the hotplate test (Chessell et al. 2005). The location of P2X? receptors 
is not clear although recent studies have shown that P2X? receptors are not located
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on sensory nerves but immune cells and glial cells within the spinal cord (Kukley 
et al. 2004; Sim et al. 2004; Sperlagh et al. 2006). In addition to cation 
permeability, activation of P2 X7 receptors mediates the release of the cytokine IL- 
1 p which is responsible for mediating a number of changes during inflammation 
including the induction of COX-2 in the spinal cord, and the subsequent increase 
in prostaglandin synthesis (Samad et al. 2001). This release is attenuated in P2 X7 
receptor knockout mice with ATP-mediated release of IL-ip abolished in P2 X7 
receptor knockout mice (Solle et al. 2001; Chessell et al. 2005).
A similar role is proposed for P2 X4  receptors with their expression also limited to 
immune cells and glia within the spinal cord (Guo and Schluesener 2005; Guo et 
al. 2005; Schwab et al. 2005). Following formalin injection in the rat there was 
increased expression of P2 X4 receptors on glia within the dorsal horn of the spinal 
cord, an area which receives primary afferent fibre input (Guo et al. 2005). Also, 
in models of neuropathic pain the up regulation of P2 X4 receptors on spinal cord 
glia following nerve ligation is attributed to mediating allodynia and can be 
blocked using the antagonist TNP-ATP (Tsuda et al. 2003; Nasu-Tada et al.
2006).
L2. L 4 Substance P  -  peripheral and central actions
Substance P is a peptide found on a subset of primary afferent fibres which 
selectively express the neurotrophin Nerve Growth Factor (NGF) (Basbaum and 
Woolf 1999). Substance P binds to cell surface receptors, termed neurokinin 
receptors, of which the NKi receptor subtype binds substance P preferentially.
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They are G-protein coupled receptors which mediate their action via PLC which 
enhances calcium ion release (Alexander et al. 2006). Substance P release from 
primary afferent fibres is enhanced following the onset of inflammation (Galeazza 
et al. 1995; Seybold et al. 1995; Bileviciute et al. 1997; Wick et al. 2006). This 
efferent release of substance P enhances sensitization by increasing vascular blood 
flow to the site of inflammation and facilitates migration of inflammatory cells to 
the area which release inflammatory mediators such as 5-Hydroxtrytamine (5-HT) 
and histamine and can further increase sensitization of the peripheral terminal 
(Julius and Basbaum 2001). Indeed, NKI receptor knockout mice do not display 
neurogenic inflammation following capsaicin administration (Cao et al. 1998).
However, evidence suggests there is little tonic involvement of this peptide in 
normal sensoiy processing as NKI receptor knockout mice or animals treated 
with an antibody selective for substance P containing spinal cord neurones have 
unaltered responses to mild, acute nociceptive stimuli and high intensity noxious 
stimuli was required to observe substance P release (Mantyh et al. 1997; Nichols 
et al. 1999; Dang et al. 2002; Suzuki et al. 2003). This is also suggested in mice 
lacking the Tael gene (which produces substance P) as they display reduced 
nociceptive behaviour in the formalin test in which a 5% solution of formalin was 
used, which to provide a high intensity nociceptive stimulus (Zimmer et al. 1998).
Substance P NKI receptors are located primarily in superficial areas of the dorsal 
horn, and up to 80% of the neurons in lamina I express the NKI receptor (Suzuki 
et al. 2003; Todd et al. 2005). Followingthe onset of peripheral inflammation NKI 
receptors are increased further in the spinal cord (McCarson 1999; Allen et al.
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2003; Winter and McCarson 2005). This high expression in a nociceptive-specific 
region of the spinal cord would imply an important function for NKI receptors in 
nociceptive processing and indeed studies have shown that substance P is 
necessary for the induction of NMD A glutamate receptor mediated “wind-up” (for 
further detail see section 1.3.2.2) NKI receptor knockout mice lack the increased 
“wind-up” response which is normally apparent after repetitive primary afferent 
fibre stimulation (Herrero et al. 2000; Suzuki et al. 2003). The proposed 
mechanism for substance P facilitation of the wind-up process is complex but 
involves potentiation of glutamate-induced membrane depolarization via 
subsequent substance P-mediated calcium release (Basbaum 1999; Afi-ah et al. 
2001).
L2.2 Peripheral sensitization pathways
Activation of receptors for inflammatory mediators initiates a cascade of second 
messenger pathways that increase primary afferent fibre excitability. The most 
well characterized pathways are those that activate Protein kinase A (PKA) by 
increasing cAMP levels and those that activate Protein Kinase C (PKC), following 
liberation of DAG/ increased Ca^ "^  ion levels (although a Ca^ "^  independent form, 
PKCe, has been identified).
1.2,2.1 Protein kinase A
Transgenic mice lacking the Rip regulatory subunit for PKA which is specific to 
neuronal tissue have been created, are viable and bred normally (Brandon et al. 
1995). These mice had no differences in their basal nociceptive thresholds as
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measured by acute thermal and mechanical tests; however, the mice showed a 
marked reduction in nociceptive behaviour during various inflammatory 
nociceptive tests (Malmberg et al. 1997a). Specifically, mice injected with 
formalin did not display altered nociceptive behaviour during the first phase of the 
test when compared to wildtype mice but the total time spent biting/liking the 
injected paw was significantly reduced during the second inflammatory phase 
with a complimentary reduction in paw swelling (Malmberg et al. 1997a). Further, 
injection of the catalytic subunit of PKA was able to mimic the inflammatory 
sensitization produced after injection of PGE2 which was reversed by prior 
injection of an adenylyl cyclase inhibitor ddA (2',5'-dideoxyadenosine,) and a 
PKA inhibitor WIPTIDE (Walsh inhibitor peptide) (Aley and Levine 1999).
L2.2.2 Protein kinase C
There are ten known isomers of PKC thus study of this pathway using knockout 
technology is more complex however, transgenic mice that lack individual PKC 
isomer activity have been created (Malmberg et al. 1997b; Khasar et al. 1999). 
PKC knockout mice have unaltered responses to acute thermal and mechanical 
nociceptive stimuli compared to wildtype mice, but they do exhibit reduced 
nociceptive behaviour in response to inflammatory stimuli and, reduced 
neuropathic pain (Malmberg et al. 1997b; Khasar et al. 1999). Also, in animals 
treated with PKC inhibitors the hyperalgesia produced following CFA injection 
was substantially reduced compared to vehicle treated mice (Igwe and Chronwall 
2001). PKC levels are also increased in mice treated with carrageenan, an
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inflammatory agent whch further implicates the enzyme in mediating peripheral 
sensitization (Zhou et al. 2003).
L2.2.3 Modulation o f  ion-channels
Despite their different activation pathways, both protein kinase enzymes have 
common target proteins and thus the sensitization of the peripheral afferent fibre 
converges at this point. There are a number of studies which have shown that ion 
channels underlie the increased excitability observed in primary afferent fibres 
following initiation of inflammation, in particular are the tetrodotoxin-resistant 
voltage gated. Na^ channels (TTXr) and the TRPVl channels (see Cesare and 
McNaughton 1997; Basbaum and Woolf 1999; Millan 1999; Gold and Flake 
2005; Lee et al. 2005). There is evidence to suggest the ultimate consequence of 
inflammatory mediators binding to their receptor is activation of PKA and/or PKC 
and the subsequent modulation of TTXr (England et al. 1996; Gold et al. 1996; 
Gold et al. 1998; Rush and Waxman 2004; Baker 2005) and also the TRPVl 
channel (Cesare et al. 1999; Bhave et al. 2002; Olah et al. 2002; Porro et al. 2004; 
Mohapatra and Nau 2005; Varga et al. 2006) which together increase Na"^  influx 
and Ca^  ^entry into the peripheral terminal and are responsible for the initiation of 
peripheral sensitization. For example following release of PGE2 into peripheral 
tissues. E-type prostaglandin receptors are activated, which positively modulate 
adenylyl cyclase and increase cAMP levels within the cell (see figure 5). The rise 
in cAMP levels increases the activity of PKA and there is subsequent sensitization 
of TTXr sodium channels and an increased influx of Na^ ions into the peripheral 
terminal.
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Figure 5. Sensitization o f the peripheral afferent fibre, A peripheral terminal 
showing direct-acting inflammatory mediator signalling, modulation of 
tetrodotoxin-resistant sodium channels (TTXr) and TRPVl channels is mediated 
by protein kinase A and C. This reduces the transduction threshold and initiates 
peripheral sensitization. Adapted from Basbaum and Woolf (1999).
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1.3 Glutamate
The amino-acid glutamate is the primary excitatory transmitter within the central 
nervous system and is implicated in many aspects of normal brain functions such 
as cognition, memory, learning (see Robbins and Murphy 2006). Glutamate has a 
key role in development of the central nervous system including synapse 
formation and elimination (see Bergles et al. 2000). Glutamate also has an 
important role in peripheral processes such as endocrine function, and nociception 
(Carlton 2001). Glutamate mediates its actions via both ionotropic receptors, 
which comprise NMD A, AMP A and kainate receptors and metabotropic receptors 
comprised of mGluRl-8 (Ozawa et al. 1998; Dingledine et al. 1999).
1.3.1 Glutamate uptake mechanisms
Glutamate is abundant within the central nervous system and is found in 
concentrations as high as 1 -  15mM within brain tissue whereas cerebrospinal 
fluid concentrations are typically lOpM (Danbolt 2001). There is no known 
extracellular enzyme that rapidly degrades glutamate and so the difference 
between extracellular and intracellular glutamate concentrations requires a highly 
efficient transport system to rapidly remove glutamate from the synapse (Auger 
and Attwell 2000). Blockade of glutamate transporters increases extracellular 
glutamate concentrations rapidly and blockade of glutamate receptors in the spinal 
cord causes spontaneous nociceptive behaviour and sensory hypersensitivity 
(Liaw et al. 2005; Weng et al. 2006). Further, defective uptake mechanisms are
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implicated in many disease processes such as amyotrophic lateral sclerosis, 
Alzheimer’s disease and epilepsy (Danbolt 2001; Gegelashvili et al. 2001).
There are five high-affinity glutamate transporters identified to date, which all are 
Na"^  and dependent and termed EAATl (GLAST), EAAT2 (GET), EAAT3 
(EAAC) EAAT4 and EAAT5 (Danbolt 2001; Shigeri et al. 2004). All are 
abundant in the brain but only EAATl, EAAT2 and EAAT3 have been reported 
in the spinal cord, with EAATl and 3 being localized primarily to laminae I and 
II, with EAAT2 having a more generalized expression (Bar-Peled et al. 1997). 
The transport of glutamate is driven by the electrochemical gradient of Na'*' and 
ions across the cell membrane and for the net transport of one molecule of 
glutamate, 3 Na"^  ions and 1 ion enter the cell in exchange for 1 K"*" ion (Bar- 
Peled et al. 1997; Seal and Amara 1999; Shigeri et al. 2004).
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Figure 6. Glutamate uptake mechanisms. Glutamate released from a nerve 
terminal by exocytosis and is rapidly taken up by glutamate transporters present 
presynaptically, postsynaptically and extrasynaptically by glial cells. Glial cells 
take up glutamate and conert it to glutamine in an ATP-dependent process. 
Glutamine is subsequently released from the glial cells and taken up by neurons. 
Neurons are then able to convert glutamine back to glutamate. Synaptic vesicles 
are loaded with glutamate from cytosol by means of a vesicular glutamate 
transporter. Adapted from Danbolt (2001).
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Glutamate taken up into cells may be used for metabolic purposes (protein 
synthesis, energy metabolism, ammonia fixation) or can be reused as a 
neurotransmitter (Danbolt 2001). In nerve terminals, the reuse of glutamate as a 
neurotransmitter is straightforward as glutamate is simply transported into 
synaptic vesicles by a vesicular glutamate transporter and subsequently released 
by exocytosis (Cousin and Robinson 1999; Sudhof 2004). Also, in glial cells, 
released glutamate can be taken up fi*om the extracellular fluid then converted to 
glutamine which, unlike glutamate, is inactive and thus can be released to the 
extracellular fluid, where it is taken up by neurons and hydrolyzed to regenerate 
glutamate (Pow and Crook 1996).
1.3.2 Glutamate and nociception
There is substantial evidence implicating glutamate in nociceptive processing with 
specific cell-surface receptors for glutamate located in areas of the periphery and 
spinal cord associated with nociception (Coggeshall and Carlton 1997). Of the 
many glutamate receptor subtypes identified, it is the AMP A and NMDA 
glutamate receptors that are most widely studied with regard to nociceptive 
processing and therefore it is these that shall be discussed.
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Receptor subtype
AMPA NMDA
Na"^  (all) and Ca^  ^(receptors
Na"^  and Ca^^Ion channel permeability lacking GluR2 subunit)
Agonists (glutamate site) AMPA NMDA
(s)-5-fiurowillardine homoquinolic acid
(glycine site) N/A glycine, D-serine
(polyamine site) N/A spermidine
(ion channel) N/A N/A
Antagonists (glutamate
site) NBQX D-AP5
LY293558 CGS19755 
5,7-
(glycine site) N/A dichlorokynurate
(polyamine site) N/A ifenprodil
(ion channel) N/A MK801, PCP
ketamine
Table 2. NMDA and AMPA glutamate receptor subtypes. Adapted from Alexander 
et al. (2006)
L 3.2il AMPA glutamate receptors and nociception
The AMPA glutamate receptor is so called because of its selective activation by 
the ligand a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid. In common 
with all ion channels, it was thought that AMPA glutamate receptors consisted of 
4 trans-membrane domains, however this is now know to be incorrect as the 2"  ^
transmembranous domain actually exists as a loop which does not frilly span the 
cell membrane but exits again on the intracellular side (see figure 7) (Ozawa et al. 
1998; Dingledine et al. 1999; Wollmuth and Sobolevsky 2004).
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Functional AMPA glutamate receptors are comprised from subunits termed 
GluRl-GluR4 with a large N-terminus and regulated C-terminal domains (Ozawa 
et al. 1998). All functional complexes are permeable to both sodium and 
potassium cations and those receptors lacking the GluR2 subtype are permeable to 
calcium ions (Fundytus 2001; Mayer and Armstrong 2004). All AMPA glutamate 
receptors exist is one of two splice-variants named “flip” and “flop”, of which the 
“flip” form dominates during development whereas there is little “flop” until post­
natal day 8 when there is an increase to approximately the same level as the “flip” 
form in adult brain tissue (Ozawa et al. 1998; Dingledine et al. 1999).
m
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Figure 7. Structure o f AMPA glutamate receptor.
AMPA glutamate receptor expression is ubiquitous throughout the central nervous 
system. In the spinal cord, the distribution of AMPA glutamate receptors in 
previous studies shows a high expression in superficial laminae of the dorsal horn
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(Furuyama et al. 1993; Coggeshall and Carlton 1997; Nazli and Morris 2000). 
AMPA glutamate receptors are also found on peripheral sensory neurones 
(Kinkelin et al. 2000; Carlton 2001).
It has been documented that AMPA glutamate receptors mediate fast post- 
synaptic potentials and are therefore thought to mediate the primary response to 
noxious stimulation (Tong and MacDermott 2006). This provides evidence that 
blockade of this receptor should be usefiil for modulating nociceptive processing 
and indeed, administration of AMPA glutamate receptor antagonists is analgesic. 
Administration of the selective AMPA glutamate receptor antagonist NS1209 was 
able to increase nociceptive thresholds in the hot plate test and tail flick tests 
(Blackbum-Munro et al. 2004). Antagonism of the AMPA glutamate receptor has 
also proved useful for reducing nociceptive behaviour in the formalin test in both 
the first acute phase (Hunter and Singh 1994), the second inflammatory phase 
(Davidson et al. 1997; Omote et al. 1998) or both phases (Nishiyama et al. 1999). 
Also, tt has been shown that glutamate is released in peripheral tissues in response 
to noxious stimulation and that AMPA glutamate receptors are significantly 
increase on sensory neurones following the injection of CFA into the paw 
(Carlton and Coggeshall 1999). Further, in rats which displayed an increased 
response to thermal nociceptive stimuli following injection with carrageenan, 
intraplantar injection of the AMPA glutamate receptor antagonist CNQX was able 
to significantly increase the latency to nociceptive response (Jackson et al. 1995) 
In a similar experiment, injection of CNQX to an inflamed knee joint was able to 
increase the nociceptive threshold in a test of mechanical hyperalgesia, as well as 
radiant heat (Lawand et al. 1997). These results do suggest a role for AMPA
35
glutamate receptors in mediating peripheral nociceptive pathways but AMP A 
glutamate receptors are also involved at the level of the spinal cord.
Intrathecal administration of AMP A glutamate agonists is able to increase spinal 
cord excitability and induce hyperalgesia in nociceptive tests (Aanonsen and 
Wilcox 1987; Aanonsen et al. 1990). Conversely intrathecal injection of DNQX, 
a mixed AMPA/kainite glutamate receptor antagonist reduced the thermal 
withdrawl latency following intraplantar injection of the peripheral sensitizing 
agent PGE2 (Tumbach and Randich 2002). Another important role for spinal 
AMP A glutamate receptors is their facilitation of activation of NMDA glutamate 
receptors and subsequent spinal cord sensitization. AMP A glutamate agonists 
depolarize the post-synaptic membrane which removes the Mg^^ block of NMDA 
glutamate receptor and this allows Ca^ "^  entry and initiates spinal cord 
sensitization (see Herrero et al. 2000; Szekely et al. 2002).
L3.2.2 NMDA glutamate receptors and nociception
The NMDA glutamate receptor name refers to the original ligand used for 
identification of the receptor N-methyl-D-aspartate. NMDA glutamate receptors 
have a common structure to AMP A glutamate receptors with 2 transmembrane 
domains, a hair-pin loop that doesn’t traverse the membrane followed by a final 
transmembranous domain (Ozawa et al. 1998; Dingledine et al. 1999) (see figure 
8). Functional NMDA glutamate receptors are formed fi*om an NRl subunit in 
combination with NR2A-D or NR3 subunits (Murray et al. 2000; Furukawa et al. 
2005). However, electrophysiology studies using DRG neurones cultured from
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rats provides evidence that the main subunit conformation in primary afferent 
fibres which mediate nociception are NR2B containing receptors which have high 
sensitivity to Mg^ "*" block (Li et al. 2004). This is of some importance as the 
subunit composition alters the properties of the receptor such as affinity for 
glutamate, voltage-dependent block by Mg^^ and time-course of receptor opening 
(Holden and Pizzi 2003; Li et al. 2004; Wollmuth and Sobolevsky 2004; 
Furukawa et al. 2005).
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Figure 8, Structure o f NMDA glutamate receptor
NMDA glutamate receptors function as voltage-dependent ligand-gated ion 
channels as the channel pore is blocked at resting membrane potential by Mg^* 
ions and require partial depolarization for activation (Mayer and Armstrong 
2004). Activation of the NMDA glutamate receptor permits sodium, potassium 
and, importantly, calcium to enter the cell (MacDermott et al. 1986). NMDA
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receptors require both glutamate and glycine, an essential co-agonist, to bind for 
channel activation and in addition there are modulatory binding sites including a 
polyamine binding site, zinc modulatory site and a redox binding site (Cotman et 
al. 1988).
Behavioural studies provide evidence that glutamate acting at its NMDA receptor 
is a key proponent for the transmission of nociception. Centrally applied NMDA 
agonists act to enhance nociception to noxious and non-noxious stimuli in neurons 
of the dorsal horn (Holden and Pizzi 2003). Also application of NMDA agonists 
to dorsal horn neurons will elicit spontaneous pain behaviour (Sato et al. 2003). 
Therefore, blockade of the receptor in many paradigms produces antinociception 
or analgesia. Intraperitoneal administration of a variety of NMDA receptor 
antagonists reduces nociceptive behaviour in the formalin test (Berrino et al. 
2003). Mice with a section of tail surgically removed had a long lasting (>7 days) 
reduction in nociceptive thresholds. However, pre-treatment with NMDA 
antagonists wwa able to significantly reduce the hyperalgesia so that nociceptive 
thresholds were unaltered from baseline values (Zhuo 1998). In animal models 
where the sciatic nerve has been ligated, it has been shown that there is a decrease 
in nociceptive threshold during testing with von-Frey fibres and NMDA 
antagonists are able to mask the painful effects, returning threshold to baseline 
levels (Yashpal et al. 2001).
NMDA receptors are present on pre-synaptic terminals of primary afferent fibres 
in the spinal cord and they have been shown to increase the release of substance P 
(Afiah et al. 2001). After direct application of capsaicin to the rat spinal cord via a
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microdialysis probe the levels of substance P measured by radioimmunoassay 
were increased, and this increase was significantly reduced by the addition of the 
NMDA receptor antagonist D-APV but not by the AMP A receptor antagonist 
NBQX (Afi*ah et al. 2001). The release of substance P following membrane 
depolarization will further increase membrane depolarization by release of 
intracellular calcium stores, which, in turn, further facilitates glutamate release 
and subsequent causes greater excitability of the post-synaptic membrane (Afi*ah 
et al. 2001). Continued peripheral nociceptive stimulation augments glutamate 
release in the dorsal horn of the spinal cord which can now activate NMDA 
glutamate receptors, as result of the partial depolarization of the membrane (see 
fig. 9). The activation of NMDA glutamate receptors causes an influx of calcium 
which initiates release of PGE2 into the synaptic space, which would then act back 
on their receptors and further enhance glutamate release (Vetter et al. 2001). This 
convergence of pronociceptive signals directed at increasing spinal cord neuronal 
activity via the NMDA receptor highlights its importance in nociceptive signalling 
as widespread activation of NMDA glutamate receptors following repetitive 
noxious stimulation of primary afferent fibres causes a large influx of calcium 
ions and initiates spinal cord sensitization (see Li et al. 1999a; see Herrero et al. 
2000; Fundytus 2001; Petrenko et al. 2003).
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Figure 9, Spinal cord sensitization. Following persistent noxious stimulation of 
the primary afferent fibre there is sufficient depolarization of the postsynaptic 
membrane to release the magnesium block and recruit NMDA glutamate 
receptors. This causes a large influx of calcium ions and initiates a number of 
changes including tonic activation of NMDA receptors increasing postsynaptic 
membrane excitability. The augmented release of glutamate is further facilitated 
by induction of COX-2 and the subsequent production of PGE2 which is released 
into the extracellular space and can activate pre-synaptic receptors. PKs indicate 
protein kinases which play an important role in maintaining NMDA glutamate 
channel activation by phosphorylation of the receptor.
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The best studied example of central sensitization is a process known as “wind-up” 
which is an activity-dependent increase in response to continued nociceptive input 
resulting from activation of NMDA glutamate receptors and the subsequent 
calcium ion influx (Li et al. 1999a). Wind-up is thought to he the process that 
initiates spinal cord sensitization which is manifested behaviourally as 
hyperalgesia, an enhanced response to noxious stimuli, and allodynia, a 
nociceptive response to a normally non-noxious stimulus (lASP 1994) both of 
which are characteristics of the formalin test (see Sawynok and Liu 2004). Wind­
up can be clearly demonstrated in vitro and in vivo using spinal cord nerve 
preparations in which a train of stimuli causes an increased response with each 
stimulus thereafter and blockade of NMDA glutamate receptors abolishes this 
effect (Davies and Lodge 1987; Dickenson and Sullivan 1987a; Parada et al. 
1997; Morisset and Nagy 2000). Further, the influx of calcium ions causes 
activation of proteins kinases and phosphorylation of NMDA glutamate receptors 
which abolishes the magnesium blockade at resting membrane potentials (Guo et 
al. 2002; Sato et al. 2003; Caudle et al. 2005) thus any subsequent noxious 
stimulus to peripheral tissues would elicit a greater response in the spinal cord as 
a result of both AMPA and NMDA glutamate receptor activation.
Peripheral NMDA receptors are also involved in nociception, for example 
following intraplantar administration of CFA mice have increased 
immunohistochemical labelling for the NMDA NRl receptor subunit in the paw 
which lasts up to 7 days following CFA injection, which is the time course 
associated with CFA-induced hyperalgesia (Du et al. 2003). In the same study, the 
authors investigated the effect of ImM injection of NMDA into naïve animals.
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The injection of NMDA was able to mimic the reduction in nociceptive threshold 
seen in CFA-treated animals, and this was inhibited with the selective NMDA 
glutamate receptor antagonist MK801 (Du et al. 2003). Also, injection of 
glutamate to the rat knee joint produced a reduction in nociceptive withdrawal 
latency which was similar to that observed following kaolin and carrageenan 
injection (Lawand et al. 1997). Also, Patients diagnosed with arthritis had 
elevated circulating glutamate levels when compared to control patients which 
suggests a role for altered peripheral glutamate receptors in the pathology of 
arthritis (Lawand et al. 2000; McNeamey et al. 2000). Further, peripheral 
administration of antagonists attenuates nociceptive behaviour; intraplantar 
injection of MK801 reduced biting/licking behaviour following formalin 
injection, but only during the second phase which is known to involve NMDA 
glutamate receptor activation (Davidson et al. 1997). Moreover, administration of 
the non-competitive NMDA glutamate receptor antagonist, ketamine reduced the 
effects of intra-articular administration of kaolin and carrageenan (Lawand et al.
1997).
1 ,4  A den osin e
The endogenous purine mediator adenosine regulates a wide variety of both 
neuronal and non-neuronal cellular functions such as modulation of inflammatory 
cells, sleep and nociceptive processes (Ohta and Sitkovsky 2001; Sawynok and 
Liu 2003; Basheer et al. 2004). Adenosine mediates its effects via specific cell- 
surface receptors of which four have been identified and are termed Ai, A2A, A2B, 
and A3 (Fredholm et al. 2001). Due to the widespread consequences of adenosine
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release extracellular levels of adenosine are tightly controlled by production, 
metabolism and transport mechanisms (Latini and Pedata 2001).
L 4 ,l  Formation o f  adenosine
Under physiological conditions adenosine is continuously formed via both 
intracellular and extracellular mechanisms. Intracellular formation of adenosine is 
primarily the result of dephosphorylation of adenosine 5’-monophosphate (AMP) 
via the enzyme 5’-nucleotidase which catalyzes the reaction (Sala-Newby et al. 
1999). However, another method for the production of adenosine is the hydrolysis 
of S-adenosyl-homocysteine (SAH) via the enzyme SAH hydrolase which 
releases homocysteine as a by-product (Dunwiddie and Masino 2001). A further 
indirect mechanism for formation of adenosine is the degradation of intracellular 
ATP via ATPase enzymes which sequentially dephosphorylates ATP to ADP to 
AMP where it is acted upon by the previously mentioned 5’-nucleotidase 
(Dunwiddie and Masino 2001). The formation of extracellular adenosine is 
similar to that described for intracellular conditions, however there are 
differences. Adenosine is formed primarily by the metabolism of released 
nucleotides, particularly ATP, by a family of ecto-nucleotidase enzymes, of which 
ecto-5’-nucleotidase is the major enzyme responsible for the reaction 
(Zimmermann et al. 1998). Finally both intracellular and extracellular cAMP can 
provide a physiologically relevant source of adenosine following degradation by 
phosphodiesterase activity (Brundege et al. 1997).
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1,4,2 Metabolism o f  adenosine
Metabolism of adenosine, whether intracellular or extracellular, is rapid and 
occurs via two main routes, the first, phosphorylation by adenosine kinase to 
reform AMP and the second, deamination to inosine by adenosine deaminase 
(Latini and Pedata 2001). The phosphorylation of adenosine by adenosine kinase 
to reproduce AMP reverses the action of 5’-nucleotidase enzymes and thus 
provides a constant cycling between the two compounds and allows a dynamic 
control of adenosine levels. Inhibition of adenosine kinase is able to augment 
local adenosine concentrations and can provide a useful pharmacological tool for 
modulation of various physiological processes such as nociception, stroke, and 
epilepsy (Jarvis et al. 2002; Boison 2006). Indeed, the importance of adenosine 
kinase in the metabolism of adenosine is such that adenosine kinase knockout 
mice die by postnatal day 14 with high levels of liver related disease with low 
levels of adenine nucleotides and very high levels of SAH (Boison et al. 2002).
Adenosine deaminase knockout mice also die perinatally further demonstrating 
the importance of regulating adenosine levels in vivo. However, one group has 
managed to produce a strain that is viable but with a number of pathological 
diseases, most notably, reduced lymphoid development which provides a model of 
the human condition, severe combined immune deficiency (Blackburn et al.
1998). The deamination of adenosine to inosine increases levels of inosine which 
are also active at adenosine receptors In addition, it has been shown that 
adenosine deaminase has extra-enzymatic effects and it has been shown to interact 
with the adenosine Ai receptor modulating its function (Ciruela et al. 1996; Saura 
et al. 1998).
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Figure 10, Formation, metabolism and transport o f adenosine. Adapated from 
Latini and Pedata (2001).
1,4, 3 Transport o f  adenosine
A further method of regulating adenosine concentration, in addition to 
metabolisation, is the bi-directional transport of adenosine enabling release into 
the extracellular space and also reuptake of adenosine into the cell (Thom and 
Jarvis 1996). The transporters have been designated according to their function, 
ENT for equilibrative nucleoside transporters (Griffiths et al. 1997a; Griffiths et 
al. 1997b; Yao et al. 1997) and CNT for concentrative nucleoside transporters
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(Yao et al. 1997; Loewen et al. 1999). There are two classes of ENT transporters 
identified according to their sensitivity to the inhibitor nitrobenzylthioinosine 
(NBMPR), with ENTl being sensitive to nanomolar ranges, whereas ENT2 is 
inhibited using micromolar concentrations of NBMPR (Thom and Jarvis 1996). 
ENTs mediate bi-directional, equilibrative transfer of adenosine along a 
concentration gradient to maintain equilibrium between intracellular and 
extracellular concentrations (Dunwiddie and Masino 2001). ENT pumps are found 
throughout the central nervous system and modulation of the transporters has been 
investigated as a possible novel therapeutic as blockade of the transporters can 
alter extracellular adenosine concentrations (Anderson et al. 1999; Govemo et al. 
2005; King et al. 2006).
CNTs pump adenosine in an active process along the transmembrane Na"^  gradient 
and 3 classes of pump have been characterized, and are termed CNT 1-3. CNTl 
and CNT2 transport one nucleoside per sodium ion whereas CNT3 requires 2 
sodium ions per nucleoside; all three are able to pump adenosine (Pastor-Anglada 
et al. 2005). These pumps fulfil an important function in many tissues, for 
example, in the kidney, CNT pumps actively reabsorb adenosine from the apical 
membrane which conserves adenosine whereas the toxic metabolite 2 - 
deoxyadenosine is actively secreted by the kidney (Mangravite et al. 2003). Also, 
in astrocytes, CNT pumps are present to facilitate the active uptake of adenosine 
which the authors suggest is both to facilitate nucleotide synthesis but also to 
reduce extracellular adenosine concentration and thereby limiting the modulatory 
of adenosine (Peng et al. 2005).
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L4.4 Adenosine and nociception
Adenosine is not a classical neurotransmitter but a neuromodulator and has 
complex effects on nociceptive pathways where it can act to enhance or decrease 
nociception depending on the site of administration and the receptor subtype 
activated (Sawynok 1998; Sawynok and Liu 2003). Adenosine is released directly 
from both neuronal and non-neuronal sources or it may be formed by the 
enzymatic breakdown of ATP which is itself a nociceptive transmitter (see section 
1.2.1.3). Therefore, the activation of adenosine receptors following ATP 
breakdown is secondary to the initial pro-nociceptive effects of ATP binding to P2 
receptors.
Of the four identified adenosine receptors, the Ai and A2A subtypes are located on 
neurones and have the highest affinity for adenosine with EC50 values of 
approximately 70 and 150nM respectively compared to 5100 and 6500nM for the 
A2B and A3 subtypes (Dunwiddie and Masino 2001; Sawynok and Liu 2003). 
Because of this, it is the Ai and A2A receptor subtypes that are most likely to be 
activated at physiological concentrations of adenosine and thus to be most 
relevant to nociceptive processes, nevertheless adenosine A2B and A3 receptor 
subtypes maybe indirectly involved, and will be discussed in brief.
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Receptor subtype
Ai A2A A2B A3
Adenosine EC50: '-70nM ~150nM ~5100nM ~6500nM
G-protein
interaction: Gi and Go Gs Gs and Gq Gi and Go
Transduction
pathways: i  cAMP
iCa^^
channels
TK""
channels
tP L C
Î cAMP t  cAMP 
TPLC
i  cAMP 
TPLC
Agonists: CPA CGS21680 NECA IB-MECA
Antagonists: DPCPX SCH58261 MRS 1754 MRS1191
Table 3. Adenosine Aj and Â2a receptor subtypes. Adapted from Dunwiddie and 
Masino (2001), Fredholm et al. (2001) and Sawynok and Lui (2003).
1.4.4A Adenosine Aj receptors and nociception
Adenosine Ai receptors are seven transmembrane domain, G-protein-coupled 
receptors, and are linked to a variety of transduction mechanisms (Fredholm et al. 
2001). The human adenosine Ai receptor consists of 326 amino acid residues with 
the amino-terminus positioned extracellularly whereas the carboxyl-terminal is 
positioned intracellularly (Olah and Stiles 2000; Yaar et al. 2005) There are 
cysteine residues located on the extracellular loop that are thought to participate in 
disulphide bond formation which could alter receptor conformation (Olah and 
Stiles 2000). Site-directed mutagenesis of the receptor has enabled key residues to 
be identified including a highly conserved histidine residue in position 278, which 
when replaced with leucine nearly abolished all agonist and antagonist binding 
and transmembrane domains 1 and 2  are thought to provide the ligand specificity
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for this receptor (Olah and Stiles 2000). The adenosine A% receptor is coupled to 
Gi and Go classes of G-protein which initiates activation of channels and 
inhibition of Ca^ "^  channels, in addition to inhibition of adenylyl cyclase reducing 
cAMP levels, all of which inhibit neuronal activity (Dunwiddie and Masino 
2001). Adenosine Ai receptors have a widespread expression throughout both the 
periphery and central nervous system with high expression in areas implicated in 
nociception such as the cortex, hippocampus and the dorsal horn of the spinal cord 
(Fredholm et al. 2001).
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Figure 11. Structure o f adenosine Ai receptor
Plenty of evidence exists that suggests adenosine Ai receptors are predominantly 
antinociceptive and selective activation of these receptors has been shown to be 
analgesic in many acute nociceptive tests as well as models of inflammatory pain, 
but also in neuropathic pain states (See Dickenson et al. 2000). Administration of
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the selective adenosine Ai receptor agonist CCPA significantly reduced the 
number of abdominal writhes observed in the acetic acid test, and also the 
nociceptive threshold was increased in the hot plate test (Bastia et al. 2002). 
Further, in the formalin test co-administration of the adenosine Ai receptor 
agonist CPA was able to effectively reduce nociceptive behaviour measured by 
time spent biting/licking the formalin injected paw in both phases of the test 
(Borghi et al. 2002; Yoon et al. 2005). There is also ample evidence to implicate 
the role of adenosine A% receptors in mediating the analgesic effects of opioid 
drugs as activation of adenosine Ai receptors is able to potentiate the anti­
nociceptive actions of opioids at the spinal cord (Sawynok et al. 1989; Cahill et al. 
1995; Ackley et al. 2005). The generation of adenosine Ai receptor knockout mice 
confirms the antinociceptive role for the Ai receptor as they display greater 
sensitivity to nociceptive stimuli and the effects of intrathecal morphine 
administration are reduced (Johansson et al. 2001; Wu et al. 2005).
The antinociceptive/analgesic effect observed after systemic administration of 
selective adenosine Ai receptor ligands is predominantly mediated by the 
presence of adenosine Ai receptors within the spinal cord (Sawynok and Sweeney 
1989; Nakamura et al. 1997; Sawynok 1998; Sawynok and Liu 2003). There is a 
high density of adenosine A% receptors located within the dorsal horn of the spinal 
cord (Geiger et al. 1984; Bailey et al. 2002), and in particular there is heavy 
staining of neurones within lamina II, an area rich in GAB A containing 
intemeurones (Schulte et al. 2003; Wu et al. 2003; Hantman et al. 2004). Indeed, 
direct spinal administration of lOOpM adenosine has been shown to reduce 
excitatory post-synaptic currents in rat spinal cord, reducing the excitability of
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spinal cord neurones (Lao et al. 2001) and adenosine analogues are also effective 
in reducing spinal activity following noxious stimulation (Honore et al. 1998). 
Further, administration of selective adenosine Ai receptor ligands is also, 
unsurprisingly, antinociceptive in a number of testing paradigms and confirms the 
antinociceptive role for the Ai adenosine receptor subtype. For example, 
administration of R-PIA dose-dependently inhibited spinal cord excitability and 
reduced both mustard oil sensitization and noxious stimulation of peripheral 
afferent fibres (Sumida et al. 1998; Patel et al. 2001). Similar effects were seen 
after administration of the selective adenosine Ai receptor agonist CPA, which 
was blocked by addition of the selective antagonist, DPCPX (Lao et al. 2001).
It is also assumed that adenosine Ai receptors are located at the peripheral 
terminal of primary afferent fibres although no studies to date have directly 
visualized adenosine Ai receptors on sensory fibres. However, there is 
experimental evidence to suggest their involvement in peripheral nociceptive 
processes. Indeed, intradermal injection of the selective adenosine A% receptor 
agonist CPA following PGEi-induced mechanical hyperalgesia was analgesic and 
was abolished by administration of the adenosine Ai receptor antagonist PACPX 
(Aley and Levine 1997). Also, peripheral administration of adenosine analogues 
are antinociceptive during the formalin test, with a reduction in nociceptive 
behaviour following addition of selective adenosine Ai receptor antagonist to the 
injection solution (Karlsten et al. 1992). Further, it has been shown that there is 
peripheral adenosine release fi*om sensory afferent fibres following noxious 
stimuli such as formalin injection which could activate adenosine Ai receptors 
and provide an antinociceptive effect (Liu et al. 2000; 2002a; 2002b).
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The antinociceptive use of adenosine in nociceptive testing paradigms as well as 
neuropathic pain states in animals is also evident in human subjects as it has been 
shown that adenosine produces analgesic effects in patients with both 
inflammatory and neuropathic pain, which is currently poorly treated with 
conventional analgesic medicines (see Kingery 1997; Holden and Pizzi 2003). 
Indeed, systemic administration of adenosine given at a dose of 50pg/kg/min for 
60 minutes was able to reduce tactile allodynia in patients suffering from 
neuropathic pain (Sjolund et al. 2001). In a similar trial, patients were also 
administered adenosine SOpg/kg/min for 60 minutes and pain scores were 
analyzed; adenosine significantly reduced pain scores in 4 measures and as a 
result of the trial, 3 patients experienced a long-term reduction of pain (Lynch et 
al. 2003). Intrathecal administration of adenosine has also been effective in 
reducing tactile allodynia and spontaneous pain, with 12 of 15 patients benefiting 
from the treatment with only minor side-effects (Belfrage et al. 1999). This 
provides evidence that adenosine Ai receptor agonists could potentially be a novel 
method for the treatment of neuropathic pain although side-eefcet s are a 
potential problem of which the most commonly noted are cardiovascular effects 
and a transient increase in pain at the site of injection.
L 4.4,2 Adenosine A 2A receptors and nociception
In common with the adenosine Ai receptor, and indeed with all the adenosine 
receptors, the adenosine A2A receptor is a 7-transmembrane domain G-protein 
coupled receptor (Fredholm et al. 2001). The human adenosine A2A receptor
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consists of 409 amino acids making it larger than all other adenosine receptors, 
which is due to an elongated carboxyl-terminal (Olah and Stiles 2000; Yaar et al. 
2005). Adenosine A2A receptors also have cysteine residues located on the 
extracellular loop which are thought to participate in disulphide bond formation 
and thus, could alter receptor conformation (Olah and Stiles 2000). Site directed 
mutagenesis of the receptor has enabled key residues to be identified including a 
highly conserved histidine residue in position 278, which when replaced with 
leucine nearly abolished all agonist and antagonist binding and transmembrane 
domains 5, 6  and 7 are thought to provide the ligand specificity for this receptor 
(Olah and Stiles 2000). The signal transduction mechanism identified for this 
receptor is via coupling to Gg and Goif stimulating adenylyl cyclase with a 
subsequent increase in cAMP levels within the cell (Dunwiddie and Masino 
2001).
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Figure 12. Structure o f adenosine A2A receptor.
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Unlike, the Ai receptor subtype, adenosine A2A receptors have been shown to be 
expressed within the brain but not in the spinal cord with their expression highly 
localized to the striatum, an area not recognized to be associated with supraspinal 
nociceptive processing (Kaelin-Lang et al. 1999). It has also been shown that the 
receptor is detectable in the brain but not in the spinal cord by autoradiographic 
studies using two adenosine A2A receptor specific radioligands (Bailey et al. 2002; 
Bailey et al. 2004; Kelly et al. 2004). However, in another study which failed to 
detect adenosine A2A receptor expression in the spinal cord, mRNA transcripts 
were found in dorsal root ganglion, and this would suggest transport of receptors 
to the peripheral terminal only (Kaelin-Lang et al. 1998).
Whilst the role of adenosine Ai receptors in nociceptive processes is well 
characterized, it is less so for adenosine A2A receptors, but there is mounting 
evidence to suggest that adenosine A2A receptors do have an important role to play 
in peripheral nociception. Peripheral administration of the selective adenosine A2A 
receptor agonist CGS21680 to the rat paw has been shown to reduce the 
nociceptive threshold by a maximum of 30% in a model of mechanical 
hyperalgesia (Khasar et al. 1995; Aley et al. 1998; Aley and Levine 1999; Aley et 
al. 2000). This decrease was similar to that observed for PGE2 in that study and 
can be attributed to the similar signal transduction mechanism of the two 
compounds whereby they increase cAMP levels in the peripheral terminal by 
positively coupling to adenylyl cyclase (Taiwo and Levine 1991). Further, co­
administration of CGS21680 with formalin increased the number of flinches 
observed by up to 75% in the rat whilst the adenosine A2A receptor antagonist
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DMPX reduced flinching behaviour by 32% in the same testing paradigm (Doak 
and Sawynok 1995). Administration of selective adenosine A2A antagonists have 
been shown to be antinociceptive in various models of nociception. 
Intraperitoneal injection of SCH58261 was able to increase thermal withdrawal 
thresholds in both the tail immersion and hotplate tests (Godfrey et al. 2006). 
Further, SCH58261 was also able to reduce the number of abdominal writhes 
observed after injection of acetic acid to such an extent that if given at a dose of 
lOmg/kg, the number of writhes was abolished completely (Bastia et al. 2002).
Mice lacking the adenosine A2A receptor have been generated and have helped to 
provide clarification for the role of adenosine A2A receptor in peripheral 
nociceptive processing (Ledent et al. 1997). Adenosine A2A receptor knockout 
mice were shown to have reduced responses to thermal nociceptive stimuli with 
nociceptive latency in the hot plate test being significantly increased compared to 
wildtype control animals (Ledent et al. 1997). Also, adenosine A2A receptor 
knockout mice had a significantly increased latency to tail flick, which was also 
reported by Bailey et al. (2002). Interestingly, adenosine A2A receptor knockout 
mice were also shown to have altered spinal delta and kappa opioid receptor 
binding profiles paralleled by changes in analgesic responses to delta and kappa 
receptor selective opioid agonists (Bailey et al. 2002). This finding suggests 
possible important interactions between the peripheral adenosine system and 
spinal opioid receptors. Indeed, an interaction between adenosine Ai receptors and 
mu-opioid receptors has already been identified within the spinal cord (Sawynok 
et al. 1989; Cahill et al. 1995; Ackley et al. 2005). Further, Ledent et al. (1997) 
also described reduced protachykinin mRNA levels in brain tissue from adenosine
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A2A receptor knockout mice. This could also be present within the spinal cord and 
indicate another possible interaction between the peripheral adenosine system and 
spinal cord tachykinin receptors.
Adenosine A2A receptors also have an indirect role in peripheral nociception by 
virtue of its well defined regulatory effect via activation of receptors located on 
bone-marrow derived inflammatory cells. In contrast to its proposed role as a pro­
nociceptive mediator via sensitization of primary afferent fibres, activation of 
adenosine A2A receptors has an anti-inflammatory action on inflammatory cells 
(see Hasko and Cronstein 2004). Adenosine A2A receptors are located on many 
inflammatory cells including neutrophils, basophils, mast cells, monocytes, 
macrophages and lymphocytes (see Thiel et al. 2003). In a number of studies, it 
has been shown that activation of adenosine A2A receptors located on these cells 
has an anti-inflammatory effect. The selective adenosine A2A receptor antagonist 
ZM 241385 was able to selectively block the anti-inflammatory properties of the 
selective adenosine A2A receptor agonist CGS 21680 in a model of LPS-induced 
systemic inflammation as measured by the production of the pro-inflammatory 
cytokine TNE-a (Zhang et al. 2005). Further evidence to support the role of the 
adenosine A2A receptor comes fi*om the use of adenosine A2A receptor knockout 
mice. In a similar protocol to the previously mentioned study, LPS was injected 
and the amount of serum cytokines were measured in both wildtype and adenosine 
A2A receptor knockout mice. The levels of the pro-inflammatory cytokine TNF-a, 
were significantly increased in samples from adenosine A2A receptor knockout 
mice 1 hour following LPS injection compared to wildtype mice and remained
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elevated compared to wildtype mice 16 hours after injection of LPS (Ohta and 
Sitkovsky 2001).
L4.4.3 Adenosine Â 2B receptors and nociception
Adenosine A2B receptors activate the same transduction pathway as adenosine A2A 
receptors and are positively coupled to adenylyl cyclase which increases 
intracellular levels of cAMP and increases the activation of protein kinase A. 
However, in addition adenosine A2B receptors also induce phospholipase C and 
therefore increase the production of IP3 and DAG with subsequent protein kinase 
C activation (Fredholm et al. 2001; Sawynok and Liu 2003). Adenosine A2B 
receptors are not located on neurones but have been identified on inflammatory 
cells and are considered to have in important role in mediating the pathology in 
asthma via mast cells (Feoktistov and Biaggioni 1997; Feoktistov et al. 1998).
The role of adenosine A2B receptors in nociception is not clear and there is 
contradictory evidence supporting both pro-nociceptive and anti-nociceptive 
actions and any involvement would be indirect. Nevertheless, mice administered 
the selective adenosine A2B receptor antagonist PSB1115 had increased 
nociceptive thresholds in the hot-plate and tail-immersion tests of thermal 
nociception (Abo-Salem et al. 2004; Godfrey et al. 2006). It has also been 
suggested that caffeine, the non-selective adenosine antagonist, mediates some of 
its effect via blockade of adenosine A2B receptors as the analgesia produced by 
PSB1115 was similar to that observed with caffeine (Abo-Salem et al. 2004). 
However, adenosine A2B receptor activation has been shown to reduce production 
of pro-inflammatory TNF-a (Munro et al. 1998). The regulation of inflammatory
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cell function is similar to that described for adenosine A2A receptors and during 
conditions where there is increased adenosine release adenosine A2B receptors 
would provide additional regulation of inflammatory cell action, via an increase in 
cAMP, which would be anti-nociceptive, albeit indirectly.
L4.4.4 Adenosine A 3 receptors and nociception
Adenosine A3 receptors mediate their action via Gi and Gq g-protein coupled 
receptors which act to reduce activity of adenylyl cyclase and decrease cAMP 
levels and increase phospholipase C activity and subsequently increase IP3 and 
DAG levels within the cell increasing PKC recruitment (Fredholm et al. 2001). 
Adenosine A3 receptors are not expressed on neurones but are located on 
inflammatory cells (Baraldi et al. 2000) It is for this reason that any involvement 
in nociceptive processes via activation of the receptor on inflammatory cells 
would be indirect.
Adenosine A3 receptor knockout mice have been created which has provided an 
insight into any possible effect on nociceptive pathway (Salvatore et al. 2000). 
These mice have unaltered baseline nociceptive response which is consistent with 
the lack of receptors on primary afferent fibres. However, following carrageenan 
injection, adenosine A3 receptor knockout mice did have reduced paw swelling 
and decreased nociceptive responses in the Hargreaves’s thermal withdrawal test 
(Wu et al. 2002). Also, a key property of adenosine A3 receptors is to potentiate 
mast cell degranulation and this was abolished in adenosine A3 receptor knockout 
mice following addition of the selective adenosine A3 receptor agonist 2C1-IB- 
MECA (Salvatore et al. 2000). Also, activation of adenosine A3 receptors located
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on inflammatory cells has been shown to reduce production of pro-inflammatory 
cytokines, including TNF-a and IL-12 which would be anti-inflammatory (Hasko 
et al. 1998; Szabo et al. 1998).
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L 5 Research hypothesis and aims
The research within this thesis tests the hypothesis that adenosine A2A receptors 
modulate peripheral nociceptive pathways by sensitizing primary afferent fibres 
projecting to the spinal cord. The hypothesis is evaluated using adenosine A2A 
receptor knockout mice and wildtype controls in a number of experiments 
including autoradiographic and behavioural experiments.
The aim of the experiments in chapter three is to analyze spinal cord receptor 
binding in sections taken fi*om treatment-naive mice. This enables any differences 
resulting fi*om genetic knockout of adenosine A2A receptors to be identified. 
AMPA glutamate receptors, NMDA glutamate receptors and NKl receptors for 
substance P are analyzed. In addition, uptake of [^"^C]-2-deoxyglucose into spinal 
cord sections fi*om treatment-naiVe mice is presented to identify if there are 
alterations in baseline neuronal activity within the spinal cord.
The aim of chapter four is to identify whether there are any behavioural 
differences between adenosine A2A receptor knockout mice and wildtype controls 
following the well characterized noxious stimulus of intraplantar formalin 
injection. Behavioural experiments using the formalin test are also carried out 
using wildtype mice injected with the selective adenosine A2A receptor antagonist 
SCH 58261 to mimic the loss of adenosine A2A receptors and provide further 
evidence for the role of these receptors in peripheral pain pathways. The chapter 
also aims to examine whether there is altered nociceptive processing in adenosine 
A2A receptor knockout mice by autoradiographic analysis of AMPA and NMDA
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glutamate receptors and uptake of [^"^C]-2-deoxyglucose into spinal cord sections 
following formalin injection which is used to provide an index of neuronal 
activity.
Finally, the aim of chapter five is to analyze the role of adenosine A2A receptors in 
mediating the response to a more prolonged nociceptive stimulus. Repeated PGE2 
injection followed by mechanical paw pressure is used to provide a model of 
inflammation. Autoradiography of NMDA glutamate receptors and uptake of 
[^"^C]-2-deoxyglucose into spinal cord sections are presented to provide a measure 
of primary afferent fibre activity and its influence on spinal processing.
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Chapter 2 :
General methods:
Breeding and maintenance 
of adenosine A2A receptor 
knockout mouse colony
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2.0 Breeding and maintenance o f  transgenic mouse colony
2.1 General information
All animals used throughout this thesis were male mice bred on a CDl 
background aged 8 - 1 2  weeks from the breeding colony at University of Surrey 
(see section 2.1.2). Female mice were culled at birth, male mice were genotyped 
at weaning and separated into wildtype and adenosine A%A receptor knockout mice 
and housed up to four per cage with water and standard rodent chow available ad 
libitum. Mice were kept on a 12 hour light/dark schedule in a temperature and 
humidity controlled animal housing facility. Animals were age matched 
throughout with a maximum of one week difference between groups of mice used 
for comparative experiments. All experiments described follow protocols agreed 
by the UK Home Office in accordance with the Animals (Scientific Procedures) 
Act 1985, UK.
2.1.1 Generation o f  adenosine A 2A receptor knockout mice
All transgenic mice were bom from heterozygote male and female breeding pairs 
maintained at University of Surrey although original heterozygote mice were 
obtained from Catherine Ledent’s group (IRIBHN, Belgium). Adenosine A2A 
receptor knockout mice contained a single mutation that caused dismption of the 
gene encoding the adenosine A2A receptor. The generation of the mutation is 
described in detail elsewhere (Ledent et al. 1997) but briefiy, the gene encoding 
the adenosine A2A receptor was disrupted in embryonic stem cells by replacement
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of exon-1 with a neomycin-resistance cassette. Successfully disrupted cells were 
identified through use of southern blotting. Cells were incorporated with pre­
implantation embryos from CDl strain mice and transferred to a foster uterus. The 
resultant chimeric offspring were mated with pure bred wildtype CDl mice to 
produce first generation heterozygote mice. These were then subsequently mated 
to produce wildtype, heterozygous and homozygous adenosine A2A receptor 
knockout mice.
2 .L 2  Breeding o f  adenosine A 2A receptor knockout mouse colony
To maintain CDl genetic background, wildtype female mice, pure bred on a CDl 
background were obtained from Charles River UK and paired with heterozygote 
male mice obtained from the breeding programme at University of Surrey at 
approximately 9 month intervals. Wildtype female and heterozygote males were 
paired producing litters consisting of wildtype and heterozygote male and female 
mice. Heterozygote male and female mice from these litters were then paired to 
provide an average litter of 14 mice consisting of wildtype, heterozygote and 
homozygous knockout mice lacking adenosine A2A receptors (see figure 13) in 
Mendelian proportion. Only male mice were then selected and individually 
genotyped using PCR analysis.
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Heterozygote CDl male mice X Wildtype CDl female mice 
(University of Surrey) (Charles River)
II
(genotyping)
II
Heterozygote and wildtype offspring 
Heterozygote male mice X Heterozygote female mice
I1
(genotyping)
II
Wildtype, heterozygous and homozygous knockout mice
I
I
(Cull heterozygotes except for breeding)
II
Wildtype and knockout mice
Figure 13, Breeding and genotyping procedure for generation o f adenosine Â2a 
receptor knockout mice and wildtype controls.
2,1,3 Genotyping o f  adenosine Â 2a receptor knockout mouse colony
At weaning, male mice from each litter were individually marked and a 3-5mm 
sample of tail was taken for genotype identification. DNA from each tail sample 
was stabilised, purified and extracted using a DNeasy tissue kit (Qiagen, UK) 
before being used in a PCR protocol to determine individual genotypes. Samples 
were digested using proteinase K dissolved in buffer ATL overnight in a shaking 
water bath kept at 55^C before cell lysis with buffer AL-ethanol at room 
temperature overnight. The crude extracts were pipetted onto DNeasy spin- 
columns (Qiagen, UK). The DNA was bound to the column membrane and 
washed twice using buffers AWl and AW2 according to Qiagen kit instructions. 
Elution of purified DNA was achieved using elution buffer AE before being used 
in a PCR protocol using Taq polymerase. PCR was carried out using a
65
thermocycler (GeneAmp 2700, Applied Biosystems, UK) with the following 
parameters:
Initial dénaturation: 94°C for 2 minutes
Dénaturation: 94®C for SOseconds |
Annealing: 55®C for 1 minute j repeat for 40 cycles
Elongation: 72®C for 1 minute 15 seconds j
Final extension: 72^0 for 5 minutes
The resultant PCR products were visualised by loading onto a 2% agarose 
electrophoresis gel (Invitrogen, UK) and a 200 base pair ladder was added to 
ensure the bands visualised corresponded to the anticipated size. Gels were run for 
20 minutes at 40 volts and 60 milli amps current. The unaltered wildtype allele 
was identified using primer sequences A2R3 (GT GT AC AT CAT GGT GG AGC) 
and A2D3 (CATGGTTTCGGGAGATGCAG) which produce a single band of 
572 base pairs. The knockout allele was identified using primers NeoR3 
(AAGAAGGGTGAGAACAGA) and A2D3 which produced a single band of 229 
base pairs. Heterozygous mice carrying one copy of the unaltered wildtype allele 
and one copy of the knockout allele produced two bands corresponding to each of 
the individual bands as described for wildtype or knockout mice (figure 14). Mice 
were then ear marked by cutting a small section of the lefi; ear to denote knockout 
genotype and a small section of the right ear to denote heterozygote genotype 
when appropriate. Wildtype mice were left with no ear marking.
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Wildtype allele Modified knockout allele
A2R3
,  572 bp ^ NeoR3 229 bo
A2D3 A2D3
Marker -/- +/+ -/- +/-
Lane 1 -  200 base pair ladder
Lane 2 - knockout allele 1000
(single band at ~600bp only) ’ 800 bp
Lane 3 -  wild type allele ^qq ^
(single band at ~200bp only)
Lane 4 -  knockout allele
(single band at ~600bp only)
Lane 5 -  heterozygote 200 bp
(both bands present)
400 bp
Figure 14. Separation of PCR products by gel electrophoresis.
2.1.4 Validation o f  genotyping procedure by receptor autoradiography
To ensure the validity of the genotype procedure, adenosine A%A receptor 
autoradiography was carried out on a random selection of brains of mice that had 
previously been genotyped using the procedure described above. Coronal brain 
sections were cut at the level of the caudate putamen, as this is an area known to 
be abundant in adenosine Aia receptors (see Fredholm et al. 2001). For detailed 
autoradiography procedures see section 3.2 but the procedure used, in brief was as 
follows.
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Sections were pre-incubated for 20 minutes at room temperature in 170mM Tris 
buffer (Trizma, Sigma, UK) at pH 7.4 containing ImM EDTA (Sigma, UK) and 2 
units of adenosine deaminase (ADA) / ml of pre-incubation buffer (sigma, UK). 
Sections were then washed twice in 170mM Tris buffer for 10 minutes at room 
temperature with a change of buffer for each wash. Total binding was determined 
by incubating in the pre-incubation buffer with lOmM MgCli and lOnM [^H]- 
CGS 21680 (Perkin Elmer Life Sciences, USA) for 2 hour at 25^C. Adjacent 
sections were incubated in the additional presence of 20pM NECA (Sigma, UK) 
to determine non-specific binding. Sections were then washed three times in 
170mM tris buffer for 5 minutes with a change of buffer for each wash followed 
by a final brief dip wash in distilled water at 0°C. Sections were dried in a stream 
of cool air and stored for 24 hours. Sections were apposed to [^H]-hyperfilm (GE 
healthcare, UK) for three weeks before development (see section 3.2.1). The 
resulting autoradiograms were visualized and brain sections from adenosine A%A 
knockout mice should be indistinguishable from background compared to a clear 
image from wildtype mice (see figure 15). Heterozygous mice had approximately 
50% of the total binding seen in wildtype mice. These results were then checked 
against the original genotyping results for confirmation of genotypes.
wildtype heterozygote knockout NSB
Figure 15. Pseudocolour images o f [  HJ-CGS21680 binding to wildtype, 
heterozygote and adenosine A2A receptor knockout mice brains. Validation of 
genotype analysis was carried out by autoradiography of brain sections from 
wildtype, heterozygous and homozygous knockout mice using the selective 
adenosine A%A receptor ligand [^H]-CGS21680.
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Chapter 3
Autoradiographic analysis 
of spinal cords from naive 
wildtype and adenosine A2A 
receptor knockout mice
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3.1 Introduction
3.1.1 Adenosine and nociception
The endogenous purine mediator adenosine is a neuromodulator with complex 
effects on nociceptive pathways. It can act to enhance or decrease nociception 
depending on the site of administration and the receptor subtype activated 
(Sawynok 1998; Sawynok and Liu 2003). Four adenosine receptors have been 
identified and are termed Ai, A2A, A2B, and A3 (Fredholm et al. 2001). Adenosine 
acting at its A2A receptor is thought to be pronociceptive, and this effect has been 
proposed to result from the stimulation of adenylyl cyclase resulting in an increase 
in cAMP levels in the sensory nerve terminal (Taiwo and Levine 1990; Khasar et 
al. 1995).
Indeed, adenosine A2A receptor knockout mice have a higher nociceptive 
threshold and this has been suggested to be attributable to the lack of peripheral 
adenosine A2A receptors (Ledent et al. 1997). The adenosine A2A receptor has 
been shown to have a restricted expression within the brain and is highly localised 
to the striatum, an area not thought to be associated with nociceptive processing 
(Kaelin-Lang et al. 1999). It has also been shown that the receptor is absent from 
the spinal cord in autoradiographic studies using two adenosine A2A receptor 
specific radioligands (Bailey et al. 2002; Bailey et al. 2004; Kelly et al. 2004). As 
mRNA transcripts are found in dorsal root ganglion, this would suggest transport 
of receptors to the peripheral terminal only (Kaelin-Lang et al. 1998). Mice 
lacking the adenosine A2A receptor have been shown to have reduced responses to
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thermal nociceptive stimuli in several testing paradigms (Ledent et al. 1997; 
Bailey et al. 2002; Godfrey et al. 2006). Also, behavioural studies using selective 
adenosine A2A receptor ligands have demonstrated a pronociceptive role for the 
A2A receptor, as administration of the agonist CGS 21680 causes hyperalgesia in 
the paw pressure test (Khasar et al. 1995) and the antagonists DMPX and SCH 
58261 have been shown to reduce nociceptive behaviour in animal models (Doak 
and Sawynok 1995; Godfrey et al. 2006). Further, adenosine A2A receptor 
knockout mice have altered spinal opioid receptor binding profiles paralleled by 
changes in analgesic responses to opioid agonists, suggesting possible important 
interactions between the peripheral adenosine system and spinal opioid receptors 
(Bailey et al. 2002). Indeed, another interaction does exist in the spinal cord 
between the adenosine and glutamate systems as adenosine acting via its 
inhibitory Ai receptor subtype modulates the release of glutamate, the primary 
nociceptive transmitter, in the spinal cord (see Brambilla et al. 2005; Li and 
Eisenach 2005).
3,1,2 Glutamate, substance P  and nociception
Activation of glutamate receptors located on the synaptic terminals of primary 
afferent fibres within the spinal cord has been proposed as the main mechanism 
for upward transmission of pronociceptive information from peripheral C-fibre 
nerve terminals (see Millan 1999). Administration of NMDA elicits spontaneous 
nociceptive behaviours and induces mechanical and thermal hyperalgesia 
(Aanonsen and Wilcox 1987; Kolhekar et al. 1993; Meller et al. 1996). Glutamate 
acting at its AMP A receptor mediates fast synaptic transmission within the spinal
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cord and is responsible for the response to low-threshold nociceptive stimuli 
(Dingledine et al. 1999; Tong and MacDermott 2006). In addition, application of 
AMP A to the spinal cord causes an increase in spinal cord excitability (Aanonsen 
et al. 1990). Substance P is thought to act as a co-transmitter with glutamate at 
spinal terminals as primary afferents containing substance P also contain clear 
round vesicles which label with antibodies to glutamate (De Biasi and Rustioni 
1988). Substance P acting at the NKl receptor is thought to be a necessary 
component of initiating the wind-up response mediated by NMDA glutamate 
receptors which is apparent after repetitive stimulation of primary afferent fibres 
as NKl receptor knockout mice do not exhibit wind-up phenomenon (Suzuki et 
al. 2003).
3,1,3 Use o f  radiolabelled 2~deoxyglucose to measure neuronal 
activity
The uptake of radiolabelled 2-deoxyglucose (labelled using either or [^^F]) 
was first proposed in 1977 as a measure of neuronal activity on the basis that 
cellular processes require an increased level of energy utilization compared to 
basal conditions and this increase in glucose utilization can provide a measure of 
neuronal activity (Sokoloff et al. 1977). Uptake of radiolabelled 2-deoxyglucose is 
a reliable and well-established method for the assessment of neuronal activity in 
many cells (Sharp et al. 1993; Porro and Cavazzuti 1996) and has previously been 
used to provide an index of neuronal activity in the spinal cord (Schadrack et al. 
1999). The technique relies on the failure of 2-deoxyglucose to be properly 
metabolised. In its unaltered form, glucose is metabolized as part of the glycolysis
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pathway via a series of enzyme catalysed reactions to glyceraldehyde-3 -phosphate 
which then enters the TCA cycle and is subsequently used to produce ATP. 
However, 2-deoxyglucose is not metabolized beyond the hexose kinase reaction 
and is thus “locked” within the cell due to its polar phosphate group (see figure 
16). The presence of radiolabelled 2-deoxyglucose within a cell is the marker used 
to determine the relative activity within the region of interest.
glucose
ATP Hexokinase/
glucokinaseADP " 
Glucose-6 -phosphate
2-deoxyglucose
ATP Hexokinase/
A D p ^ i  glucokinase
2-deoxyglucose-6-phosphate
Phosphohexose
isomerase <S>Phosphohexoseisomerase
Fructose-6 -phosphate
Rest of glycolysis/TCA cycle
Fructose-6 -phosphate
Rest of glycolysis/TCA cycle
Figure 16. Metabolic trapping o f 2-deoxyglucose within a cell. Glucose is 
metabolized within a cell and used as an energy substrate via a series of reactions 
(left side). However, the enzyme phosphohexose isomerase does not accept 2- 
deoxyglucose a substrate so it remains within a cell and can be used to measure 
neuronal activity.
3.1.4 Research aims
The aim of this chapter was to provide an investigation into the consequences of 
genetic deletion of adenosine A2A receptors and to provide some explanation for 
the hypoalgesia observed in these animals. As an indirect measure of nociceptive 
processing from sensory nerves, receptors for transmitters associated with
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nociception have been labelled in spinal cord sections to provide a comparative 
indirect measure of nociception between wildtype and adenosine A2A receptor 
knockout mice. NMDA and AMP A glutamate receptors have been labelled as 
glutamate is the primary nociceptive transmitter (see Millan 1999). The substance 
P NKl receptor was labelled as it is a recognised co-transmitter with glutamate at 
the central terminals of primary afferent fibres projecting to the spinal cord 
(Omote et al. 1998; Suzuki et al. 2003). In addition this chapter reports 
autoradiographic analysis of [^"^C]-2-deoxyglucose uptake into the spinal cord as a 
measure of neuronal activity within the spinal cord.
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3.2 M ethods
3.2.1 Spinal cord receptor autoradiography
3.2.1.1 Removal of spinal cord
Mice used were those described in section 2.1 and were killed by cervical 
dislocation and spinal cords were rapidly dissected out by removal of spinal 
column with sharp dissecting scissors followed by separation into four sections 
roughly corresponding to the four anatomical regions of the spinal cord (cervical, 
thoracic, lumbar and sacral). The spinal cord sections were ejected into ice-cold 
physiological saline (pH 7.4) using hydraulic pressure applied by a 5ml syringe 
(BD, UK) attached to rubber tubing. Spinal cords were frozen in isopentane 
cooled by solid carbon dioxide and stored at -80^C for no more than 6  months 
until required.
3.2.1.2 Gelatine coating of microscope slides
Slides were soaked in warm dilute detergent overnight before being washed in 
running distilled water. Slides were then removed and soaked in 90%/10% 
hydrochloric acid (lOM, VWR, UK)/ethanol (96%, VWR, UK) mix for 20 
minutes before a further wash for 5 min in running distilled water. 5 grams of 
gelatine (BDH chemicals, UK) was dissolved in 500ml of water to which 0.35 
grams of chromium potassium sulphate (Sigma-Aldrich, UK) was added. The 
solution was warmed until hot but not boiling before being filtered (Whatman 
GF/B grade) onto the prepared slides. Each rack of slides were left for
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approximately 2  min before being removed and left to dry in a cool, dry place. 
Gelatine-coated slides were kept in labelled boxes until required.
3.2.1.3 Sectioning of spinal cords
Spinal cords were removed ft"om the ft-eezer and placed into plastic containers 
(measuring 3cm x 3cm x 0.5cm) containing OCT solution (VWR, UK) and cooled 
until the OCT was solid. 20pm thick sections were cut fi'om all four anatomical 
regions of the spinal cord using a crysostat (Microm 505E, Zeiss, UK) maintained 
at -20°C and the sections were thaw-mounted onto gelatine-coated slides. Sections 
were cut for determination of total binding and adjacent sections were taken and 
used for determination of non-specific binding (NSB). In addition two further 
slides contained sections designated for scrape binding (see section 3.2.1.7). 
Slides with tissue sections were placed into storage boxes containing desiccant 
(Drierite, VWR, UK) for a period of two hours at 4®C before being frozen at - 
20°C for a period of at least 4 days to ensure adequate adhesion to the gelatine- 
coated slides prior to use.
3.2.1.4 ^ H]-MK801 binding
Sections were pre-incubated in 50mM Tris buffer (Trizma, Sigma, UK) at pH 7.4 
containing IpM glutamate, IpM glycine and IpM spermidine for 20 minutes at 
room temperature. Total binding was determined by incubating in the same buffer 
but with 70nM [^H]-MK801 (Perkin Elmer Life Sciences, USA) for 1 hour at 4°C. 
This concentration was chosen as it represents -3-4 x IQ value reported for this 
ligand in mouse spinal cord (Li et al. 1999b). Adjacent sections were incubated in
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the additional presence of ImM unlabelled MK801 (Sigma, UK) to determine 
non-specific binding. Sections were washed for a total of 60 seconds in three 
changes of ice-cold buffer before being briefiy rinsed in distilled water and then 
dried in a stream of cool air.
3.2, L 5 fH]-substance P binding
Sections were pre-incubated in 50mM Tris buffer (Trizma, Sigma, UK) at pH 7.4 
containing 0.02% BSA for 15 min at room temperature. Total binding was 
determined by incubating in Tris-HCl buffer containing 0.02% BSA (A7409, 
Sigma, UK), 3mM MnCl2, 0.04mg/L bacitracin, 0.004mg/L leupeptin, 0.002mg/L 
chymostatin with 2nM [^H]-substance P (GE Healthcare, UK) for 90 minutes at 
room temperature. Adjacent sections were incubated in the additional presence of 
IpM unlabelled substance P (Sigma, UK) to determine non-specific binding. 
Sections were washed for a total of 120 seconds in four changes of ice-cold buffer 
containing 0.02% BSA before being briefly rinsed in distilled water and then 
dried in a stream of cool air. This protocol followed that described by Mantyh et 
al. (1984).
3.2.1.6l^H]-AMPA binding
Sections were pre-incubated in 50mM Tris buffer (Trizma, Sigma, UK) at pH 7.4 
containing 50mM sodium thiocyanate for 20 minutes at room temperature. Total 
binding was determined by incubating in the same buffer but with 75nM [^H]- 
AMPA (Perkin Elmer Life Sciences, USA) for 45 minutes at room temperaure. 
Adjacent sections were incubated in the additional presence of ImM CNQX
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(Sigma, UK) to determine non-specific binding. Sections were washed for a total 
of 60 seconds in three changes of ice-cold buffer before being briefly rinsed in 
distilled water and then dried in a stream of cool air. The procedure was that 
described by Duncan et al. (2002).
3.2.1.7 Determination of scrape binding values
Scrape binding sections were used to allow an assessment of radioligand binding. 
Two slides containing sections designated for scrape binding were cut in the same 
manner as described in section 3.2.1.3 with one section taken for assessment of 
total binding and the adjacent section taken for assessment of non-specific 
binding. Scrape binding slides were processed in the same way as other slides but 
sections were not allowed to dry. Instead, sections were removed fi'om the slide 
using filter paper (Whatman, UK) and placed into a scintillation vial containing 
4.5ml scintillation fluid (Unisolve-E) and 0.5ml tissue solubliser (Triton X I00). 
The contents were vortexed and disintegrations per minute were counted in a 
scintillation counter (Perkin Elmer, UK). The counts obtained from vials 
containing non-specific binding sections were subtracted from those taken from 
total binding sections to allow an estimate of specific binding. This was necessary 
to check that radioligand binding was successful before apposing processed 
sections to radioactive sensitive film.
3.2.1.8 Autoradiography procedure and development of films
After incubation with the relevant -ligand and washing as described in 
sections 3.2.1.4 -  3.2.1.6 , slides were dried in a cool stream of air and returned to
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storage boxes containing desiccant overnight. Slides were placed into 
autoradiography cassettes (G.E. Healthcare, UK) and apposed to [^H]-Hyperfilm 
(GE Healthcare, UK) in a darkroom under red safelight conditions alongside [^H]- 
microscales of known radioactive concentrations (4048 Bq/mg -  3.74 Bq/mg, 
G.E. Healthcare, UK). Exposure times varied according to protocol for specific 
radioligand used and are detailed below in table 4. The resultant autoradiograms 
were developed in Develex developer (Patterson Scientific, UK) for 5 minutes, 
washed in distilled water for 30 seconds and fixed in Amfix (Patterson Scientific, 
UK) for 4 minutes. Films were washed for 30 minutes in distilled water then air- 
dried and labelled prior to analysis.
Radioligand Exposure time
[^H]-MK801 3 weeks
[^H]-AMPA 8 weeks
[^H]-substance P 12  weeks
Table 4. Exposure times for radioligands used.
3.2.1.9 Autoradiographic film analysis procedure
Radioligand binding was quantified by reference to [^H]-microscale standards 
(GE Healthcare, UK) and expressed as fmol/mg tissue using the calibration 
provided with the standards. Quantitative analysis of spinal cord receptor binding 
was performed using an MCID imaging system (Imaging Research, Canada). For 
each region of spinal cord examined, at least three sections were used for 
quantification. Measurements were taken from laminae I-II, III-VI, VII-IX and X 
on both left and right sides for each section analysed, therefore representing a 
duplicate determination in each section except for lamina X where only one
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measurement was taken. The procedure for determination of specific binding was 
dependent on the non-specific ligand binding image produced. If non-specific 
ligand binding was homogenous a single representative section was analysed and 
the value obtained was subtracted fi'om the total binding value to obtain specific 
binding. In cases where non-specific binding was not homogeneous, specific 
binding was obtained using digital alignment to subtract the non-specific binding 
image from the total binding image. All anatomical areas of the spinal cord were 
analysed by free-hand drawing. Spinal cord structures were referenced to the rat 
atlas of Paxinos and Watson (1986) as there is no atlas available for identifying 
mouse spinal cords sections.
3.2.3 Autoradiographic assessment o f  -2-deoxyglucose uptake
3.2.3.1 Injection o f  -2-deoxyglucose and spinal cord removal
Mice were restrained in a plastic cylinder, their tails warmed under a heat lamp 
and 3700kBq/kg [^"^C]-2-DG dissolved in sterile saline (stock concentration of 
3700kBq/ml, ARC, USA) was injected intravenously via the tail vein. Mice were 
killed by cervical dislocation after 2 0  minutes and spinal cords were rapidly 
dissected out by removal of spinal column with sharp dissecting scissors followed 
by separation into four sections roughly corresponding to the four anatomical 
regions of the spinal cord (see section 3.2.1.1). The spinal cord was ejected into 
ice-cold physiological saline (pH 7.4) using hydraulic pressure applied by a 5ml 
syringe attached to rubber tubing. Spinal cords were frozen in isopentane (cooled 
to -20°C - 30°C by solid carbon dioxide) and stored at -80°C until required.
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S.2.3.2 Autoradiography procedure and development of autoradiographic 
films
2 0 pm thick sections were cut from all four anatomical levels of the spinal cord 
(cervical, thoracic, lumbar and sacral) using a crysostat (Microm 505E, Zeiss, 
UK) and thaw-mounted onto gelatine-coated slides (see section 3.2.1.3) Sectioned 
slides were either placed into storage boxes containing desiccant (Drierite, VWR, 
UK) and kept at 4®C or immediately dried using a slide warmer before apposition 
to Kodak MR-1 film in a darkroom under red safelight conditions alongside 
microscale standards of known radioactive concentration (31.89kBq/g -  
l.llkB q/g, G.E. Healthcare, UK). Autoradiographic exposure time was three 
weeks. The resultant autoradiograms were developed in Kodak D-19 developer 
for 75 seconds, washed in distilled water containing acetic acid for 30 seconds and 
fixed in Kodak rapid fixer for 3 minutes. Films were washed in distilled water for 
30 minutes and then air-dried prior to analysis.
3,2,3.3 Autoradiographic film analysis procedure
2-DG uptake was quantified by reference to -microscale standards (GE 
Healthcare, UK) and expressed as kBq/g using the calibration provided with the 
standards. Quantitative analysis of spinal cord receptor binding was performed 
using an MCID imaging system (Imaging Research, Canada). For each region of 
spinal cord examined, a minimum of three sections were used for quantification. 
Measurements were taken from dorsal horn (laminae I -  VI), ventral horn (VII -  
IX) and lamina X on both left and right sides for each section analysed, therefore 
representing a duplicate determination in each section except for lamina X where 
only one measurement was taken. All anatomical areas of the spinal cord were
81
analysed by free-hand drawing. Spinal cord structures were referenced to the rat 
atlas of Paxinos and Watson (1986) as described previously (see section 3.2.1.9).
3.2,4 Statistical Analysis
Statistical analysis of receptor autoradiography and uptake of [^ "^ C]-2- 
deoxyglucose was carried out using two-way ANOVA for factors lamina and 
genotype. Post-hoc analysis using Fischer’s LSD test was carried out where 
appropriate. A P<0.05 was taken to be significant in all cases.
82
3.4 Results
3.4.1 NMDA glutamate receptor autoradiography
There was a wide distribution of [^H]-MK801 binding observed throughout the 
spinal cord with the highest levels in the grey matter in all levels and laminae with 
homogeneous binding throughout the laminae. Average binding throughout all 
regions of the spinal cord was 487 finol/mg (Fig. 18). Non-specific binding 
typically comprised 40% of the total binding (Fig. 17).
Two-way ANOVA revealed that there was a substantial reduction in specific 
binding of [^H]-MK801 in all regions of the spinal cords from adenosine A2A 
receptor knockout mice (P<0.05 Fig 18A-D). The greatest decrease in receptor 
binding was observed within lumbar and sacral regions of the spinal cord with a 
mean decrease of 54% to 257 finol/mg in lumbar regions and a 42% decrease to 
272 frnol/mg in sacral sections from adenosine A2A receptor knockout mice (Fig. 
18CD). There was a 40% decrease in thoracic regions where mean binding was 
reduced to 346 finol/mg in adenosine A2A receptor knockout mice (Fig. 18B). 
Cervical regions had a reduction of 29% to 327 finol/mg in adenosine A2A 
receptor knockout mice (Fig. 18A).
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Figure 17. Representative pseudocolour images o f fH]-MK801 binding to 
spinal cord sections from wildtype and adenosine Â2a receptor knockout mice. 
Total binding was determined by incubating with 70nM [^H]-MK801 for 1 hour. 
Adjacent sections were incubated in the additional presence of ImM unlabelled 
MK801 to determine non-specific binding. Sections were apposed to [^H]- 
sensitive film with microscale standards and developed after 3 weeks. 
Quantitative analysis of spinal cord receptor binding was performed using an 
MCID imaging system.
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Figure 18. Specific binding o f [  HJ-MK801 to NMDA glutamate receptors in 
spinal cord sections from wildtype and adenosine A2A receptor knockout mice 
(mean ± S.E.M., n=7-10). Measurements were taken from (A) cervical (B) 
thoracic (C) lumbar and (D) sacral regions. Two-way ANOVA revealed a 
significant difference between genotypes (P<0.05) in all regions. In all cases filled 
bars represent wild-type and open bars represent adenosine A2A receptor knockout 
mice.
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3,4,2 AMP A glutamate receptor autoradiography
Specific binding of [^H]-AMPA to AMP A glutamate receptors was present in all 
regions of the spinal cord with the highest binding detected in lamina I -  II in all 
regions of the spinal cord with a mean binding of 21.6 finol/mg compared to 11.1 
finol/mg for laminae III -  X in wildtype mice (Fig. 20). Mean binding in all 
laminae throughout the spinal cord was 14.5 finol/mg. Non-specific binding 
typically comprised less than 10% of the total binding (Fig. 19).
Two-way ANOVA revealed there was no significant overall effect of genotype 
observed on specific binding of [^H]-AMPA in any region of the spinal cords 
fi’om adenosine A2A receptor knockout mice (P>0.05 Fig. 20A-D). Mean binding 
in cervical sections from wildtype mice was 16.0 finol/mg compared to 13.6 
finol/mg in adenosine A2A receptor knockout mice (Fig. 20A). Thoracic regions 
from wildtype mice had overall mean binding of 15.1 finol/mg and thoracic 
sections from adenosine A2A receptor knockout mice had 18.8 finol/mg (Fig. 
20B). Lumbar sections had an overall mean binding value of 13.7 finol/mg 
compared with 15.9 finol/mg in adenosine A2A receptor knockout mice and in 
sacral regions 13.0 finol/mg compared with 16.6 finol/mg in adenosine A2A 
receptor knockout mice (Fig. 20CD). However, post-hoc analysis with Fischer’s 
LSD test revealed significant increases in AMP A glutamate binding in laminae I -  
II but only in lumbar and sacral sections of spinal cords from adenosine A2A 
receptor knockout mice. There was a 30% increase in lumbar regions to 25.8 
finol/mg and a 25% increase in sacral sections to 25.2 finol/mg from adenosine 
A2A receptor knockout mice (P<0.05 Fig. 20CD).
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Wildtype Aia knockout NSB
fmol/ing
Figure 19. Representative pseudocolour images of [  H]-AMPA binding to spinal 
cord sections from wildtype and adenosine A2A receptor knockout mice. Total 
binding was determined by incubating with 70nM [^H]-AMPA for 45 minutes. 
Adjacent sections were incubated in the additional presence of ImM unlabelled 
CNQX to determine non-specific binding. Sections were apposed to [^H]-sensitive 
film with microscale standards and developed after 3 weeks. Quantitative analysis 
of spinal cord receptor binding was performed using an MCID imaging system.
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Figure 20. Specific binding of fH]-AMPA to AMPA glutamate receptors in 
spinal cord sections from wildtype and adenosine A 2A receptor knockout mice 
(mean ± S.E.M., n=3-4). Measurements were taken from (A) cervical (B) thoracic 
(C) lumbar and (D) sacral regions. Two-way ANOVA revealed no significant 
difference overall between genotypes (P>0.05) in all regions, however Fischer’s 
LSD revealed significant laminae differences in lumbar and sacral regions 
(*P<0.05). Filled bars represent wild-type and open bars represent adenosine A2A 
receptor knockout mice.
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3.43 Neurokinin 1 receptor autoradiography
Specific binding of [^H]-substance P to NKl receptors was detected in all regions 
and lamina of the spinal cord. The highest binding was seen in lamina X in all 
regions of the spinal cord with an overall mean binding of 48.4 finol/mg 
compared to 25.1 finol/mg for laminae I -  IX (Fig. 22). Non-specific binding 
typically comprised less than 10% of the total binding (Fig. 21).
Two-way ANOVA revealed there were no significant genotype differences 
observed in specific binding of [^H]-substance P in any region of the spinal cords 
fi*om adenosine A2A receptor knockout mice (P>0.05 Fig. 21A-D). Mean binding 
in cervical sections from wildtype mice was 27.2 finol/mg compared to 23.4 
frnol/mg in adenosine A2A receptor knockout mice. Thoracic regions from 
wildtype mice had overall mean binding of 33.6 finol/mg and thoracic sections 
from adenosine A2A receptor knockout mice had 26.3 finol/mg. Lumbar sections 
had an overall mean binding value of 33.0 finol/mg compared with 31.8 frnol/mg 
in adenosine A2A receptor knockout mice and in sacral regions 29.8 finol/mg 
compared with 28.5 finol/mg in adenosine A2A receptor knockout mice.
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Figure 21. Representative pseudocolour images o f [  HJ-substance P  binding to 
spinal cord sections from wildtype and adenosine Aza receptor knockout mice.
Total binding was determined by incubating with 70nM [^H]-substance P for 1 
hour. Adjacent sections were incubated in the additional presence of ImM 
unlabelled substance P to determine non-specific binding. Sections were apposed 
to [^H]-sensitive film with microscale standards and developed after 3 weeks. 
Quantitative analysis of receptor binding was performed using an MCID imaging 
system.
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Figure 22. Specific binding o f [^H]-substance P to N K l receptors in spinal cord 
sections from wildtype and adenosine A 2A receptor knockout mice (mean ± 
S.E.M., n=7-10). Measurements were taken from (A) cervical (B) thoracic (C) 
lumbar and (D) sacral regions. Two-way ANOVA revealed no significant 
difference between genotypes in all regions (P>0.05). In all cases filled bars 
represent wild-type and open bars represent adenosine A2A receptor knockout 
mice.
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3.4 4 Uptake o f [^"^CJ-2-deoxyglucose
Uptake of ['"^C]-2-deoxyglucose was identified in all regions of the spinal cord 
with the highest levels in the grey matter. There was an equal distribution of 
uptake throughout cervical, thoracic and lumbar levels with an overall mean 
uptake of 2.71 kBq/g in cervical, 2.61 kBq/g in thoracic and 2.54 kBq/g in lumbar 
sections from wildtype mice. Sacral sections had a slightly reduced uptake with an 
overall mean of 1.88 kBq/g in wildtype mice (Fig. 23).
Although a similar pattern of distribution was identified in adenosine A2A receptor 
knockout mice, two-way ANOVA revealed that there was a significant genotype 
difference observed in uptake of [^^C]-2-deoxyglucose in each region of the spinal 
cord from adenosine A2A receptor knockout mice (P<0.05 Fig. 24A-D). The 
greatest mean decrease was identified in thoracic sections with a 51% decrease to 
1.26 kBq/g in adenosine A2A receptor knockout mice (Fig. 24B). There was a 
significant difference in cervical regions with a 27% decrease in uptake to 1.98 
kBq/g (Fig. 24A). In lumbar sections a 35% decrease in uptake to 1.66 kBq/g was 
observed (Fig. 24C) and in sacral regions the decrease was 48% to 0.97 kBq/g 
(Fig24D).
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Wildtype A2A Knockout
kBq/g
Figure 23. Representative pseudocolour images o f f ‘^ C]-2-deoxyglucose uptake 
into spinal cords from wildtype and adenosine A 2A receptor knockout mice. 
Mice were injected with 3700kBq/kg [^"^C]-2DG intravenously via tail vein and 
left for 20 minutes prior to killing. Spinal cord sections were apposed to ['"^C]- 
sensitive film with microscale standards and developed after 3 weeks. 
Quantitative analysis of receptor binding was performed using an MCID imaging 
system. Images are of cervical, thoracic, lumbar and sacral sections (from top -  
bottom).
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Figure 24. Uptake o f [^"^C]-2-deoxyglucose into spinal cord sections from  
wildtype and adenosine Aza receptor knockout mice (mean ± S.E.M., n=7-ll). 
Measurements were taken from (A) Cervical (B) thoracic (C) lumbar and (D) 
sacral regions. Two-way ANOVA revealed a significant difference between 
genotypes (P<0.05) in all regions. In all cases filled bars represent wild-type and 
open bars represent adenosine A2A receptor knockout mice
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3.5 Discussion
3.5.1 NMD A glutamate receptor autoradiography
Autoradiography of NMD A glutamate receptors spinal cord setions taken from 
treatment-naive mice is in agreement with previous studies which have shown 
homogenous binding throughout all laminae of the spinal cord (Furuyama et al. 
1993; Pellegrini-Giampietro et al. 1994). However, there was a significant 
reduction in binding of [^H]-MK801 in all regions and laminae of spinal cords 
from mice lacking adenosine A2A receptors compared to wildtype mice. 
Activation of adenosine A2A receptors positively modulates adenylyl cyclase and 
increases production of cAMP (see Fredholm et al. 2001). An increased level of 
cAMP in the peripheral terminal activates protein kinase A which mediates a 
reduction in nociceptive threshold for subsequent primary afferent fibre firing 
(Malmberg et al. 1997a). Thus, the loss of adenosine A2A receptors on sensory 
nerve terminals may reflect reduced peripheral sensory input to the spinal cord 
during development and be responsible for the reduction in NMDA glutamate 
receptor binding in the spinal cord of adenosine A2A receptor knockout mice. The 
decrease in NMDA glutamate receptor binding is most likely related to the 
observed hypoalgesia in this genotype as mice treated with NMDA glutamate 
receptor selective antagonists are also hypoalgesic (Jackson et al. 1995; Yashpal 
et al. 2001; Soliman et al. 2005).
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3.5.2 AMPA glutamate receptor autoradiography
The distribution of AMPA glutamate receptors within the spinal cord in this study 
agrees with previous studies that show a high expression in superficial laminae of 
the dorsal horn (Furuyama et al. 1993; Coggeshall and Carlton 1997; Nazli and 
Morris 2000). There were no overall significant genotype changes overall 
observed between wildtype and adenosine A2a receptor knockout mice. However, 
there were laminae-specific significant increases in AMPA glutamate receptor 
binding in spinal cord sections firom adenosine A2A receptor knockout mice but 
only in lumbar and sacral regions. The increased AMPA glutamate receptor 
binding in these regions could represent a compensatory change in response to the 
reduction in NMDA glutamate receptor binding. A key property of NMDA 
glutamate receptors is their permeability to calcium which initiates a number of 
changes in the post-synaptic terminal causing central sensitization (see Herrero et 
al. 2000). AMPA glutamate receptors Which lack GluR2 subunits are also 
permeable to Ca^ "^  ions and these have been shown to be located on neurones 
found in superficial layers of the dorsal horn (Engelman et al. 1999). The 
increases observed in AMPA glutamate receptor binding were identified in 
superficial laminae of lumbar and sacral regions in adenosine A2A receptor 
knockout mice and thus an increase in calcium permeable AMPA glutamate 
receptors could partially compensate for the complimentary loss in NMDA 
receptor binding in these regions.
3.5.3 N K l receptor autoradiography
Autoradiography of NKl receptors showed no significant difference between 
genotypes in any region or laminae within the spinal cords. It is surprising that
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there are no changes in another spinal cord nociceptive transmission system 
closely linked to glutamate as a previous study has shown a decreased level of 
mRNA coding for the precursor to substance P, preprotachykinin-A (PPT-A) in 
the brains of mice lacking adenosine A2A receptors (Ledent et al. 1997). However, 
a decrease in PPT-A mRNA does not directly infer changes to receptor number, 
although PPT-A gene knockout mice have increased NKl receptor mRNA in the 
brain (Zimmer et al. 1998). Nevertheless, the unaltered [^H]-substance P binding 
in the spinal cords of mice lacking adenosine A2A receptors in this study was 
perhaps to be expected as evidence suggests there is little tonic involvement of 
this peptide in normal sensory processing. NKl receptor knockout mice or 
animals treated with an antibody selective for substance P containing spinal cord 
neurones have unaltered responses to mild, acute nociceptive stimuli and high 
intensity noxious stimuli wa:s required to observe substance P release (Mantyh et 
al. 1997; Nichols et al. 1999; Dang et al. 2002; Suzuki et al. 2003).
3,5.4 Uptake o f [^"^C]-2-deoxyglucose
Mice lacking adenosine A2A receptors had a significant reduction in uptake of 
[^"^C]-2-deoxyglucose compared to wildtype control mice in all regions of the 
spinal cord. The uptake of [^"^C]-2-deoxyglucose was used to provide an index of 
neuronal activity within the spinal cord and the reduction in uptake of [^ "^ C]-2- 
deoxyglucose suggests that adenosine A2A receptor knockout mice have reduced 
sensory input to the spinal cord. This apparent reduction in afferent fibre activity 
correlates well with the reduction in NMDA glutamate receptor binding (see 
section 3.5.1) and could relate to the hypoalgesia observed in adenosine A2A
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knockout mice. The results also corroborate another study which also showed a 
reduction in uptake of [^"^C]-2-deoxyglucose as a result of a genetic reduction in 
NMDA glutamate receptor number (Duncan et al. 2002).
5.5.5 General conclusion
The decrease in spinal cord NMDA glutamate receptor binding and the reduced 
uptake of [ -2-deoxyglucose in adenosine A%A receptor knockout mice were 
most probably caused by changes occurring in peripheral nociceptive transmission 
as a consequence of the genetic knockout of adenosine A2A receptors at sensory 
terminals. The different effects caused by the lack of the adenosine A2A receptor 
on NMDA glutamate, AMPA glutamate and NKl receptor binding suggests a 
specific role for the adenosine A2A receptor in glutamate-mediated nociceptive 
pathways. Collectively, these results support a key role for adenosine A2A 
receptors in peripheral nociceptive pathways that influence spinal cord processing.
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Chapter 4
Behavioural responses to 
formalin injection and 
spinal cord neurochemistry 
in wildtype and adenosine 
A2A receptor knockout mice
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4.1 Introduction
4.1.1 Use o f  dilute formalin injection as a test o f  nociception
Injection of a dilute formalin solution into peripheral tissue elicits nociceptive 
behaviour that is reproducible and reliable. The method was first proposed by 
Dubuisson and Dennis (1977) for use in cats and rats using a rating system to 
indicate the intensity of nociceptive behaviour. The test was modified for use in 
mice (Hunskaar et al. 1985) and a new scoring method was proposed which used 
time spent biting/licking the formalin-injected paw rather than a qualitative 
system based on descriptive statements. In both rats and mice there was a biphasic 
response observed with intense nociceptive behaviour seen for up to 15 minutes 
after formalin injection followed by a period of reduced activity lasting 5 minutes. 
The second nociceptive phase which began 20 minutes after injection persisted 
until 60 minutes post injection (Dubuisson and Dennis 1977; Hunskaar et al. 
1985).
The formalin test is generally regarded as a model of tonic pain partly involving 
inflammation and is considered to be more relevant to clinical pain states than 
acute nociceptive tests (see Tjolsen et al. 1992; see Sawynok and Liu 2004). The 
first phase is associated with direct stimulation of peripheral sensory nerves 
whereas the second phase involves more complex processing involving 
inflammatory, sensitization (see Dubuisson and Dennis 1977; see Sawynok and 
Liu 2004). However the two phases are very much linked with the second phase 
being partly mediated by continuing afferent fibre input and it has been
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demonstrated that modulation of the first phase can alter the second phase. 
Indeed, administration of local anaesthetics during the first phase are able to 
reduce the second phase response but only if given prior to formalin injection 
(Dickenson and Sullivan 1987c; Puig and Sorkin 1996). The lack of effect seen if 
local anaesthetics are given after formalin injection is explained by the more 
complex nature of the second phase as it involves the release of inflammatory 
mediators. Blockade of receptors activated by inflammatory mediators has been 
able to attenuate primarily the second phase (Hunskaar and Hole 1987; Doak and 
Sawynok 1997; Choi et al. 2001; Parada et al. 2001).
4.1.2 Role o f  spinal cord AMPA and NMDA glutamate receptors in 
mediating the response to formalin injection
Glutamate is the main nociceptive transmitter released by primary afferent fibres 
entering the spinal cord as a result of noxious stimulation (see Fundytus 2001). 
The role of glutamate receptors in mediating the response to formalin is dependent 
upon which subtype is activated. It is believed that AMPA glutamate receptors are 
mostly involved in mediating responses to the first, acute phase as AMPA 
glutamate receptor antagonists are only able to block the first phase of the test 
(Hunter and Singh 1994). The second phase of the test represents more complex 
nociceptive processing within the spinal cord in which the NMDA glutamate 
receptor is thought to be a key proponent as it is implicated in initiating spinal 
cord sensitization which causes an enhancement of nociceptive behaviours 
following repeated noxious stimulation (see Baranauskas and Nistri 1998).
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The most widely used experimental model to examine spinal cord sensitization is 
a phenomenon known as ‘wind-up’ (Li et al. 1999a). The phenomenon has been 
described as, “a progressive, frequency-dependent facilitation of the responses of 
a neurone observed after the application of repetitive stimuli of constant intensity” 
(see Herrero et al. 2000). Wind-up is thought to be the process that initiates spinal 
cord sensitization, which is manifested behaviourally as hyperalgesia, an 
enhanced response to noxious stimuli, and allodynia, a nociceptive response to a 
normally non-noxious stimulus (lASP 1994) both of which are characteristics of 
the formalin test (see Sawynok and Liu 2004). Wind-up can be clearly 
demonstrated in vitro using spinal cord nerve preparations in which a train of 
stimuli causes an increased response with each stimulus thereafter and blockade 
of NMDA glutamate receptors abolishes this effect (Davies and Lodge 1987; 
Dickenson and Sullivan 1987a; Parada et al. 1997; Morisset and Nagy 2000).
There is also a large body of behavioural evidence that supports the role of 
NMDA glutamate receptors in mediating central sensitization as blockade of the 
receptor in many paradigms of persistent noxious stimulation produces 
antinociception or analgesia. For example, intraperitoneal administration of a 
variety of NMDA receptor antagonists reduces nociceptive behaviour in the 
formalin test (Berrino et al. 2003). Mice with a section of tail surgically removed 
had long lasting (>7 days) reductions in nociceptive thresholds (hyperalgesia). 
However, pre-treatment with NMDA antagonists was able to significantly reduce 
the hyperalgesia so that nociceptive thresholds were unaltered from baseline 
values (Zhuo 1998). Further, in animal models where the sciatic nerve has been 
damaged, there is a decrease in nociceptive threshold during testing with Von
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Frey fibres and NMDA antagonists are able to block the painful effects, returning 
the nociceptive threshold to baseline levels (Yashpal et al. 2001).
4,2 Research aims
In chapter three, autoradiographic analysis of spinal cord glutamate receptors and 
uptake of [^"^CJ-2-deoxyglucose into the spinal cord was carried out in naïve 
wildtype and adenosine A2A receptor knockout mice. There were differences in 
both AMPA and NMDA glutamate receptor binding in addition to reduced uptake 
of -2-deoxyglucose in adenosine A2A receptor knockout mice, providing 
evidence that adenosine A2A receptors are involved in peripheral sensory 
transmission pathways. To further test this theory, behavioural responses to the 
formalin test were studied in wildtype and adenosine A2A receptor knockout mice 
to examine whether the changes in receptor binding in treatment naïve adenosine 
A2A receptor knockout mice correlate with altered nociceptive behaviour. To 
clarify and validate the role of adenosine A2A receptors in mediating any 
behavioural changes seen during the formalin test, the selective adenosine A2A 
receptor antagonist, SCH 58261 was administered to wildtype mice to mimic the 
loss of adenosine A2A receptors prior to injection of formalin and nociceptive 
behaviour was studied. Further, in addition to behavioural data, autoradiography 
of AMPA and NMDA glutamate receptors was carried out as well as analysis of 
neuronal activity using uptake of radiolabelled 2-deoxyglucose into spinal cords 
of mice following formalin injection to identify where there is altered nociceptive 
processing in adenosine A2A receptor knockout mice.
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4.3 M ethods
4.2.1 Formalin test
4.2.1.1 Drug treatment
In experiments where mice received drug treatment in addition to formalin 
injection, the selective adenosine A2A receptor antagonist SCH 58261 (Sigma, 
UK) was given at a dose of 3mg/kg or lOmg/kg intraperitoneally 30 minutes prior 
to intraplantar injection of 20pL of 5% formalin solution (VWR, UK). SCH 
58261 was given at a dose of 3mg/kg and lOmg/kg on the basis of their selectivity 
for adenosine A2A receptors as shown in previous in vivo studies using rats and 
mice (see Ongini 1997; Monopoli et al. 1998; Bastia et al. 2002; El Yacoubi et al.
2003). SCH 58261 was dissolved in DMSO (VWR, UK) and further diluted using 
phosphate-buffered saline to produce a final concentration of 20% DMSO in the 
drug injection solution. Control mice were injected with vehicle (20% DMSO). 
All mice received either drug or vehicle control in an injection volume of 
lOml/kg.
4.2.1.2 Formalin test procedure
Intraplantar injection of formalin (5%, v/v diluted using phosphate-buffered 
saline) was used to induce nociceptive responses. Both wildtype and adenosine 
A2A receptor knockout mice were used. After one hour habituation in the test 
observation chamber (clear plastic, 25x25x15cm), mice were lightly restrained 
before receiving a single 20pl injection of 5% formalin solution subcutaneously
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into the ventral, plantar surface of the left hind paw using a 30 gauge needle 
(Becton and Dickenson, UK). Mice were immediately returned to their 
observation boxes and the total time spent biting/licking the formalin injected paw 
and the total number of flinches were recorded for 12 x 5 minute periods over a 
total of 60 minutes.
4.2.1,3 Statistical analysis
Results were analysed using two-way ANOVA for factors genotype and time with 
separate analysis carried out on each of the two phases of the formalin test. The 
first phase was defined as 0-15 minutes and the second phase as 15-60 minutes 
which is agreement with other studies (Hunskaar et al. 1985; Dickenson and 
Sullivan 1987c; Porro and Cavazzuti 1993; Borghi et al. 2002; Sawynok and Liu
2004). A probability value of P<0.05 was considered significant in all cases.
4.2.2 Spinal cord receptor autoradiography in mice injected with 
formalin
4.2.2.1 Anim al groupings and test procedure
Mice were assigned to one of two groups designated ‘early’ or ‘late’. Mice 
assigned to ‘early’ group were killed 15 minutes after formalin injection, whereas 
mice designated to ‘late’ grouping were killed 60 minutes following formalin 
injection. Spinal cords from mice belonging to the ‘late’ group were taken from 
mice used for the behavioural analysis work. Animals belonging to the ‘early’ 
group were independent of the behaviour study.
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After 1 hour habituation in the test observation chamber, mice were lightly 
restrained before receiving a single 20|xl injection of 5% formalin solution 
subcutaneously into the ventral, plantar surface of the left hind paw using a 30 
gauge needle. Mice were then immediately returned to the observation chamber 
and killed according to their grouping. Spinal cords were dissected out and 
separated into four sections roughly corresponding to the four anatomical regions 
of the spinal cord (as described in section 3.2.1.1).
4.2.2.2 ^ H]-MK801 binding
This procedure was carried out as described in chapter 3 (section 3.2.1.4). In brief, 
sections were pre-incubated in 50mM Tris buffer (Trizma, Sigma, UK) at pH 7.4 
containing IpM glutamate, IpM glycine and IpM spermidine for 20 minutes at 
room temperature. Total binding was determined by incubating in the same buffer 
but with 70nM [^H]-MK801 (Perkin Elmer Life Sciences, USA) for 1 hour at 4®C. 
Adjacent sections were incubated in the additional presence of ImM unlabelled 
MK801 (Sigma, UK) to determine non-specific binding.
4.2 2.3 f  H]-AMPA binding
This procedure was carried out as described in chapter three (section 3.2.1.5). in 
brief, sections were pre-incubated in 50mM Tris buffer (Trizma, Sigma, UK) at 
pH 7.4 containing 50mM sodium thiocyanate for 20 minutes at room temperature. 
Total binding was determined by incubating in the same buffer but with 75nM 
[^H]-AMPA (Perkin Elmer Life Sciences, USA) for 45 minutes at room
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temperature. Adjacent sections were incubated in the additional presence of ImM 
CNQX (Sigma, UK) to determine non-specific binding.
4.2.3 Uptake o f  -2-deoxyglucose following formalin injection
4.2.3.1 Animal groupings and test procedure
Mice used in these experiments were independent of those used for the 
behavioural analysis. Mice were assigned to one of four groups which were 
designated ‘early’, ‘early control’, ‘late’, or ‘late control’. Mice belonging to 
‘early’ groups were killed 20 minutes after injection of -2-deoxyglucose, 
whereas ‘late’ groups were killed 60 minutes following injection of [ '^^C]-2- 
deoxyglucose.
After 1 hour habituation in the test observation chamber mice designated to the 
‘early’ group were restrained in a plastic cylinder, their tails warmed under a heat 
lamp and 3700kBq/kg [^^C]-2-DG dissolved in sterile saline (stock concentration 
of 3700kBq/ml, ARC, USA) was injected intravenously via the tail vein. This 
procedure usually took less than one minute. Mice were returned to the test 
observation chamber for five minutes before being lightly restrained and injected 
with 20pL of 5% formalin solution into the left hind paw. Mice were returned to 
the test observation chamber for a further 15 minutes. ‘Early control’ mice 
followed the treatment protocol as above except no formalin injection was 
administered. “Late” mice were lightly restrained and received 20pL of 5% 
formalin solution into the left hind paw before being returned to the test 
observation chamber. After 15 minutes mice were lightly restrained in a plastic
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cylinder, their tails warmed under a heat lamp and 3700kBq/kg [^"^C]-2-DG 
dissolved in sterile saline (stock concentration of 3700kBq/ml, ARC, USA) was 
injected intravenously via the tail vein. Mice were returned to observation 
chamber for a further 45 minutes. “Late control” mice followed the treatment 
protocol as “late” mice but received no formalin injection.
Upon completion of the relevant time period as detailed above, mice were killed 
via cervical dislocation and spinal cords were dissected out and separated into 
four sections roughly corresponding to the four anatomical regions of the spinal 
cord and then processed for autoradiography as detailed previously (see section 
3.2.3.2.).
4.3.4 Data manipulation and Statistical Analysis
Although data was originally obtained from ipsilateral and contralateral sides of 
the spinal cord there were no significant differences observed between the two 
sides so, data were pooled. Also, because of the different control values observed 
between naïve wildtype and adenosine A2A receptor knockout mice, data were 
transformed to generate values as a % of control. These values were used for 
comparison of genotypes using two-way ANOVA. However, unpaired t-tests 
were carried out on the raw data to identify any differences between control 
values and thé data obtained at 15 and 60 minutes following formalin injection. A 
probability value P<0.05 was taken to be significant in all cases.
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4.3. Results
4.3.1 Formalin test
Following intraplantar injection of formalin (20pl, 5%) both genotypes showed a 
significant time-dependent response as measured by time spent biting/licking the 
formalin injected paw (?<0.001 Fig. 25A). In wild-type mice the characteristic 
two phase response was observed with an initial peak during the first phase of the 
test (0-15 min) followed by a further peak during the second phase (15-60 min). 
Adenosine A2A receptor knockout mice spent a significantly reduced amount of 
time biting/licking the formalin injected paw during the first phase with a decrease 
of 36% averaged over the 3 time points of the first phase (P<0.05 Fig. 25A). No 
significant difference was seen during the second phase as genotypes displayed 
identical nociceptive behaviour (P>0.05 Fig. 25A).
A similar time dependent response to formalin injection was also observed in both 
genotypes as measure by flinches, with an initial peak during the first phase and a 
second peak during the second phase with a period of quiescence occurring 
between the two (P<0.001 Fig. 25B). A significant difference between genotypes 
was identified during the first phase with a mean overall decrease of 75% 
compared to wildtype mice averaged over the 3 time points of the first phase 
(P>0.001 Fig. 25B). Additionally there was a statistical difference observed 
between genotypes during the second phase with a adenosine A2A receptor 
knockout mice having a mean overall decrease of 36% compared to wildtype mice 
averaged over the 8 time periods of the second phase (P<0.001 Fig. 25B).
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Figure 25. Behavioural response to formalin injection in wildtype and 
adenosine Â2A knockout mice (mean ± S.E.M., n = 11-13). All mice received a 
single injection of 20|xl 5% formalin solution into the left hind paw and were 
observed for 60 minutes (first phase 0-15 min, second phase 15-60 min). (A) 
Time spent biting/licking after injection. (B) Number of flinches observed after 
formalin injection. Two-way repeated measures ANOVA revealed significant 
genotype differences in both behavioural assessments during the first phase 
(P<0.05) and in the number of flinches during the second phase (P<0.001). Filled 
symbols represent wildtype and open symbols represent adenosine A2A receptor 
knockout genotype.
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4,3.2 Modulation o f  response to formalin test with SCH 58261
Vehicle-treated animals showed the same time dependent response to formalin 
injection as observed previously in wildtype mice. There was an initial period of 
biting/licking of the formalin injected paw during the first phase followed by a 
period of reduced activity before the second phase response (P<0.001 Fig. 26A). 
The selective adenosine Â2a antagonist SCH 58261 given at a dose of 3mg/kg or 
lOmg/kg i.p. attenuated the nociceptive response to the formalin test in a manner 
indistinguishable from that observed in adenosine A2A knockout mice. There was 
no significant difference between data obtained from adenosine A2A receptor 
knockout mice and those treated with SCH 58261 (one-way ANOVA, P>0.05). 
Both 3mg/kg and lOmg/kg doses significantly reduced the time spent 
biting/licking the formalin injected paw during the first phase of the test (P<0.05 
Fig. 26A). During the second phase the time spent biting/licking the formalin 
injected paw in mice treated with SCH 58261 was unaltered from the values 
observed in the vehicle-treated mice (P>0.05 Fig. 26A).
The number of flinches observed in vehicle-treated mice was also consistent with 
the values obtained in the wildtype mice with a two-phase response, consisting of 
an initial peak during first phase before a period of reduced activity followed by 
an increase in the second phase (P<0.001 Fig. 26B). SCH 58261 (3mg/kg and 
lOmg/kg) significantly reduced the number of flinches observed during both 
phases of the test (P<0.001 Fig. 26B) although the reduction did not vary 
according to the dose of SCH 58261 given. This reduction in nociception was
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similar to that seen in adenosine A2A receptor knockout mice and comparative 
analysis showed there was no significant difference between the response 
observed in adenosine A2A receptor knockout mice and those treated with SCH 
58261 (one-way ANOVA, P>0.05).
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Figure 26. Modulation o f the formalin test by SCH 58261 in wildtype mice 
(mean ± S.E.M., n = 6-7). All mice received an injection of vehicle, 3mg/kg or 
lOmg/kg SCH 58261 30 minutes prior to 20pl 5% formalin solution into the left 
hind paw and were observed for 60 minutes (first phase 0-15 min, second phase 
15-60 min). (A) Time spent biting/licking after injection. (B) Number of flinches 
observed after formalin injection. Two-way repeated measures ANOVA revealed 
significant genotype differences in both behavioural assessments during the first 
phase (P<0.05) and the number of flinches observed during the second phase 
(P<0.001), Square symbols represent vehicle control and triangular symbols 
represent mice treated with SCH 58261.
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4.33 Spinal cord AM P A glutamate receptor autoradiography
following formalin injection
There were region specific changes in AMPA glutamate receptor binding in spinal 
cords of wildtype and adenosine A2A receptor knockout mice as a result of 
intraplantar injection of formalin into the left hind paw. Two-way ANOVA 
revealed no significant genotype difference between wildtype and adenosine A2A 
receptor knockout mice in cervical, thoracic or sacral regions of the spinal cord 
(P<0.05 Fig. 28A,B,D) In wildtype mice unpaired t-test analysis revealed that 
there were no significant differences in AMPA receptor binding in cervical, 
thoracic or sacral regions of the spinal cord 15 minutes or 60 minutes following 
injection of formalin when compared to control (P>0.05, Fig. 28A,B,D,). A 
similar pattern to that observed in wildtype mice was also observed in cervical, 
thoracic and sacral sections of spinal cords taken from adenosine A2A receptor 
knockout mice. There were no significant differences observed in AMPA 
glutamate receptor binding at either 15 or 60 minutes following formalin injection 
(P>0.05,Fig28A,B,D).
Two-way ANOVA revealed a significant effect of genotype following formalin 
injection in lumbar regions of the spinal cord (P<0.05, Fig. 28C). In wildtype 
mice treated with formalin, t-test analysis revealed that there was no significant 
increase in AMPA glutamate receptor binding observed 15 minutes following 
formalin injection compared to control values (P>0.05, Fig. 28C). However, in 
wildtype mice there was a significant increase in [^H]-AMPA binding 60 minutes 
following formalin injection with a 64% increase compared to control values
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(P<0.05, Fig. 28C) This is in contrast to lumbar regions of spinal cords from 
adenosine A2A receptor knockout mice as there was no significant difference in 
[^H]-AMPA binding observed at either 15 or 60 minutes following formalin 
injection (P>0.05 Fig. 28C).
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Figure 27. Representative pseudocolour images o f [  HJ-AMPA binding to spinal 
cords o f wildtype and adenosine A2A receptor knockout mice following formalin 
injection. Naïve mice received no formalin injection. All other mice received a 
single injection of 20pl 5% formalin solution into the left hind paw. Mice were 
killed either 15 minutes or 60 minutes following formalin injection and their 
spinal cords were removed. Total binding was determined by incubating with 
70nM [^H]-AMPA for 45 minutes. Adjacent sections were incubated in an excess 
of unlabelled CNQX (ImM) to determine non-specific binding. Sections were 
apposed to [^H]-sensitive film with microscale standards and developed after 3 
weeks. Quantitative analysis of spinal cord receptor binding was performed using 
an MCID imaging system.
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Figure 28. Changes in [  HJ-AMPA binding to AMPA glutamate receptors in 
spinal cord sections from wildtype and adenosine Aza receptor knockout mice 
following formalin injection (mean ± S.E.M., n=3-5). Measurements were taken 
from (A) cervical (B) thoracic (C) lumbar and (D) sacral regions. Two-way 
ANOVA revealed a significant effect of genotype in lumbar regions of the spinal 
cord (P<0.05). Unpaired t-tests were carried out on raw data to reveal any 
differences between control values and the data obtained at 15 and 60 minutes 
after formalin injection * = P<0.05 time point vs naïve control. Filled circles 
represent wild-type and open circles represent adenosine AiA receptor knockout 
mice.
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4.3.4 Spinal cord NMD A glutamate receptor autoradiography
following formalin injection
In cervical sections, two-way ANOVA revealed a significant effect of genotype 
following injection of formalin (P<0.01, Fig. 30A). In cervical sections from 
wildtype mice there was a significant reduction in NMDA glutamate binding 15 
minutes following formalin injection when compared to control value (P<0.05, 
Fig. 30A) This reduction in [^H]-MK801 binding was maintained in spinal cords 
taken from wildtype mice 60 minutes following formalin injection (P<0.05, Fig 
30A). In cervical sections from adenosine A2A receptor knockout mice there were 
no reductions in [^H]-MK801 binding at either 15 or 60 minutes following 
formalin injection (P>0.05, Fig. 30A).
Two-way ANOVA also revealed a significant effect of genotype in thoracic 
regions of the spinal cord (P<0.05, Fig. 3 OB). In wildtype mice there was a similar 
reduction in [^H]-MK801 binding similar to that seen in cervical sections of spinal 
cords from wildtype mice following formalin injection. There was a significant 
reduction in NMDA glutamate receptor binding observed 15 minutes following 
formalin injection in thoracic regions of the spinal cord (P<0.05, Fig. 3OB). There 
was also a s i^ fican t reduction in [^H]-MK801 binding in sections taken from 
wildtype mice 60 minutes following formalin injection (P<0.05, Fig. 3OB). In 
adenosine A2A receptor knockout mice there was a significant reduction in NMDA 
glutamate binding to thoracic regions of the spinal cord 15 minutes following 
formalin injection (P<0.05, Fig. 3OB). However, there was no significant
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reduction in [^H]-MK801 binding revealed in thoracic sections 60 minutes 
following formalin injection (P>0.05, Fig. 3OB).
There was also a significant effect of genotype following formalin injection 
observed in lumbar and sacral sections of the spinal cord (P<0.01, Fig. 30C). In 
lumbar and sacral sections taken fi*om wildtype mice there was a significant 
reduction in [^H]-MK801 binding revealed in sections taken 15 minutes following 
formalin injection (P<0.05, Fig. 30C). A similar decrease was revealed in lumbar 
and sacral sections taken from wildtype mice 60 minutes following formalin 
injection (P<0.05, Fig. 30C). Unlike in thoracic sections, but similar to cervical, 
there were no significant differences in NMDA glutamate receptor binding in 
lumbar and sacral sections taken from adenosine A2A receptor knockout mice 15 
minutes following formalin injection (>0.05, Fig. 30C). In common with cervical 
and thoracic sections there was no significant difference in [^H]-MK801 binding 
60 minutes following formalin injection in lumbar and sacral sections from 
adenosine A2A receptor knockout mice (P>0.05, Fig. 30C).
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Figure 29. Representative pseudocolour images o f [  HJ-MK801 binding to 
spinal cords o f wildtype and adenosine A2A receptor knockout mice following 
formalin injection. Naïve mice received no formalin injection. All other mice 
received a single injection of 20gl 5% formalin solution into the left hind paw. 
Mice were killed either 15 minutes or 60 minutes following formalin injection and 
their spinal cords were removed. Total binding was determined by incubating with 
70nM [^H]-MK801 for 60 minutes. Adjacent sections were incubated with an 
excess of unlabelled MK801 (ImM) to determine non-specific binding. Sections 
were apposed to [^H]-sensitive film with microscale standards and developed after 
3 weeks. Quantitative analysis of spinal cord receptor binding was performed 
using an MCID imaging system.
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Figure 30, Changes in [  HJ-MK801 binding to NMDA glutamate receptors in 
spinal cord sections from wildtype and adenosine Â 2a receptor knockout mice 
following formalin injection (mean ± S.E.M., n=4-6). Measurements were taken 
from (A) cervical (B) thoracic (C) lumbar and (D) sacral regions. Two-way 
ANOVA revealed a significant effect of genotype in every region of the spinal 
cord following formalin injection (P<0.05). Unpaired t-tests were carried out on 
non-transformed data to reveal any differences between control values and the 
data obtained at 15 and 60 minutes after formalin injection * = P<0.05 time point 
vs control. Filled circles represent wild-type and open circles represent adenosine 
A2A receptor knockout mice.
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4,3,5 Uptake o f  [^"^C]-2~deoxyglucose following formalin injection
There were region specific changes in uptake of [^"^C]-2-deoxyglucose in spinal 
cords of wildtype and adenosine A2A receptor knockout mice as a result of 
intraplantar injection of formalin into the left hind paw. Two-way ANOVA 
revealed no significant effect of genotype in cervical, thoracic or sacral regions of 
the spinal cord (P>0.05, Fig. 32ABD). In wildtype mice, unpaired t-test analysis 
revealed that there were no significant differences in uptake of [^ "^ C]-2- 
deoxyglucose binding in cervical, thoracic or sacral regions of the spinal cord 15 
minutes or 60 minutes following injection of formalin when compared to control 
(P>0.05, Fig. 32A,B,D,). A similar pattern to that observed in wildtype mice was 
also observed in cervical, thoracic and sacral sections of spinal cords taken firom 
adenosine A2A receptor knockout mice as there were no significant differences 
observed in uptake of [*"^C]-2-deoxyglucose at either 15 or 60 minutes following 
formalin injection (P>0.05, Fig 32A,B,D).
In lumbar regions of wildtype mice treated with formalin there was a significant 
effect of genotype revealed by two-way ANOVA (P<0.05, Fig. 32C). In wildtype 
mice, t-test analysis revealed that there was no significant increase in uptake of 
[^"^C]-2-deoxyglucose 15 minutes following formalin (P>0.05, Fig. 32C). 
However, in wildtype mice there was a significant increase in uptake of [^ t]-2 - 
deoxyglucose 60 minutes following formalin injection compared to control 
(P<0.01, Fig. 32C) This is in contrast to sacral regions of spinal cords from 
adenosine A2A receptor knockout mice as there was no significant difference in
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uptake of [^"^C]-2-deoxyglucose observed at either 15 or 60 minutes following
formalin injection (P>0.05, Fig. 32C).
123
Wildtype A2A knockout
Early
control
Early
formalin
Late
control
Late
formalin
Figure 31. Representative pseudocolour images o f [^^C]-2-deoxyglucose uptake 
into the lumbar region of spinal cords from wildtype and adenosine A 2A receptor 
knockout mice following formalin injection. Control mice received no formalin 
injection but were administered 3700kEq/kg [^"^C]-2DG intravenously via the tail 
vein and killed either 20 minutes (early) or 45 minutes (late) after injection. ‘Early 
formalin’ group mice were administered 3700kBq/kg [ '^^C]-2DG intravenously via 
the tail vein followed 5 minutes later by a single injection of 20pl 5% formalin 
and were killed 15 minutes after injection. ‘Late formalin’ group received a single 
injection of 20gl 5% formalin solution into the left hind paw followed 15 minutes 
later by injection of [^"^C]-2DG and were then killed 45 minutes later. Spinal cords 
were removed and 20pm sections were apposed to -sensitive film with 
microscale standards and developed after 3 weeks. Quantitative analysis of 
receptor binding was performed using an MCID imaging system.
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Figure 32, Uptake o f C]-2-deoxyglucose into spinal cords from wildtype and 
adenosine A2A receptor knockout mice following formalin injection, (mean ± 
S.E.M., n=4-6) Measurements were taken from (A) cervical (B) thoracic (C) 
lumbar and (D) sacral regions. Two-way ANOVA revealed a significant effect of 
genotype in lumbar sections of the spinal cord (P<0.05). Unpaired t-tests were 
carried out non-transformed raw data to reveal any differences between control 
values and the data obtained at 15 and 60 minutes after formalin injection * = 
P<0.05 time point vs control. Filled circles represent wild-type and open circles 
represent adenosine A2A receptor knockout mice.
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4,4 Discussion
4,4,1 Formalin test and modulation o f  response with SCH 58261
In this study the response to dilute formalin injection was investigated in mice 
lacking adenosine A2A receptors to elucidate further the role of the A2A receptor in 
peripheral nociceptive processing. The results showed that there was a significant 
reduction in nociceptive behaviour as measured by both bites/licks and flinches in 
response to formalin injection during the first phase of the test, but that only 
flinches are reduced during the second phase. This pattern was similar when the 
selective adenosine A2A receptor antagonist SCH 58261 was administered to 
wildtype mice to block adenosine A2A receptors and mimic the genetic deletion of 
the adenosine A2A receptor gene. Although the response to SCH 58261 was not 
dependent on dose in the present study, 3mg/kg and lOmg/kg were chosen on the 
basis of their selectivity for the adenosine A2A receptor as shown in previous in 
vivo studies using rats and mice (see Ongini 1997; Monopoli et al. 1998; Bastia et 
al. 2002; El Yacoubi et al. 2003). In this study the selectivity of this ligand for 
adenosine A2A receptors was also suggested by the similar profile of the results 
obtained using adenosine A2A receptor knockout mice and SCH 58261.
Although the mechanisms underlying the formalin test are complex it was chosen 
as it consists of two distinct phases, with the first phase generally accepted to be 
mediated primarily by direct stimulation of peripheral sensory nerves whilst the 
second phase is due to an inflammatory component and involves more complex 
pain circuitry (Dickenson and Sullivan 1987c; Sawynok and Liu 2004). The
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reduced response observed during the first phase in adenosine A2A knockout mice 
further suggests that peripheral adenosine A2A receptors are involved in 
stimulation of nociceptive afferent fibres projecting to the spinal cord. This 
contrasts with Borghi et al. (2002b) who showed that administration of the 
selective A2A agonist CGS 21680 caused a reduction in nociceptive behaviour 
during the first phase which might suggest the receptor has an antinociceptive role 
during this phase. However in that study the drug was administered 
intraperitoneally at a dose that could also activate adenosine A% receptors which 
are antinociceptive, and the mice also showed significant sedation. The results in 
the study described in this thesis do concur with Doak and Sawynok (1995) who 
showed that administration of DMPX, an antagonist at the adenosine A2A 
receptor, reduces the behavioural response to formalin injection in rats.
The significant reduction in nociceptive behaviour observed during the second 
phase of the formalin test as measured by flinches in both adenosine A2A receptor 
knockout mice and mice treated with SCH 58261 could be linked to altered 
nociceptive signalling mediated by NMDA glutamate receptors. The NMDA 
glutamate receptor is a key proponent of the wind-up phenomenon which is 
though to initiate central sensitization. This is a feature of the second phase of the 
formalin test and occurs as a result of repetitive stimulation of primary afferent 
fibres projecting to the spinal cord. This repetitive stimulus induces activation of 
the NMDA glutamate receptor and leads to calcium entry through the receptor and 
the consequent changes in the post-synaptic membrane (Dickenson and Sullivan 
1987b; Herrero et al. 2000). Thus, the loss or blockade of adenosine A2A receptors 
would cause a reduction in nociceptive behaviour in the first phase (as
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demonstrated in this study) which is associated with reduced direct activation of 
primary afferent fibres and therefore decreased activation of NMDA glutamate 
receptors located centrally and this is likely to result in a reduction of the central 
sensitization which characterizes the second phase.
The difference between behavioural measures seen during the second phase of the 
test was a surprising result although it may indicate that flinches are a more 
sensitive measure of nociception than time spent biting/licking the formalin- 
injected paw. .Flinching is regarded as a more robust measure of nociception and 
less influenced by motor behaviour (see Sawynok and Liu 2004). In addition, 
these authors suggest the mechanisms of the two behaviours are distinct, as 
chronic implantation of an intrathecal catheter abolished bting/licking of the 
formalin injected paw, whilst flinching behaviour was unaltered (Sawynok and 
Reid 2003). Further, differential modulation by some drugs has been previously 
observed. For example, systemic administration of tricyclic anti-depressants 
increased flinching behaviour whereas time spent biting/licking was reduced 
(Sawynok and Reid 2001).
4,4,3 Ipsilateral and contralateral differences in spinal cord 
neurochemistry following formalin injection
In this present study there were no significant differences observed between 
ipsilateral and contralateral sides of the spinal cord despite formalin injection into 
only one of the hind paws. It should be noted that there were absolute differences 
observed between ipsilateral and contralateral sides of the spinal cord in NMDA
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and AMPA glutamate receptor binding and uptake of [^"^C]-2-deoxyglucose, 
however they were not significant. In many studies there are examples of 
contralateral activation of spinal cord neurones despite initiation of unilateral 
inflammation (see Shenker et al. 2003). Also, in previous behavioural studies 
using the formalin test, it has been documented that nociceptive behaviour was 
directed at the contralateral paw with a bilateral increase in uptake of [^ "^ C]-2 - 
deoxyglucose to the contralateral side of the spinal cord (Aloisi et al. 1993). 
Further, in a study that used a model of adjuvant-induced monoarthritis to 
measure uptake of [^"^C]-2-deoxyglucose into the spinal they found uptake of 
[^"^C]-2-deoxyglucose to be significantly altered after 2 days but to a similar extent 
on both sides with no significant differences. They did, however, report 
significant ipsilateral/contralateral side differences but only after 14 days of 
persistent nociceptive input to the spinal cord (Schadrack et al. 1999). It is, 
therefore perhaps not so surprising that the results reported in this study do not 
have significant ipsilateral/contralateral side differences.
4,4,4 Spinal cord AMPA glutamate receptor autoradiography 
following formalin injection
There is evidence to suggest that AMPA glutamate receptors have a role in 
mediating the response to the first phase of the formalin test but not the second as 
antagonists have only attenuated the first phase (Hunter and Singh 1994). 
However, in the present study, there were no changes in [^H]-AMPA binding 15 
minutes following formalin injection, which might be attributed to the rapid 
trafficking of AMPA receptors at the cell-surface membrane (Luscher et al. 1999).
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Behaviourally there exists a period of quiescence between the two phases of the 
formalin test and AMPA receptors may have returned to control levels by 15 
minutes because there is evidence to suggest that changes to AMPA glutamate 
receptor expression at the cell-surface membrane are rapid (Luscher et al. 1999).
In other studies it has been shown that selective AMPA glutamate receptor 
antagonists were effective in modulating the behavioural response to both phases 
of the formalin test (Nishiyama et al. 1999) and this is also suggested in the 
current study as AMPA glutamate receptor binding was shown to be increased in 
wildtype mice, but only in lumbar regions, 60 minutes following formalin 
injection. It has been shown that there is recruitment of AMPA receptors to the 
plasma membrane following noxious stimulation (Galan et al. 2004) and therefore 
the increase in [^H]-AMPA binding seen in wildtype mice in the current study 
correlates well with the increased nociceptive behaviour observed during the 
formalin test. The region specific increase in AMPA glutamate receptor binding 
can be attributed to the observation that sensory fibres from the hind paws 
primarily enter lumbar regions of the spinal cord and therefore it is likely that 
lumbar regions would receive the primary nociceptive input (Takahashi et al. 
2003).
It has been documented that AMPA glutamate receptors exhibit fast post-synaptic 
potentials and are thought to mediate the primary response to noxious stimulation 
(Tong and MacDermott 2006). Therefore, the lack of any significant difference 
compared to control values in AMPA receptor binding to spinal cord sections 
fi-om adenosine A2A receptor knockout mice further suggests a role for these
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receptors in nociception as the lack of any change in [^H]-AMPA binding in 
adenosine A2A knockout mice is indicative of reduced nociceptive input to the 
spinal cord.
4,4.5, spinal cord NMDA glutamate receptor autoradiography 
following formalin test
In this study there were a number of changes in NMDA glutamate receptor 
binding occurring as result of formalin injection at both 15 and 60 minutes after 
injection but only in wildtype mice. There were no significant differences in 
NMDA glutamate binding when compared to control values in spinal cords of 
adenosine A2A receptor knockout mice. The behavioural response observed in the 
second phase of the formalin test is mediated by more complex inflammatory 
processes involving continuing peripheral nerve activation but also central 
processes such as ‘wind-up’ facilitation of the response to sensory nerve activity 
which involves NMDA glutamate receptors (Tjolsen et al. 1992; Sawynok and 
Liu 2004).
There was a significant reduction in NMDA glutamate receptor binding observed 
in all regions and laminae of the spinal cord obtained 15 and 60 minutes after 
formalin injection but only in wildtype mice. There are a number of possible 
causes for the altered receptor binding observed in the present study such as 
receptor desensitization; decreased channel opening; an increase in Mg^ "^ ; reduced 
glutamate release; inhibitory mechanisms and receptor internalization. However 
in the current study it is most probably due to receptor desensitization as a result
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of sustained nociceptive input from primary afferent fibres following formalin 
injection. Although down-regulation of NMDA glutamate receptors cannot be 
ruled out per se there is experimental evidence that NMDA glutamate receptors 
are relatively stably expressed at the cell-surface membrane compared to AMPA 
glutamate receptors (Luscher et al. 1999; Roche et al. 2001; Groc and Choquet 
2006). However, NMDA glutamate receptor desensitization does occur and 
following sustained noxious stimulation, it has been well documented that 
phosphorylation of NMDA glutamate receptors does occur and leads to increased 
channel opening, a process known to be involved in mediating spinal cord 
sensitization (Guo et al. 2002; Sato et al. 2003; Brenner et al. 2004). The 
increased activation of NMDA glutamate receptors and the subsequent influx of 
cations, particularly calcium ions, has previously been shown to trigger NMDA 
glutamate receptor desensitization (Kyrozis et al. 1996; Vissel et al. 2002; Jackson 
et al. 2006). Further, in wildtype mice there was increased AMPA glutamate 
receptor binding observed 60 minutes following formalin injection and this is 
likely to indicate continuing nociceptive input to the spinal cord and thus would 
explain the continuing receptor desensitization observed in lumbar sections from 
wildtype mice.
There were no significant differences in NMDA glutamate binding to spinal cords 
from adenosine A2A receptor knockout mice when compared to control values. 
Indeed, in lumbar and sacral regions there were absolute increases in [^H]-MK801 
60 minutes following formalin injection, albeit not significantly different from 
control values. This represents a wholly different response to formalin injection 
compared to wildtype mice, which still had a significant reduction in [^H]-MK801
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60 minutes following formalin injection. The increase in [^H]-MK801 binding 
most probably reflects normal sensory signalling via phosphorylated NMDA 
glutamate receptors in the spinal cords from adenosine A2A receptor knockout 
mice as nociceptive behaviour was still observed in these mice 60 minutes 
following formalin injection. Phosphorylation of the NMDA receptor increases 
channel opening and therefore the increased [^H]-MK801 binding most probably 
reflects this as MK801 binds to the open channel pore complex (see Dingledine et 
al. 1999).
The differences in NMDA glutamate receptor binding were most probably a 
consequence of greater nociceptive input to the spinal cord in wildtype mice, 
when compared with adenosine A2A receptor knockout mice, as they displayed 
greater nociceptive behaviour in the formalin test (see section 4.2.1). Therefore, 
the increased nociceptive input to the spinal cord in wildtype mice compared to 
adenosine A2A receptor knockout mice would cause greater activation of NMDA 
glutamate receptors and a greater influx of calcium ions which would induce 
greater desensitization and thus might be responsible for the reductions in [^H]- 
MK801 binding observed in wildtype mice compared to adenosine A2A receptor 
knockout mice.
4,4.6 Uptake o f [^"^C]-2-deoxyglucose (2-DG) after formalin injection
In this study there was no significant increase in uptake of [^ -2 -deoxyg lucose 
in wildtype mice 15 minutes following formalin compared to control values. This 
is perhaps slightly surprising as wildtype mice do show a significant increase in
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nociceptive behaviour during the first phase of the formalin test compared to 
adenosine A2A receptor knockout mice.
In other studies employing this method, there was a significant increase in uptake 
of [^'^C]-2-deoxyglucose following formalin injection in rats and mice in both the 
early and late phases of the test (Porro et al. 1991; Aloisi et al. 1993; Porro and 
Cavazzuti 1993). In the present study there was only a significant difference in 
uptake of [''^C]-2-deoxyglucose compared to control values in lumbar regions 60 
minutes after formalin injection in wildtype mice. However, a confounding factor 
in the previous studies was the survival time after injection of [^ "^ C]-2 - 
deoxyglucose. Animals were injected with [^"^C]-2-deoxyglucose and left for 45 
minutes before being killed, regardless of which phase was being investigated and 
so the 45 minute period would then include up to 30 minutes of the second phase 
of the test. In the present study mice were injected with [^"^C]-2-deoxyglucose and 
killed 15 minutes following formalin injection to better correspond to the early 
phase of the test and therefore provide a better analysis of neuronal activity. It has 
also been demonstrated that intravenous administration of [^"^C]-2-deoxyglucose 
causes a plateau of plasma levels “in less than 10 minutes” (Meibach et al. 1980) 
so the extended survival time in previous studies is not necessary as quantitative 
results have indeed been obtained with survival times of as little as only 5 minutes 
following intravenous injection of [ -2-deoxyglucose (Duncan et al. 2002).
However, a genotype difference does exist in uptake of [^-2-deoxyglucose in 
spinal cords taken 15 minutes following formalin injection but as the results were 
expressed as % of control this difference is not obvious. Control values refer to
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uptake of [^"^C]-2-deoxyglucose in naïve mice and wildtype mice were shown to 
have a significantly higher uptake of -2 -deoxyglucose compared to adenosine 
A2A receptor knockout mice (see 3.4.4). So, in this study the lack of any 
significant time-dependent change in uptake of [^-2-deoxyglucose 15 minutes 
following formalin injection in either wildtype or adenosine A2A receptor 
knockout mice merely mirrors the uptake of [^"^C]-2-deoxyglucose observed in 
naïve mice. Therefore, wildtype mice do have increased uptake of [^ "^ C]-2- 
deoxyglucose compared to adenosine A2A receptor knockout mice 15 minutes 
following formalin injection.
The results in the present study showed a significant increase in uptake of [^ "^ C]-2- 
deoxyglucose in wildtype mice in lumbar regions of the spinal cord 60 minutes 
following formalin injection although it should be noted that there were also 
absolute increases in uptake of -2 -deoxyglucose in cervical, thoracic and 
sacral regions, but they were not significant. In contrast, there were no increases 
in uptake of [^"^C]-2-deoxyglucose in any region of the spinal cord mice 60 
minutes following formalin injection in adenosine A2A receptor knockout. The 
lack of any significant difference in uptake of -2 -deoxyglucose in any region 
of the spinal cord when compared to control values correlates well with the 
reduced nociceptive behaviour observed in adenosine A2A receptor knockout mice 
in the formalin test. The uptake of -2-deoxyglucose into the spinal cord was 
used as an indirect measure of neuronal activity as [^"^C]-2-deoxyglucose is taken 
up by metabolically active cells as if  it was glucose but it is ‘trapped’ within a cell 
and can therefore provide evidence of changes in neuronal activity following the 
injection of formalin (Sokoloff et al. 1977; Duncan and Stumpf 1991). Therefore,
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the reduction in uptake of [^"^C]-2-deoxyglucose indicates reduced nociceptive 
input into the spinal cord in adenosine A%A receptor knockout mice.
4.5, General conclusion
In this chapter both behavioural and autoradiographic analysis of spinal cord 
NMD A and AMP A glutamate receptors as well as uptake of [ -2-dexyglucose 
has been carried out using wildtype and adenosine A%A receptor knockout mice 
following formalin injection to clarify the role of adenosine A2A receptors in 
peripheral nociceptive pathways. There were reduced behavioural responses 
observed in both phases of the formalin test and this can be correlated with the 
altered spinal cord glutamate receptor binding and reduced uptake of [^^C]-2- 
deoxyglucose in adenosine A2A receptor knockout mice. The changes observed 
were indicative of reduced nociceptive input to the spinal cord from peripheral 
sensory nerves as a consequence of genetic deletion of adenosine A2A receptors. 
Further, the reduction in nociceptive behaviour observed in the formalin test can 
be mimicked using the selective adenosine A2A receptor antagonist SCH 58261, 
which suggests that blockade of adenosine A2A receptors located on peripheral 
terminals of primary afferent fibres could be a novel treatment for the reduction of 
inflammatory pain.
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Chapter 5
spinal cord neurochemistry 
following repetitive 
nociceptive stimulation 
after PGE2 induced 
inflammatory sensitization
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5.1 Introduction
5.1.1 Role o f  PGE2 in sensitizing peripheral nociceptive pathways
Prostaglandin E2 (PGE2) is a single member of a family of chemical mediators 
called prostanoids which comprise prostaglandins, prostacyclin and 
thromboxanes. They are all produced by a common pathway from arachidonic 
acid which is a ubiquitous component of all phospholipids in cell membranes and 
is released by the action of the phospholipase A2 enzymes (see Samad et al. 2002). 
Arachidonic acid is then metabolised by cyclooxygenase (COX) enzymes 
producing the intermediate metabolites PGG2 and PGH2. Tissue specific enzymes 
then catalyse the formation of specific end products of which PGE2 is the most 
used experimentally (Smith et al. 2000). PGE2 exerts its biological function via 
four specific cell surface G-protein coupled receptors termed EP% -  EP4. The 
mechanism of action proposed for PGE2 acting through EP receptors is not 
uniform and depends upon the receptor subtype activated. However, the primary 
mechanism of action is excitatory with receptor subtypes EP2, and EP4 causing 
stimulation of adenylyl cyclase and enhancing the production of cAMP and PKA 
and EPi inducing mobilization of calcium stores and activation of PEG. However, 
the EP3 receptor subtype is negatively coupled to adenylyl cyclase and thus 
reduces production of cAMP (see Narumiya and FitzGerald 2001).
All prostanoids are generated in response to injury or inflammation, but PGE2 has 
been used most frequently to generate hyperalgesia (Smith et al. 1998). PGE2 has
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been shown to sensitize, or directly activate sensory nerve endings in several 
animal models of nociception, both in vitro and in vivo where it has been 
implicated in mediating the increased afferent excitability as a consequence of the 
onset of inflammation. For example, application of PGE2 to cultured rat dorsal 
root ganglion cells caused an increase in the peak amplitude recorded using the 
patch clamp method and also mediated a train of action potentials, a characteristic 
of sensitization (England et al. 1996). The authors suggested the mechanism of 
action was via enhancement of tetrodotoxin-sensitive sodium channels (TTXr) 
activated by protein kinase A (PKA) as blockade of PKA abolishes the inward 
sodium current. However, this is not the only postulated mechanism of action on 
primary afferent cells as addition of PGE2 to the cell culture medium of DRG cells 
causes an increase in intracellular calcium most probably via its action at EP% 
receptors (Linhart et al. 2003).
In vivo behavioural studies corroborate the in vitro evidence as EP3 or EPi 
receptor knockout mice have reduced nociceptive responses in the formalin test 
but only during the second phase which involves inflammatory mechanisms 
(Minami et al. 2001). Thus, the lack of EP receptors at which PGE2 is the 
preferred ligand is only prevalent after the establishment of inflammation which 
occurs during the first phase of the test. Furthermore, EPi receptor knockout mice 
have a reduced response in the writhing test with a 50% reduction compared to 
wildtype mice of the same strain (Stock et al. 2001).
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5.1.2 Regulatory role o f  adenosine Â 2a receptors located on 
inflammatory cells
After the onset of inflammation, following the initial release of inflammatory 
mediators such as PGE2, there is recruitment of inflammatory cells many of which 
express adenosine A2A receptors including neutrophils, basophils, mast cells, 
monocytes, macrophages and lymphocytes (see Thiel et al. 2003). There is a well 
defined regulatory role for adenosine A2A receptors located on bone-marrow 
derived inflammatory cells (see Hasko and Cronstein 2004). In a number of 
studies, it has been shown that activation of adenosine A2A receptors located on 
these cells has an inhibitory effect. The selective adenosine A2A receptor 
antagonist ZM 241385, was able to selectively block the anti-inflammatory 
properties of the selective adenosine A2A receptor agonist CGS 21680 in a model 
of EPS-induced systemic inflammation, as measured by the production of the pro- 
inflammatory cytokine TNF-a (Zhang et al. 2005). Despite the authors not 
studying nociceptive behaviour in these animals it is likely that the loss of 
adenosine A2A receptors located on inflammatory cells is pro-nociceptive rather 
than anti-nociceptive. This is in opposition to the possible analgesic effects from 
loss or blockade of adenosine A2A receptors located on peripheral sensory fibres. 
Further evidence to support the role of the adenosine A2A receptor comes from the 
use of adenosine A2A receptor knockout mice. In a similar protocol to the 
previously mentioned study, EPS was injected and the amount of serum cytokines 
were measured in both wildtype and adenosine A2A receptor knockout mice. The 
levels of the pro-inflammatory cytokine TNF-a, were significantly increased in 
samples from adenosine A2A receptor knockout mice 1 hour following EPS
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injection compared to wildtype mice and remained elevated compared to wildtype 
mice 16 hours after injection of LPS (Ohta and Sitkovsky 2001).
5.1.3 Research aims
The results presented in chapter four showed adenosine A2A receptor knockout 
mice had reduced nociceptive behaviour following formalin injection. There were 
also complimentary changes in glutamate receptor autoradiography and uptake of 
[^"^C]-2-deoxyglucose into the spinal cord of adenosine A2A receptor knockout 
mice indicative of reduced sensory input to the spinal cord. The experiments in 
this chapter seek to extend that work by examining the effects of repeated PGE2 
injection and mechanical paw pressure in wildtype and adenosine A2A receptor 
knockout mice. Autoradiography of spinal cord NMDA glutamate receptors 
provided a measure of increased peripheral input to the spinal cord in wildtype 
and adenosine A2A receptor knockout mice as spinal cord NMDA glutamate 
receptors are key mediators of spinal cord sensitization (Herrero et al. 2000; 
Fundytus 2001). Also, uptake of [^"^C]-2-deoxyglucose into spinal cord sections 
fi-om wildtype and adenosine A2A receptor knockout mice was carried out to 
examine whether there were any increases in spinal cord neuronal activity. 
Collectively, these experiments will aim to identify if  adenosine A2A receptors are 
involved in sensitization of the peripheral terminal of sensory fibres.
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5.2. M ethods
5.2.1 Spinal cord NMDA glutamate receptor autoradiography 
following repeated PGE2 injection and mechanical paw pressure
5.2.1.1 Treatment procedure
Mice were designated to one of five experimental groupings which corresponded 
to the time point at which they were to be killed (see table 5). The five groupings 
were naïve control, t=0, t+3, t+6 and t+24 with groups of mice identified by tail 
markings. Mice were left for 30 minutes prior to commencement of the 
experiment once assigned to a grouping. Naïve control mice received no injection 
before being killed. Mice designated to treatment groups were lightly restrained 
before receiving lOOng of prostaglandin-E2 (Sigma, UK) into the dorsal surface of 
the left hind paw using a 30 gauge needle (Becton and Dickenson, UK). PGE2 was 
dissolved in ethanol and further diluted using phosphate-buffered saline so that 
the amount of ethanol injected was less than 1%. Drug injection volume was 5pi. 
Peripheral injection of PGE2 has been widely used as an inflammatory mediator to 
model mechanical hyperalgesia following inflammation (see Khasar et al. 1995; 
Aley et al. 1998; Aley and Levine 1999; Aley et al. 2000) and thus PGE2 injection 
followed by mechanical paw pressure provides a reliable and robust inflammatory 
stimulus.
Mice received a total of three injections of PGE2 into the same paw with a one 
hour interval between injections. One hour after each PGE2 injection and
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immediately prior to subsequent injection, mice were lightly restrained and the 
injected paw was placed under a pressure bar. The apparatus used was an Ugo- 
Basile analgesymeter modified by Kitchen (1984). It was used to provide a 
linearly increasing pressure force with a preset maximum of 250g. Mice received 
a total of three applications of up to 250g pressure to the paw with one hour 
intervals between applications. Upon completion of the final paw pressure this 
time was designated t=0 and defined the start of the neurochemical analysis. Mice 
were killed at the relevant time point according to the group they were assigned 
(see table 5.).
Timings (Experiment time point) Procedure
Start of experiment Animals from naive group killed 
Injection of PGE2
One hour after start Application of paw pressure 
2 nd pQ£^ injection
Two hours after start 2°  ^Application of paw pressure 
r^d injection
Three hours after start (t=0) 3^  ^Application of paw pressure 
Animals from t=0 group killed
Six hours after start (t+3) Animals from t+3 group killed
Nine hours after start (t+6) Animals from t+6 group killed
Twenty-seven hours after start (t+24) Animals from t+24 group killed
Table 5. Time course for repeated injection ofPGE2 and mechanical paw pressure.
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5.2.L2 NMDA glutamate receptor autoradiography
Spinal cords were dissected out and separated into four sections roughly 
corresponding to the four anatomical regions of the spinal cord (as described in 
section 3.2.1.1). Mice spinal cords were then used for NMDA glutamate receptor 
autoradiography. The methodology used has been described in detail elsewhere 
(see 3.2.1.4) but briefly, sections were pre-incubated in 50mM Tris buffer 
(Trizma, Sigma, UK) at pH 7.4 containing IpM glutamate, IpM glycine and IpM 
spermidine for 20 minutes at room temperature. Total binding was determined by 
incubating in the same buffer but with 70nM [^H]-MK801 (Perkin Elmer Life 
Sciences, USA) for 1 hour at 4°C. Adjacent sections were incubated in the 
additional presence of ImM unlabelled MK801 (Sigma, UK) to determine non­
specific binding.
5.2.2. Uptake o f  [^"^C]-2-deoxyglucose (2-DG) following PGE2  
injection and mechanical paw  pressure
5.2.2.1 Animal groupings and test procedure
The methods for this experiment follow that described in section 5.2.1.1 but with 
the following adjustments. Control mice of wildtype and adenosine A2A receptor 
knockout genotypes received no injection of PGE2 or mechanical paw pressure 
but were restrained in a plastic cylinder, their tails warmed under a heat lamp and 
3700kBq/kg [^"^C]-2-DG dissolved in sterile saline (stock concentration of 
3700kBq/ml, ARC, USA) was injected intravenously via the tail vein. This 
procedure usually took less than one minute. Mice were killed 20 minutes after
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injection of [^"^C]-2-deoxyglucose. All other mice received PGE2 injection and 
mechanical paw pressure as described previously, however 5 minutes prior to the 
relevant time point (see table 5) mice were restrained in a plastic cylinder, and 
3700kBq/kg [^^C]-2-DG was injected intravenously as described above. Mice 
were then placed into a holding cage so that each mouse survived for a further 15 
minutes. Upon completion of the 20 minute survival period, mice were killed via 
cervical dislocation and spinal cords were dissected out and separated into four 
sections roughly corresponding to the four anatomical regions of the spinal cord 
and then processed for autoradiography (see section 3.2.3.2.)
5.2, L 2 Data manipulation and statistical analysis
Although data was initially analyzed from ipsilateral and contralateral sides of the 
spinal cord there were no significant differences in NMDA glutamate binding 
observed between the two sides so, data were pooled. Also, because of the 
different control values observed for NMDA glutamate binding between treatment 
naïve wildtype and adenosine A2A receptor knockout mice, data were transformed 
to generate values as a % of control. These values were used for comparison of 
genotypes using two-way ANOVA. However, one-way ANOVA followed by 
Dunnett’s post-hoc test was carried out on the raw data to identify any differences 
between control values and the data obtained from spinal cords taken from mice 0, 
3, 6 and 24 hours following PGE2 injection and mechanical paw pressure. A 
probability value of P<0.05 was taken to be significant in all cases.
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5.3 Results
5.3.1 Behavioural responses following PGE2 injection and 
mechanical paw pressure
Following PGE2 and mechanical paw pressure all mice displayed signs of 
inflammation in the injected paw. There was also altered weight bearing with 
mice favouring the contralateral paw. Despite this no recordable nociceptive 
behaviour was displayed, which could have provided a reliable and robust 
measure of nociception, during the application of mechanical paw pressure 
following PGE2 injection and so no data was collected. This was also due, in part, 
because of the level of restraint required to position the mice and thus could have 
masked any subtle nociceptive responses.
5.3.2 Spinal cord NMDA glutamate receptor autoradiography 
following PGE2-injection and mechanical paw  pressure
In spinal cord sections taken from cervical and thoracic regions, two-way 
ANOVA revealed no significant effect of genotype on NMDA glutamate binding 
following PGE2 injection and mechanical paw pressure (P>0.05 Fig. 33AB). Also, 
there was no significant differences observed in [^H]-MK801 binding at any time 
point compared to control in either wildtype or adenosine A2A receptor knockout 
mice following PGE2 injection and mechanical paw pressure (P>0.05 Fig. 33AB).
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However, two-way ANOVA revealed there was a significant effect of genotype 
on NMDA glutamate receptor binding observed in lumbar and sacral regions of 
the spinal cord following PGE2 injection and mechanical paw pressure (P<0.001, 
Fig. 33CD). In both lumbar and sacral regions of the spinal cord taken from 
wildtype mice, one-way ANOVA revealed a significant effect of time following 
PGE2 injection and mechanical paw pressure (P>0.05, Fig. 33CD). There was a 
significant increase in [^H]-MK801 binding observed 3 hours after PGE2 and 
mechanical paw pressure when compared to control values (P<0.05 Fig. 33CD). 
In lumbar and sacral regions of the spinal cord taken from adenosine A2A receptor 
knockout mice one-way ANOVA revealed a significant effect of time following 
PGE2 injection and mechanical paw pressure (P<0.05, Fig. 33CD). There was a 
significant increase in [^H]-MK801 binding revealed at 3 hours after PGE2 and 
mechanical paw pressure when compared to control values (P<0.05, Fig. 33CD).
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Figure 33. [  HJ-MK801 binding to NMDA glutamate receptors in spinal cords 
of wildtype and adenosine Â 2a receptor knockout mice after repeated PGE2 
injection and mechanical paw pressure (mean ± S.E.M, n=3-7). Measurements 
were taken from (A) cervical, (B) thoracic, (C) lumbar and (D) sacral regions. 
Two-way ANOVA revealed a significant genotype effect in lumbar and sacral 
regions (P<0.05). *=P<0.05, time point vs control. One-way ANOVA followed by 
Dunnett’s post-hoc test on raw data to reveal time differences.
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5.3.3 Uptake o f  [^"^C]-2-deoxyglucose following PGE2 injection and 
mechanical paw pressure
In cervical sections of the spinal cord following PGE2 injection and paw pressure 
two-way ANOVA revealed a significant effect of genotype on uptake of [^ "^ C]-2- 
deoxyglucose in mice treated with PGE2 and mechanical paw pressure (P<0.01 
Fig. 34A). However, post-hoc analysis revealed that the uptake of [^ "^ C]-2- 
deoxyglucose into cervical regions of spinal cords taken from both wildtype and 
adenosine A2A receptor knockout mice was not significantly altered from control 
values following injection of PGE2 and mechanical paw pressure at any time point 
compared to control (P>0.05 Fig. 34A).
There was a significant genotype effect observed on uptake of [^ "^ C]-2- 
deoxyglucose. in thoracic regions of the spinal cord following PGE2 injection and 
mechanical paw pressure revealed by two-way ANOVA (P<0.01, Fig. 34B). In 
wildtype mice there was no significant differences observed in uptake of [^ "^ C]-2- 
deoxyglucose at any time point following injection of PGE2 and mechanical paw 
pressure in wildtype mice (P>0.05 Fig.34B). There was a significant effect of time 
revealed by one-way ANOVA in thoracic regions of the spinal cord from 
adenosine A2A receptor knockout mice (P<0.05, Fig. 34B). There was a significant 
increase in uptake of [^"^C]-2-deoxyglucose when compared to control values in 
thoracic regions from adenosine A2A receptor knockout mice 3 hours following 
PGE2 and mechanical paw pressure (P<0.05, Fig. 34B).
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In lumbar and sacral regions of spinal cords taken from wildtype and adenosine 
A2A receptor knockout mice two-way ANOVA revealed a significant effect of 
time and genotype on uptake of [^"^C]-2-deoxyglucose (P<0.001) Fig. 34CD). 
There was no significant time effect observed in wildtype mice compared to 
control values following PGE2 injection and mechanical paw pressure (P>0.05 
Fig. 34CD). However, in lumbar and sacral regions of spinal cords taken from 
adenosine A2A receptor knockout mice there was a significant effect of time as 
revealed by pne-way ANOVA (P<0.05, Fig. 34CD). There were significant 
increases in uptake of [^"^C]-2-deoxyglucose observed at both 0 and 3 hours after 
PGE2 and mechanical paw pressure compared to control values (P<0.05 Fig. 
34CD).
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Figure 34, Uptake o f f"^C]~2-deoxyglucose into spinal cord sections o f wildtype 
and adenosine A2A receptor knockout mice after repeated PGE2 injection and 
mechanical paw pressure (mean ± S.E.M, n=3-7). Measurements were taken 
from (A) cervical, (B) thoracic, (C) lumbar and (D) sacral regions. Two-way 
ANOVA revealed a significant genotype effect in lumbar and sacral regions 
(P<0.05). *=P<0.05, time point vs control. One-way ANOVA followed by 
Dunnetf s post-boc test on untransformed data to reveal time differences.
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5,4 Discussion
5,4,1 Spinal cord NMDA glutamate receptor autoradiography
following PGE2 injection and mechanical paw  pressure
Inflammatory pain was induced by injection of tbe inflammatory mediator 
prostaglandin. E2 (PGE2) and followed by mecbanical paw pressure to provide a 
model of prolonged peripheral inflammatory sensitization with tbe treatment 
lasting for a three hour period. Autoradiography of NMDA glutamate receptors 
was carried out a various time points following tbe end of tbe treatment procedure 
to identify whether there were any changes in NMDA glutamate receptor binding 
to spinal cords of adenosine A2A receptor knockout mice compared to wildtype 
mice.
Tbe injection of PGE2 sensitizes tbe peripheral afferent fibre to both mecbanical 
and beat stimuli with a rapid onset of 5 minutes post injection and a maximal 
reduction in nociceptive threshold lasting 1 hour and returning to control values 
after approximately 3 hours (Aley and Levine 1999; Reinold et al. 2005). PGE2 is 
a directly acting inflammatory mediator and acts via specific cell surface receptors 
which ultimately increases tbe activity of both protein kinase A and C within tbe 
peripheral terminal (see Zeilbofer 2006). As a consequence of increased protein 
kinase activation a number of ion channels, particularly tetrodotoxin-resistant 
sodium channels, are altered which has been shown to be involved in sensitization 
of tbe peripheral primary afferent fibre (England et al. 1996; Gold et al. 1996; 
Rush and Waxman 2004; Moriyama et al. 2005). Tbe peripheral sensitization used
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in this study initiated by PGE2 injection mimics inflammatory pain states in a 
similar manner to that described for tbe second phase of tbe formalin test with 
complex changes occurring in both tbe periphery and spinal cord as a result of 
altered gene expression and increased NMDA glutamate receptor activation (see 
Basbaum and. Woolf 1999; Millan 1999; Woolf and Salter 2000). However in this 
model tbe effects of inflammation have been studied over a greater time period, 
which enables an extended observation of changes occurring in tbe spinal cord as 
a result of a more prolonged nociceptive input.
In tbe present study there was no significant increase in NMDA glutamate binding 
observed in spinal cord sections taken immediately after tbe final mecbanical paw 
pressure. Tbe model used in this study caused a prolonged inflammatory response 
rather than repetitive nociceptive stimulation. Activation of NMDA glutamate 
receptors is a consequence of repetitive nociceptive stimulation rather than acute 
nociceptive stimulation which is mediated by AMP A glutamate receptors 
(Dickenson et al. 1997; Engelman et al. 1999; Tong and MacDermott 2006). It is 
therefore unlikely that there would be any substantial changes in NMDA 
glutamate receptor binding at time point 0 in this study.
However, there was a significant increase in NMDA glutamate binding in lumbar 
and sacral regions of the spinal cord 3 hours following the final paw pressure 
which was 6 hours following the initial injection of PGE2. After the onset of 
inflammation there are a number of chemical mediators released of which 
interleukin-Ip has been shown to be critical for the inducing increased COX-2 
expression within both the periphery and spinal cord (Samad et al. 2001; Shi et al.
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2006). An increase in COX enzyme expression augments prostaglandin release, 
particularly PGE2 which is a key inflammatory sensitizing agent within these 
tissues, and indeed inhibition of COX enzymes is the primary target for the non­
steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and aspirin 
(Vasquez et al. 2001; Yaksh et al. 2001; Samad et al. 2002). In peripheral tissues, 
there is a large increase in IL-ip following inflammation which activates the 
transcription factor nuclear factor-kappa B (NF-kB), which has been shown to 
induce increased expression of COX-2 in the spinal cord with maximal levels 
observed 6 hours following inflammation (Lee et al. 2004). There is also a 
complimentary increase in the synthase enzymes responsible for the formation of 
prostaglandins including PGE2 within the spinal cord reaching a peak 6 hours 
following inflammation (Guay et al. 2004).
Therefore, in the present study it is most likely that the increase in NMDA 
glutamate binding observed 3 hours following PGE2 injection and mechanical 
paw pressure can be attributed to prostaglandin-mediated sensitization of the 
spinal cord. It has been shown that PGE2 is able to increase the release of the 
peptide substance P and also glutamate (White 1996; Southall et al. 1998; Pitcher 
and Henry 1999). Thus, the enhanced release of glutamate and substance P 
mediated by spinal cord EP receptors would enhance the nociceptive input fi'om 
the inflamed paw and thus facilitate activation of NMDA glutamate receptors. The 
chosen ligand used for autoradiography of NMDA glutamate receptors was 
MK801 which binds to the open channel of the activated receptor (see Dingledine 
et al. 1999). It is therefore possible that the increased [^H]-MK801 binding is 
representative of greater channel opening, occurring as a result of inflammatory
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sensitization within the spinal cord following repeated PGE2 injection and 
mechanical paw pressure.
Increased [^H]-MK801 binding was not observed at time points 6 and 24 hours 
after PGE2 injection and mechanical paw pressure with NMDA glutamate binding 
unaltered from control values despite repeated PGE2 injections and mechanical 
paw pressure application. It has been shown that peripheral inflammation does not 
maintain elevated COX-2 expression within the spinal cord as IL-lp levels fall 
rapidly and are at control levels 4 hours following PGE2 release with a 
complimentary reduction in COX-2 expression (Samad et al. 2001; Reinold et al. 
2005; Shi et al. 2006). Further, these findings are in agreement with other studies 
who have found that PGE2 is only involved in the development of inflammatory 
sensitization but not the maintenance, as application of the NSAID indomethacin 
failed to reduce the effect of spinally applied NMDA 6 hours following initiation 
of inflammation (Vasquez et al. 2001).
The lack of any significant alteration in NMDA glutamate binding observed in 
cervical and thoracic regions of the spinal cord is most probably due to the 
localized nature of the inflammation in the present study. Only the left hind paw 
was injected with PGE2 and subjected to mechanical paw pressure. Peripheral 
primary afferent fibres from the hind paws enter at lumbar and sacral levels of the 
spinal cord and it is in this region of the spinal cord that significant changes in 
NMDA glutamate binding were observed (Takahashi et al. 2003). Also, an 
increase in NMDA glutamate receptor binding in distal regions of the spinal cord
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would indicate greater primary afferent fibre input from other sensory 
dermatomes whereas inflammation was only induced in one hind paw.
In spinal cord sections taken from adenosine A2A receptor knockout mice a similar 
response profile is seen to that in wildtype mice with a significant increase in 
[^H]-MK801 binding to lumbar and sacral sections taken from mice 3 hours 
following PGE2 injection and mechanical paw pressure. However, there was a 
significant effect of genotype observed in the study with adenosine A2A receptor 
knockout mice having an exaggerated response to PGE2 injection and mechanical 
paw pressure at all time points except 24 hours following PGE2 injection and 
mechanical paw pressure in which NMDA glutamate binding was no different 
from control values in both wildtype and adenosine A2A receptor knockout mice.
The exaggerated response observed in spinal cord sections from adenosine A2A 
receptor knockout mice was most probably caused by the lack of modulatory 
adenosine A2A receptors located on inflammatory cells. There is a well defined 
regulatory role for adenosine A2A receptors whereby activation of A2A receptors 
and the subsequent increase in cAMP reduces the activity of inflammatory cells 
and thereby acts to regulate the inflammatory response (see Hasko and Cronstein 
2004). Neutrophils are one of the primary inflammatory cells recruited to the site 
of inflammation and they release many inflammatory cytokines of which IL-lp is 
present (McDonald et al. 1997). In a preparation of neutrophils taken from 
wildtype and adenosine A2A receptor knockout mice stimulated with LPS there 
was a significant increase in the expression of IL-lp in the preparation containing 
neutrophils from adenosine A2A receptor knockout mice (McColl et al. 2006).
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Further, inflammatory cells also release the pre-cursor enzyme responsible for the 
release of arachidonic acid, phospholipase-A2 which further acts to facilitate the 
inflammatory process (Triggiani et al. 2006). Thus, a lack of modulatory 
adenosine A2A receptors located on inflammatory cells present during the complex 
processes that initiate inflammation could enhance the response and therefore 
could explain the overall increase in NMDA glutamate binding following PGE2 
and mechanical paw pressure in adenosine A2A receptor knockout mice compared 
to wildtype mice.
5.4,2 Uptake o f  [^'^C]'-2-deoxyglucose following PGE2 injection and 
mechanical paw pressure
The results of the present study indicate that there was no alteration in uptake of 
[^"^C]-2-deoxyglucose into the spinal cords of wildtype mice at any time point 
following PGE2 injection and mechanical paw pressure. The uptake of [ "^^ C]-2- 
deoxyglucose into the spinal cord provides a measure of neuronal activity 
(Sokoloff et al. 1977; Duncan and Stumpf 1991). The lack of a significant 
increase in uptake of [^"^C]-2-deoxyglucose into the spinal cord at time point 0 in 
wildtype mice may reflect the acute nature of the nociceptive stimulus given as 
only a single mechanical paw pressure of 25Og was applied to the paw during the 
time period using a modified pressure bar stimulus, which provided a more even 
distribution of the mechanical pressure compared to the original apparatus (see 
Kitchen 1984).
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The uptake of [^'^C]-2-deoxyglucose was not-significantly altered from control 
values 3 hours following PGE2 injection and paw pressure treatment, this is the 
same time point at which a significant increase in NMDA glutamate binding was 
observed (see section 5.3.1). The increase in NMDA glutamate binding does not 
necessarily indicate increased input to the spinal at that particular time as it has 
been demonstrated that following activation of NMDA glutamate receptors, they 
remain phosphorylated for some time which abolishes the Mg^ '*’ block and 
increases channel opening (Guo et al. 2002; Brenner et al. 2004). The 
phosphorylation of NMDA glutamate receptors indicates previous repetitive 
nociceptive input to the spinal cord and is a component of spinal cord 
sensitization which provides the basis for enhancing nociceptive input during 
inflammation (see Baranauskas and Nistri 1998). Therefore an increase in NMDA 
glutamate receptor phosphorylation does not necessarily require continuous 
increased nociceptive input to the spinal cord and thus the unaltered uptake in 
[*"^C]-2-deoxyglucose 3 hours following PGE2 injection and mechanical paw 
pressure may reflect this. The unaltered uptake of [^"^C]-2-deoxyglucose into 
spinal cord sections from wildtype mice at time points 6 and 24 hours is in 
accordance with [^H]-MK801 binding at these time points (see section 5.3.1) in 
which there was no significant difference in NMDA glutamate receptor binding 
which would indicate the resolution of inflammation as PGE2 produces 
inflammation which resolves after approximately 4 hours (Aley and Levine 1999; 
Reinold et al. 2005).
In spinal cord sections from adenosine A2A receptor knockout mice there was a 
significant genotype effect observed in thoracic, lumbar and sacral regions of the
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spinal cord with uptake of [^"^C]-2-deoxyglucose being greater than that observed 
in wildtype mice. There was a specific significant increase in uptake of [*"^ C]-2- 
deoxyglucose. at both 0 and 3 hours following PGE2 injection and paw pressure. 
The increase 3 hours following PGE2 injection and paw pressure parallels the 
increase in NMDA glutamate binding (see section 5.3.1). However, the significant 
increase in uptake of [^"^C]-2-deoxyglucose observed immediately following the 
final mechanical paw pressure does not.
The above observations may also be related to loss of adenosine A2A receptors 
located on immune cells. The uptake of [^-2-deoxyglucose into the spinal cord 
is a measure of neuronal activity which provides an indication of greater afferent 
fibre input to the spinal cord (Sokoloff et al. 1977; Duncan and Stumpf 1991). 
Therefore, the results indicate that adenosine A2A receptor knockout mice could 
have greater nociceptive input to the spinal cord at the time points analyzed 
compared to wildtype mice. The significant increase in uptake of [^ "^ C]-2- 
deoxyglucose at time point 0 can be attributed to greater peripheral sensitization 
resulting fi'om increased infiammatory cell activity. In has been shown that the 
level of infiammatory cytokines was increased in adenosine A2A receptor 
knockout mice when a preparation of infiammatory cells were challenged with 
LPS (Ohta and Sitkovsky 2001; McColl et al. 2006). This increase in 
infiammatory mediators would decrease the threshold further than in wildtype 
mice and could cause greater afferent fibre firing which would be responsible for 
the increased uptake of [ -2-deoxyglucose into the spinal cords of adenosine 
A2A receptor knockout mice compared to wildtype mice.
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5,4,3 General conclusion
Autoradiography of spinal cord NMDA glutamate receptors and uptake of — 
2-deoxyglucose into the spinal cord of wildtype and adenosine A%A receptor 
knockout mice was carried out to investigate whether there were any changes 
occurring in the spinal cord following repeated injection of PGE2 and mechanical 
paw pressure to provide a nociceptive stimulus. There was increased NMDA 
glutamate receptor binding and increased uptake of [^"^CJ-2-deoxyglucose into 
spinal cord sections from adenosine A2A receptor knockout mice when compared 
to wildtype mice. Adenosine A2A receptors exert strong modulatory effects on 
inflammatory cells when activated and therefore these results could indicate that 
the loss of adenosine A2A receptors may increase the sensitization of nociceptive 
pathways in inflammatory pain. It highlights the neuromodulator role for 
adenosine whereby the outcome is dependent upon the site of action and receptor 
subtype activated. Unfortunately no behavioural data could be obtained to 
complement the increased NMDA glutamate receptor binding and uptake of 
2-deoxyglucose as neither wildtype nor adenosine A2A receptor knockout mice 
displayed any overt nociceptive behaviour during the test. Therefore, no definite 
conclusions can be made about the exact role of adenosine A2A receptors during 
the model used in the study. Nonetheless, it is likely that the loss of adenosine A2A 
receptors located on infiammatory cells is pro-nociceptive rather than anti­
nociceptive.
160
Chapter 6
General Discussion
161
The aim of the work presented in this thesis was to test the hypothesis that 
adenosine A2A receptors modulate peripheral nociceptive pathways by sensitizing 
primary afferent fibres projecting to the spinal cord and thus influence central 
nociceptive processing. A number of experiments were undertaken using 
adenosine A2A receptor knockout mice and wildtype controls to evaluate the 
hypothesis including autoradiography of spinal cords from treatment naïve 
animals, following a short duration inflammatory stimulus (formalin injection) 
and following a more prolonged inflammatory stimulus (repeated PGE2 injection 
and mechanical paw pressure). There was also behavioural observation 
undertaken following formalin injection in both wildtype and adenosine A2A 
receptor knockout mice to understand if there were any functional consequences 
resulting from genetic knockout or antagonism of adenosine A2A receptors. Whilst 
the overall conclusion does suggest a key role for adenosine A2A receptors in 
mediating peripheral nociception, the location of adenosine A2A receptor is key to 
the predicting the effect of blocking the receptors. Antagonism of the receptor at 
the peripheral terminal of primary afferent fibres is analgesic whereas blockade of 
the receptors located on inflammatory cells could be pro-nociceptive. Also, it is of 
some importance to note that that adenosine is continually released into the 
extracellular space and it has been estimated that the basal adenosine 
concentration within the rat paw is 230nM, a level at which both adenosine Ai 
and A2A receptor subtypes are activated (Liu et al. 2000). Therefore the loss of 
stimulatory adenosine A2A receptors located on peripheral sensory fibres would 
unmask the inhibitory effect of adenosine Ai receptors located at the peripheral 
terminal of primary afferent fibres.
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Autoradiography of NMDA and AMP A glutamate receptors in treatment naïve 
wildtype and adenosine A2A receptor knockout mice was carried out to examine 
whether there were any changes to the glutamate receptor system in adenosine 
A2A receptor knockout mice as glutamate is the primary neurotransmitter in 
sensory nerves projecting to the spinal cord (see Millan 1999). There were 
significant reductions in NMDA glutamate receptor binding in all regions and all 
laminae of the spinal cord, whereas there were small, but significant increases in 
AMP A glutamate receptor binding but only in laminae I and II of lumbar and 
sacral regions of the spinal cord. The observed changes in glutamate receptor 
number in treatment-naiVe adenosine A2A receptor knockout mice could be the 
result of decreased sensory input to the spinal cord during development. This 
could indicate a functional interaction between adenosine and glutamate receptor 
systems during development as it is believed that the adenosine receptor system is 
functionally active in the foetus earlier than the glutamate receptor system, at least 
in humans (Herlenius and Lagercrantz 2001). Indeed, an interaction between the 
adenosine and glutamate systems does exist in adult mice as adenosine acting via 
its inhibitory Ai receptor subtype modulates glutamate release both in the spinal 
cord and brain (see Brambilla et al. 2005; Li and Eisenach 2005). Thus, increased 
activation of adenosine Ai receptors located in the periphery during development 
could be responsible for the reduction in NMDA glutamate receptor binding 
observed in adult adenosine A2A receptor knockout mice.
There was also a reduction in uptake of [*"^C]-2-deoxyglucose into all regions and 
laminae of spinal cords taken fi*om treatment-naïve adenosine A2A receptor 
knockout mice compared to wildtype control mice. This would indicate reduced
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sensory input to the spinal cord in adenosine A2A receptor knockout mice and this 
was also most probably caused by increased activation of inhibitory adenosine Ai 
receptors in adenosine A2A receptor knockout mice. Adenosine A% receptors are 
coupled to the Gi and Go class of G-proteins which causes a reduction of cAMP, 
inhibits Ca^  ^ channels and increases channel opening which generally acts to 
reduce neuron excitability (Fredholm et al. 2001) Thus, the generalized inhibition 
mediated by adenosine Ai receptors could explain the reduction in uptake of 
[^-2-deoxyglucose into the spinal cord in adenosine A2A receptor knockout 
mice when compared to wildtype mice as there would be reduced sensory input to 
the spinal cord. Further, a reduction in NMDA glutamate receptor number has 
previously been demonstrated to reduce uptake of [^"^C]-2-deoxyglucose in brain 
sections (Duncan et al. 2002). Therefore, the reduction in NMDA glutamate 
receptor number in adenosine A2A receptor knockout mice would reduce 
glutamate mediated neuronal activity via spinal cord NMDA receptors and could 
also be responsible for the observed reduction in uptake of -2-deoxyglucose 
into the spinal cord of adenosine A2A receptor knockout mice.
The behavioural relevance of a reduction in NMDA glutamate receptor binding 
and decreased uptake of [^"^C]-2-deoxyglucose in adenosine A2A receptor 
knockout mice was examined using the formalin test. Adenosine A2A receptor 
knockout mice displayed a significant reduction in nociceptive behaviour during 
both phases of the test compared to wildtype mice. In addition, the involvement of 
adenosine A2A receptors in mediating the response was confirmed using the 
selective adenosine A2A receptor antagonist SCH58261. Wildtype mice injected 
with either 3mg/kg or lOmg/kg SCH58261 displayed reduced nociceptive
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behaviour in both phases of the test in a manner very similar to adenosine A2A 
receptor knockout mice. This is consistent with previous studies in which co­
administration of adenosine augmented the nociceptive response to both phases of 
the formalin test in rats and this was reduced using the A2 selective antagonist 
DMPX (Doak and Sawynok 1995). Collectively, these results are interesting as 
previous studies have shown that drugs which inhibit the action of inflammatory 
mediators such as PGE2 (via inhibition of COX enzymes), or antagonism of 
receptors for 5-HT and histamine are effective analgesics but only during the 
second, inflammatory phase of the test. (Doak and Sawynok 1997; Choi et al. 
2001; Fredholm et al. 2001; Parada et al. 2001). However, genetic knockout or 
antagonism of adenosine A2A receptors causes reduced nociceptive behaviour 
during both the first, acute phase as well as the second inflammatory phase of the 
test. This, in addition to the reduced uptake of [^"^C]-2-deoxyglucose into the 
spinal cord in treatment-naive mice, indicates that adenosine has an important role 
in modulating the excitability of peripheral sensory neurones under basal 
conditions as the extracellular adenosine concentration is sufficient to activate 
adenosine A2A receptors although there is a large increase in extracellular 
adenosine concentration following noxious stimulation (Liu et al. 2000; 2002a; 
2002c). Thus, antagonism of the adenosine A2A receptor subtype will reduce the 
excitability of sensory neurones so that these drugs are effective during the first 
acute phase of the formalin test as well as the second inflammatory phase. This 
has also been demonstrated previously, as use of adenosine A2A receptor 
antagonists or adenosine A2A receptor knockout has been analgesic in other 
models of acute nociception (Ledent et al. 1997; Bastia et al. 2002; Godfrey et al. 
2006).
165
The reduced nociceptive behaviour observed in adenosine A2A receptor knockout 
mice was also reflected in the spinal cords of mice following formalin injection 
analyzed by autoradiography of NMDA and AMP A glutamate receptors as well 
as uptake of [^"^C]-2-deoxyglucose. In adenosine A2A knockout mice there were no 
significant changes observed in any of the three measures at both 15 and 60 
minutes following formalin injection when compared to significant changes at all 
time points in wildtype mice. This observation could indicate reduced primary 
afferent fibre activation following formalin injection which is also implied by the 
unchanged uptake of [^"^C]-2-deoxyglucose, which is used as a measure of 
neuronal activity within the spinal cord (Sokoloff et al. 1977; Duncan and Stumpf 
1991). Further, the unchanged NMDA and AMP A glutamate receptor binding 
following formalin injection in adenosine A2A receptor knockout mice would also 
reflect reduced nociceptive input to the spinal cord as it has been previously 
demonstrated that changes to these receptors can be used as an indication of 
increased sensory input to the spinal cord (see Fundytus 2001).
Following repeated injection of PGE2 and mechanical paw pressure, which was 
used to provide a robust nociceptive stimulus over a period of 3 hours, adenosine 
A2A receptor knockout mice had greater increases in NMDA glutamate receptor 
binding and greater uptake of [^"^C]-2-deoxyglucose compared to wildtype mice at 
three of the time-points tested. This is in contrast to the results obtained following 
formalin injection, which suggested that adenosine A2A receptor knockout mice 
have reduced sensory input to the spinal cord. Therefore, it is conceivable that 
adenosine A2A receptor knockout mice would also have a reduced response to the
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nociceptive stimuli compared to wildtype mice in this experiment as was observed 
following formalin injection. However, in this study a more prolonged 
inflammatory stimulus was used and following initiation of inflammation there 
are a number of cytokines and chemo-attractant molecules released which 
increase the local concentration of inflammatory cells (see McDonald et al. 1997; 
McMahon et al. 2005; Triggiani et al. 2006). Inflammatory cells express 
adenosine A2A receptors on their cell surface (Thiel et al. 2003) and the increased 
localized adenosine concentrations resulting from, among other sources, 
degradation of ATP and efferent release of adenosine from neuronal sources is a 
potent anti-inflammatory signal reducing the activity of inflammatory cells via 
activation of adenosine A2A receptors (Gomez and Sitkovsky 2003). Indeed it has 
been demonstrated that there is significant tissue damage following systemic 
injection of even small volumes of LPS, a potent inflammatory stimulant, into 
adenosine A2A receptor knockout mice (Ohta and Sitkovsky 2001). Thus it is 
conceivable that in adenosine A2A receptor knockout mice there would be greater 
inflammatory cell activation and increased sensory input to the spinal cord which, 
in this case, is suggested by the increased NMDA glutamate receptor activation 
and uptake of [^'^C]-2-deoxyglucose into the spinal cord following repeated PGE2 
and mechanical paw pressure.
Unfortunately no behavioural data could be obtained to complement the increased 
NMDA glutamate receptor binding and uptake of [^"^C]-2-deoxyglucose as neither 
wildtype nor adenosine A2A receptor knockout mice displayed any overt 
nociceptive behaviour during the test. Therefore, no definite conclusions can be 
made about the exact role of adenosine A2A receptors during the model used in the
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study. Nonetheless, it is likely that the loss of adenosine A2A receptors located on 
inflammatory cells is pro-nociceptive rather than anti-nociceptive which is in 
opposition to the possible analgesic effects from loss or blockade of adenosine 
A2A receptors located on peripheral sensory fibres.
6.1 Future work
Further work would be required to clarify the role of adenosine A2A receptors in 
peripheral nociception and thus provide a clear framework in which any possible 
novel pain treatment could be investigated. An initial experiment would be to 
obtain behavioural data following the model of inflammatory pain used in this 
study. Possible behavioural correlates could include analysis of weight bearing 
ratio between the injected and contralateral paws. Also, paw swelling could be 
measured which would provide an indication of the level of inflammation 
established. The studies in this thesis used spinal cord autoradiography to examine 
primary afferent fibre activation occurring in peripheral tissues. Although the 
changes occurring in the spinal cord do accurately reflect the activation of 
peripheral sensory fibres analysis of peripherally released mediators such as 
adenosine or PGE2, for example, would allow a greater assessment of any changes 
taking place in the peripheral tissue. Thus, peripheral microdialysis of the paw 
measuring peripheral mediators could be a useful tool to examine the activation of 
peripheral sensory fibres at the site of nociceptive stimulation. Also, whilst there 
is evidence to suggest adenosine A2A receptors are located on primary afferent 
fibres no direct visualization has been published and therefore localization of 
adenosine A2A receptors directly on sensory fibres would be of interest using 
immunohistochemical techniques. Further, the use of electrophysiological
168
methods to examine the excitability of spinal cord neurones following nociceptive 
stimuli in adenosine A%A receptor knockout mice is also possible to establish their 
contribution to sensitization of the primary afferent fibres projecting to the spinal 
cord. A final study could use bone marrow transplants from wildtype mice into 
adenosine A2A receptor knockout mice to rescue adenosine A2A receptors located 
on inflammatory cells where they have a potent anti-inflammatory role.
6,1 Overall conclusion
Collectively, the results described in this thesis support the hypothesis that 
adenosine A2A receptors modulate peripheral nociceptive pathways by sensitizing 
primary afferent fibres projecting to the spinal cord. Adenosine A2A receptor 
knockout mice have displayed reduced nociceptive behaviour which was 
mimicked using selective antagonists at adenosine A2A receptors. This was 
analgesic, which indicates that modulation of the peripheral adenosine system 
may provide a novel target for the treatment of pain and could warrant further 
investigation. However, systemic administration of drugs that antagonize 
adenosine A2A receptors would also inhibit the potent anti-inflammatory effect 
that these receptors exert on inflammatory cells and this could therefore be a 
possible confounding factor in their potential use as analgesic drugs. In summary, 
this study has provided evidence that shows adenosine receptor activation has 
complex actions on peripheral nociception whereby the site of release and cell 
type involved determines whether the receptor has pro-nociceptive or ant- 
nociceptive actions.
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